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Abstract 
Familial renal cell carcinoma (RCC) only accounts for 3% of all RCC, yet the study of 
these inherited forms has provided important insights into the more common sporadic 
RCC. Somatic VHL inactivation is found in 70% of sporadic clear cell RCC (ccRCC) 
though is rarely found in other forms of RCC including papillary and chromophobe types. 
VHL-independent RCC tumourigenesis is poorly understood and current research 
involves identifying novel RCC candidate genes to further understand the mechanisms 
involved. In this study a constitutional balanced translocation, t(5;19)(p15.3;q12), 
associated with familial RCC was characterised using an oligonuleotide CGH array 
followed by genomic sequencing and the previously uncharacterised gene, UBE2QL1, 
was found to be disrupted by the 5p15.3 breakpoint. UBE2QL1 expression was down-
regulated in 78.6% of sporadic RCC and UBE2QL1 promoter region hypermethylation 
and gene deletions were detected in 20.3% and 17.3% of sporadic RCC, respectively. Re-
expression of UBE2QL1 in deficient RCC cell lines suppressed anchorage independent 
growth and colony formation. UBE2QL1 shows homology to the E2 class of ubiquitin 
conjugating enzymes and was shown to possess an active-site cysteine (C88) that is 
monoubiquitinated in vivo. In addition, UBE2QL1 co-immunoprecipitation and co-
localisation studies demonstrated a protein interaction with FBXW7 (an F box protein for 
the SCF E3 ubiquitin ligase) and was shown to facilitate the degradation of the known 
FBXW7 substrates, cyclin E1 and mTOR. These findings demonstrate that UBE2QL1 
functions as a novel renal tumour suppressor gene and ubiquitin conjugating enzyme. 
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1.1    Cancer is a genetic disease 
In 1960 the abnormal Philadelphia (ph) chromosome found in chronic 
myelogenous cells was the first evidence of a genetic abnormality causing cancer 
(Randolph 2005). Following this it was soon realised that mutations and alterations in 
normal cellular genes are able to initiate the onset of cancer leading to the now accepted 
notion that cancer is a genetic disease (Cairns 1975). Since then the central aim of cancer 
research has been to identify these cancer genes in the hope of further understanding the 
changes in the molecular biology of the cancer cell.  
 
Tumour karyotypes often show multiple abnormalities that arise due to the 
genetic instability of the cancer genome (Liang et al. 2010). This instability is due to the 
accumulation of mutations and aberrations of cancer genes along with multiple cycles of 
clonal selection leading to the disruption of cell signaling pathways involved in 
proliferation, migration, transcription, growth, DNA repair, differentiation and cell death 
(Feinberg et al. 2006). Cancer genes often play a major role in these cell signalling 
pathways and can be altered in cancers in a number of ways including single nucleotide 
mutations, small deletions, promoter methylation, whole gene deletions, alterations in 
structural components of chromosomes and whole chromosomes deletions or 
duplications (Balmain et al. 2003). Cancer genes are loosely characterised into two types; 
tumour suppressor genes and oncogenes (Cornelisse & Devilee 1997) (Figure 1.1). 
 22 
 
Figure 1.1 Clonal evolution of tumourigenesis 
The theory of cancer arising from multiple rounds of clonal selection involves the initial 
mutation(s) of important disease causing oncogenes (ONC) and/or tumours suppressor 
genes (TSG). Each ONC and/or TSG mutation is thought to give the cell a competitive 
advantage leading to the selective expansion of a clonal population. Further ONC and 
TSG mutations lead to successive waves of clonal expansion thus increasing genetic 
plasticity which ultimately leads to the progression of tumour characteristics such as 
metastasis and drug resistance (Feinberg et al. 2006). 
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1.1.1   Oncogenes and mechanisms of activation 
Cancer causing viruses provided the first evidence of cancer genes that appeared 
to drive oncogenesis in a dominant fashion and thus were subsequently termed 
oncogenes. When mouse fibroblasts were transfected with DNA from human cancer cells 
they began to show similar properties to the malignant cells. This transforming ability of 
the human DNA was found to be due to the mutated human homologue of the retroviral 
RAS oncogene (Capon et al. 1983). Since then many oncogenes have been identified and 
have often been shown to code for proteins that play an important role in cell 
proliferation, growth, differentiation and apoptosis, for example the RAS proteins were 
later found to deliver signals from cell surface receptors which fed into a number of these 
pathways (Hofer et al. 1994). 
 
The non-mutated form of an oncogene is termed a proto-oncogene: these are 
genes that have the potential to become oncogenes when mutated. There are many 
different mechanisms that can lead to the structural alteration of a proto-oncogene 
causing the activation of its oncogenic affects, these include mutations, translocations 
leading to gene fusion or juxtaposition of enhancer elements and gene amplification 
(Croce 2008). Chromosomal rearrangements can cause the transcriptional deregulation of 
an proto-oncogene, for example in Burkitt’s lymphoma the t(8;14) translocation causes 
the c-MYC proto-oncogene to be translocated next to the immunoglobulin enhancer thus 
leading to its increased expression (Joos et al. 1992). Fusion genes that are created by 
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chromosomal translocations can act in an oncogenic fashion, the most well-documented 
example of this is the ph chromosome associated with chronic myeloid leukaemia, 
created by a reciprocal translocation involving chromosomes 9 and 22 creating a 
BCR/ABL fusion protein with increased tyrosine kinase activity, thus exhibiting 
oncogenic affects (Randolph 2005). Mutations that cause the activation of an proto-
oncogene often change the structure of the encoded protein allowing the enhancement of 
its oncogenic activity, for example mutations found in the RAS oncogenes (KRAS, HRAS 
and NRAS) encode for RAS proteins that remain constitutively active thus continuously 
transduce signals (Bos 1988).  
 
1.1.2   Tumor suppressor genes and the ‘two-hit’ model 
Tumour suppressor gene (TSG) protein products often function in cell cycle 
control, growth, proliferation, apoptosis initiation, senescence and DNA damage repair 
pathways. They are inactivated through a number of mechanisms including genetic 
alterations such as nucleotide mutations, gene deletions and chromosome translocations 
or by epigenetic alterations such as DNA methylation and chromatin alterations (Berger 
et al. 2011). In 1969 a number of somatic cell fusion experiments demonstrated the 
existence of TSGs by fusing normal cells with malignant cells which caused the 
suppression of the tumorigenicity in the malignant cells (Harris et al. 1969).  These 
experiments suggested TSGs were recessive and that both alleles of the TSG must be 
completely inactive for the tumorigenicity to occur which led to the hypothesis of the 
‘two-hit’ model of tumour suppressor gene inactivation (Knudson 1971). Knudsons two-
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hit model came from his work on the genetic mechanisms of retinoblastoma, a childhood 
cancer of the retina. Researchers at the time originally thought that retinoblastoma could 
be caused by either somatic or germline mutations of the causative gene, now known as 
RB1 (Schappert-Kimmijser et al. 1966). Yet Knudsons studies observed that in some 
cases offspring from an affected parent did not develop retinoblastoma, though their 
offspring did, thus suggesting a germline mutation could be inherited without developing 
the disease. Knudson also noted that the majority of non-inherited retinoblastoma cases 
were unilateral whereas inherited cases were more commonly bilateral, more importantly 
he examined the age at which inherited bilateral cases occurred and bilateral non-
inherited cases occurred. Not surprisingly he established that diagnosis of bilateral 
inherited retinoblastoma occurred at a much younger age to that of bilateral non-inherited 
cases, suggesting only one mutation needed to occur in inherited cases. Knudson 
produced mathematical calculations from his clinical data to conclude retinoblastoma was 
most likely caused by two mutations, one in each allele of the RB1 gene, thus leading to 
the two-hit hypothesis ( Knudson 1971). It was later discovered that many families with 
familial retinoblastoma showed germline RB1 mutations or deletions (this was the first 
hit) and RB tumours were nearly always shown to contain a mutation or deletion in the 
second RB1 allele (the second hit) (Benedict et al. 1983). Biallelic disruption of RB1 was 
soon after shown to occur in non-hereditary retinoblastomas (Dryja et al. 1984). The 
‘two-hit’ model allowed an explanation for the susceptibility of hereditary cancer and 
instigated the study of chromosome deletions and genetic linkage in hereditary cancers 
along with analysis of the second alleles. These investigations ultimately led to the 
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identification of a number of important and well know tumor suppressor genes including 
TP53, BRCA1 and BRCA2 (Malkin et al. 1990; Smith et al. 1992; Gudmundsson et al. 
1995). It was initially thought that the two hits would be sufficient to cause 
tumourigenesis in some cancers where in others more mutations would be needed. It is 
now thought that in hereditary cancer syndromes complete inactivation of the cancer 
causing gene could be the rate-limiting step for the initiation of tumourigenesis yet other 
events most likely occur to promote tumour progression. Sporadic cancers are thought to 
require at least four distinct mutation events resulting in the deregulation of important 
signalling pathways (Fearon & Vogelstein 1990; Berger et al. 2011). 
 
1.1.3   Tumour suppressor gene haploinsufficiency 
Although the ‘two-hit’ model has been proven for TSGs in many cancer 
syndromes and sporadic cancers there are still cases where second hits are not found. For 
example in sporadic cancers the re-occurrence of chromosomal deletions in specific 
regions has been observed suggesting an importance of these regions in tumourigenesis, 
though second hits in the genes within these regions are not often found (Paige 2003). 
One theory to explain this is the existence of haploinsufficient tumor suppressor genes. 
Haploinsufficiency indicates that in certain circumstances one working allele is 
insufficient for the gene product to accomplish normal activity (Fisher & Scambler 
1994). There have been a number of tumour suppressor genes that have shown evidence 
of haploinsufficiency for example one study showed p53 +/- mice showed a higher 
number of chromosomal aberrations compared to p53 +/+ and a lower number compared 
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to p53-/- (Venkatachalam et al. 1998). In the cancer susceptibility syndrome Li-Fraumeni 
syndrome, caused by germline p53 mutations, loss of the wildtype p53 allele in the 
tumour is not always shown (Varley et al. 1997). Another example is the TSG PAX5 
found to be disrupted in about 30% of acute lymphoblastic leukaemia patients, although, 
in most cases, this only occurs in one allele and is thought to function as a hypomorph, 
that is the mutations only cause partial loss of the gene function (Mullighan et al. 2007). 
The hypothesis of haploinsufficient TSG involvement in cancer has been met with 
scepticism. This mainly derives from the inability to determine which single mutations 
are involved in tumourigenesis due to haploinsufficiency and which are simply passenger 
mutations caused by the genetic instability of the cancer cell (Santarosa & Ashworth 
2004). TSGs involved in tumourigenesis can be identified by the disruption of the second 
allele when applying the ‘two-hit’ model though this method cannot be applied to 
determining haploinsufficient TSGs. In fact the only method to date to determine if a 
haploinsufficient TSG is involved in tumourigenesis is by performing lengthy in vitro or 
ex vivo functional studies (Berger & Pandolfi 2011). 
 
1.1.4   Epigenetic tumour suppressor gene inactivation 
The field of cancer epigenetics is rapidly growing as it was revealed that many 
cancers show global changes in their epigenetic landscape compared to normal cells 
(Cheung et al. 2009). Cancer is no longer seen as a solely genetic disease but as a genetic 
and epigenetic disease. The term epigenetic refers to changes in gene expression that 
occur independent of changes in the primary DNA sequence. Cancer epigenetics has 
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shown disruptions in a number of epigenetic machinery including DNA methylation, 
non-coding RNAs and histone modification (Clark & Melki 2002). 
 
TSG DNA methylation has become one of the more extensively studied regions 
of cancer epigenetics. DNA methylation occurs by covalently modifying cytosine 
residues in CpG dinucleotides found at CpG islands. These CpG rich islands are located 
at the 5’ promoter regions of ~60% of human genes (Wang & Leung 2004). The CpG 
dinucleotide occurs at a much lower frequency than what would be expected within the 
human genome; the GC content is 42% in the human genome therefore the expected 
frequency of CpGs occurring due to chance should be ~4.41% (0.21 x 0.21), though 
CpGs actually occur at a frequency of ~1% within the genome. This lower frequency of 
CpG dinucleotides is thought to be due to spontaneous deamination of methylated 
cytosines (methylcytosines) to thymine as CpGs within the genome are normally 
methylated (Bird 1980). This is not the case for CpGs within CpG islands found at gene 
promoters as these are normally unmethylated and are extremely GC-rich, thus the 
human genome is made up of regions of extremely high GC content at gene promoter 
regions and low GC content elsewhere (Antequera & Bird 1999). The majority of CpG 
islands often remain unmethylated in differentiated tissue and during development. Gene 
silencing through promoter methylation normally occurs to regulate expression of tissue 
specific genes and where long term transcriptional silencing must occur for example X-
chromosome inactivation and imprinted genes (Suzuki & Bird 2008). The methylated 
CpG islands initiate gene silencing by either promoting or preventing the recruitment of 
 29 
 
regulatory proteins to the gene promoter, for example promoter methylation can block 
transcription factors from binding thus inhibiting gene transcription (Prendergast & Ziff 
1991). Methylated CpGs can also bind methyl-binding domain proteins which can 
interact with histone deacetylases instigating chromatin compaction and gene silencing 
(Szyf 2006) (Figure 1.2). 
 
Many cancer genomes are globally hypo-methylated with only site specific hyper-
methylation occurring often at the promoters of TSGs (Jones & Baylin 2002). It has been 
suggested that some of these methylation events can occur early on in the development of 
cancer and could potentially contribute to the initiation of tumourigenesis (Feinberg et al. 
2006). The first TSG promoter found to be hyper-methylated as a mechanism of gene 
inactivation was the RB gene in retinoblastoma (Greger et al. 1989). Since then, 
numerous TSGs have been found to undergo tumour-specific hyper-methylation, for 
example the BRCA1 gene in breast cancer, the VHL gene in renal cell carcinoma and the 
MLH1 mismatch repair gene in colorectal cancer (Jing et al. 2007; Gnarra et al. 1994; 
Vlaykova et al. 2011). TSG promoter methylation has therefore been shown to function 
as one of the two hits in sporadic cancers. There are also a number of cases where 
promoter methylation has constituted as a second hit in familial cancers for example APC 
and BRCA1 in breast and colorectal inherited cancers (Esteller et al. 2001). Hyper-
methylation of both alleles of known TSGs has also been noted in sporadic tumours in 
the absence of any genetic disruptions (Herman & Baylin 2003). 
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Figure 1.2 Gene silencing by methylation 
Histones linked to unmethylated genes become hyperacetylated and allow the access of 
transcription factors to the promoter region, activating gene transcription. A, Promoter 
methylation can prevent the binding of important transcription factors, inhibiting gene 
transcription. B, Methylated CpGs can recruit methyl-binding domain proteins such as 
MeCP2 which interact with histone deacetylases (HDAC) and histone methylatransferases 
such as SUVh3, which in turn  methylate H3-histones further inactivating the chromatin by 
recruiting HP1 an important component of heterochromatin packaging, thus preventing 
gene transcription (Adapted from Szyf, 2006). 
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How TSGs are specifically targeted for this aberrant methylation in cancers is still 
unclear. One idea is that random silencing of certain genes by hyper-methylation offers 
the cell a growth advantage which ultimately leads to their clonal selection and continued 
proliferation (Huang et al. 1999). Another theory involves the initial activation of 
oncogenic transcription factors which can signal to DNA methyltransferases to target 
specific genes for methylation, for example the PML-RAR fusion protein found in acute 
promyelocytic leukemia initiates the hyper-methylation and silencing of a number of 
specific genes through this mechanism (Croce et al. 2002). It has also been observed that 
direct alterations and dysregulation of histone methyltransferases that normally mark 
specific regions of the genome for methylation can lead to altered distribution of these 
marks and aberrant TSG methylation, for example the histone methyltransferase EZH2 
has often been shown to be overexpressed in prostate and breast cancers leading to hyper-
methylation of a number of TSGs in these cancers (Simon & Lange 2008). Large sections 
of DNA are commonly found to be methylated in many cancers thus resulting in the 
hyper-methylation of important TSGs due to their location within these regions (Frigola 
et al. 2006). 
  
As epigenetic changes are often reversible a number of epigenetic drugs have 
been discovered that could potentially reverse the epigenetic aberrations that occur in 
cancers. DNA methylation inhibitors 5-azacytidine (azacitidine) and 5-aza-2’-
deoxycytidine (decitabine) are nucleoside analogs which can become incorporated into 
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the DNA of tumour cells due to their rapid growth and can lead to the inhibition of DNA 
methylation as they trap DNA methyltransferases onto the DNA, inhibiting their activity. 
As the TSGs are no longer methylated in the cancer cells treated with these two drugs 
their expression causes growth inhibition (Yoo & Jones 2006). Azacitidine and decitabine 
are both FDA approved in the treatment of myelodysplastic syndromes and 
haematological malignancies (Plimack et al. 2007; Santini 2009).  
 
1.1.5   DNA repair genes in cancer development 
 Another set of genes that are often deregulated in cancers are the DNA repair 
pathway genes. The normal functioning of DNA repair pathways are essential for cell 
viability and genome integrity. DNA damage and double stranded breaks (DSB) can be 
caused by a number of factors, including environmental factors such as ionising radiation, 
UV light and some chemicals, and normal biological factors such as during DNA 
replication, V(D)J recombination and oxidative deamination (Hoeijmakers 2009). There 
are a number of DNA repair mechanisms in place to ensure the integrity of the cells 
genome including excision repair processes to repair single bases and single DNA 
strands, for example base excision repair (BER), nucleotide excision repair (NER) and 
mismatch repair (MMR) (Marti et al. 2002). When both strands of DNA are disrupted 
these are known as double stranded breaks (DSB) and can be extremely damaging to cells 
as they can cause genome rearrangements. In Eukaryotic cells there are two primary 
pathways that are involved in DSB repair; nonhomologous end joining (NHEJ) and 
homologous recombination (HR) (Chapman et al. 2012). Homologous recombination 
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(HR) involves repair of DSBs through the use of a complementary template strand of 
DNA; either a sister chromatid or homologous chromosome. HR often occurs during late 
S to G2 phase of the cell cycle when sister chromatids are present. NHEJ involves the 
joining of DNA strands without the need for a homologous template. DSB often have 
short single stranded overhangs at the ends of the strands, these are known as 
microhomologies and are often utilised in NHEJ to guide repair. When these 
microhomologies are not complementary imprecise repairing can occur leading to loss of 
nucleotides during the re-joining of strands. Inappropriate NHEJ can lead to telomere 
fusions and chromosomal translocations (Lieber et al. 2010). Failure or disruption of 
DNA repair pathways can cause permanent cell cycle arrest, cell death by apoptosis or 
can lead to unregulated cell division which can contribute to tumourigenesis.  
 
 Accumulation of DNA damage significantly contributes to the development of 
cancer due to the disruption of genes involved in the regulation of critical cell pathways 
such as proliferation. It is suggested that most cancer cells are genetically unstable due to 
selective pressures to lose their DNA repair pathway components. Therefore it is not 
surprising that a number of the components involved in DNA repair pathways have been 
found to be associated with both inherited and sporadic cancers (Jin & Robertson 2013). 
Hereditary nonpolyposis colorectal cancer (HNPCC) and lynch syndrome have both been 
associated with mutations in DNA mismatch repair (MMR) genes such as MLH1. 
Disruptions in MMR genes often lead to microsatellite instability which is a hallmark of 
HNPCC (Bellizzi & Frankel 2009; Andersen et al. 2012). BRCA1 and BRCA2 are well 
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known to be associated with both hereditary and sporadic breast cancer, both of these 
genes are important components of the HR DNA repair pathway and BRCA2 along with 
other known HR genes: PALB2, RAD51C and BRIP1, have also been associated with 
Fanconi anaemia (FA), a recessive disorder that is characterised by genomic instability 
and cancer susceptibility (Evers et al. 2010). Dysregulation of NHEJ can result in 
chromosomal rearrangements including deletions, insertions and translocations and thus 
can ultimately contribute to tumourigenesis in a number of ways, for example 
chromosomal translocations formed by inappropriate NHEJ can lead the formation of 
oncogenic fusion genes found in a number of human cancers (Kasparek & Humphrey 
2011) (see section 1.2).  
 
1.2    Chromosomal rearrangements 
Chromosomal rearrangements play an important role in human birth defects, 
infertility and cancer. In the general population the frequency of constitutional 
chromosomal rearrangements has been shown to vary in populations from 1/625 to 
1/5000 (Bandyopadhyay et al. 2002). These chromosomal aberrations can either be 
constitutional; those that are inherited from carrier parents or occur in the gametes and 
are therefore present in every cell of the body, and acquired; those that occur during the 
development or life of an organism (Page et al. 1996). They can be further divided into 
intra-chromosomal and inter-chromosomal rearrangements. Intra-chromosomal 
rearrangements are aberrations that occur in a single chromosome, either a single 
homologue or a pair of homologous chromosomes. The type of intra-chromosomal 
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aberrations that can occur include interstitial deletions and duplications (occur within the 
interior of a chromosome), terminal deletions and duplications (occur at the ends of a 
chromosome), inversions (a segment of a chromosome is flipped around and re-inserted) 
and isochromosomes (one arm is deleted and replaced with an exact copy of the other 
arm). Inter-chromosomal rearrangements involve two different chromosomes and occur 
in the form of chromosomal translocations which can be divided into Robertsonian and 
reciprocal translocations (Shaffer & Lupski 2000).  
 
1.2.1   Chromosomal translocations. 
Chromosome translocations are labelled using a standard system devised by the 
International System for Human Cytogenetic Nomenclature (ISCN), which designates 
that  t(A;B)(p1;q2) should be used where ‘t’ stands for translocation and A and B are the 
two chromosomes involved. The second parenthesis gives the exact location of the 
translocation where p refers to the short arm of the chromosome and q refers to the long 
arm. The numbers after p and q indicate the cytogenetic bands seen on the chromosome 
after staining (G-banding) which are numbered successively from the centromere 
outwards. Robertsonian translocations are denoted as rob(AqBq) where rob stands for 
Robertsonian and Aq and Bq refer to the long arms of each of the chromosomes involved 
(Gonzalez Garcia & Meza-Espinoza 2006).  
 
Robertsonian translocations occur in approximately 1/1000 individuals and 
involve whole arm exchanges between acrocentric chromosomes; chromosomes with 
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their centromere close to one end producing one very short arm and one long arm 
(Hamerton et al. 1975). There are five acrocentric chromosomes present in humans; 
chromosomes 13, 14, 15, 21 and 22. All possible combinations of acrocentric 
chromosomes in robertsonian translocations have been identified though their frequency 
is not random as rob(13q14q) and rob(14q21q) constitute for about 85% of all 
robertsonian translocations (Page et al. 1996) (Figure 1.3). 
 
Reciprocal translocations are the most common type of translocation and occur in 
approximately 1/625 individuals in the general population (Shaffer & Lupski 2000). They 
involve the transfer of material between two nonhomologous chromosomes and often 
results from a single break in each of the two chromosomes. All chromosomes have been 
shown to participate in reciprocal translocations. When there is no loss or gain of 
chromosomal material (on normal cytogenetic preps) the translocation can be described 
as balanced, conversely if there is a loss or gain of genetic material the translocation is 
said to be unbalanced (Strefford et al. 2009) (Figure 1.3). The majority of reciprocal 
translations are often random private events that are specifically found in related family 
members. However the recurrent t(11;22)(q23;q11.2) has been revealed to be relatively 
common in the general population and has been shown to be associated with increased 
risk of breast cancer (Youings et al. 2004; Lindblom et al. 1994). 
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Reciprocal translocations often occur at region specific low-copy repeats (LCRs); 
these repetitive regions of DNA are thought to predispose the region to nonhomologous 
recombination events that result in chromosomal rearrangements. The major 
recombination pathway thought to facilitate the occurrence of translocations is the repair 
of DNA double-strand breaks (DSB) by non-homologous end joining (NHEJ) (Pierce et 
al. 2001) (section 1.1.5). Other repetitive genomic regions that are often involved in 
chromosomal translocations include variable number tandem repeats (VNTRs) and AT-
rich regions (Stankiewicz & Lupski 2002). For example the common t(11;22) breakpoint 
has been mapped within a LCR on chromosome 22q and a 190bp AT-rich region on 
chromosome 11q (Edelmann et al. 1999).  
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Figure 1.3 Robertsonian and reciprocal chromosomal translocations. 
A, To the right a schematic diagram of a Robertsonian translocation where q 
stands for the q arm of the acrocentric chromosomes. The short arm fusions are 
often lost. To the left G-banding of chromosomes 13 and 14 showing rob(13q14q). 
B, To the right an illustration of a reciprocal translocation involving the ends of 
the q arms from each chromosome, disrupting two genes (shown as green or red 
bands) potentially creating a fusion gene(s). To the left G banding of 
chromosomes 9 and 22 showing t(9;22), der(22) shows the infamous  Philadelphia 
chromosome associated with CML.(G-band images taken  from Shamsi et al. 
2011; Czuchlewski et al. 2011). 
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1.2.2  Somatic chromosomal translocations in cancer 
Chromosomal translocations are frequently detected in human cancers and are 
divided into primary aberrations where by the translocation acts as an initiation event 
towards the development of cancer, or secondary aberrations that have been acquired due 
to clonal selection and often play a role in cancer progression (Mitelman et al. 2007). 
Reciprocal balanced translocations often produce fusion genes which can be found in a 
number of cancers for example the BCR/ABL fusion gene caused by the t(9;22) found in 
CML described in section 1.1.1 (Figure 1.3) and the fusion of ETS and EWS gene 
families caused by a number of different translocations often involved in Ewing’s 
sarcoma (Nambiar et al. 2008). In fact more than 350 fusion genes involving over 330 
different genes have been detected in a variety of cancers, though their prevalence varies 
considerably between tumour types with the majority occurring in malignant 
haematological disorders. (Mitelman et al. 2007).  Translocations that do not lead to the 
formation of fusion genes have also been detected in cancers including unbalanced 
translocations that lead to gene dysregulation due to the loss or gain of genetic material 
for example in acute lymphoblastic leukaemia a number of t(1;14) with interstitial 
deletions have been shown to disrupt the SCL (Stem cell leukaemia) gene locus causing 
dysregulation of SCL gene expression (Bernard et al. 1990). Translocations can also 
directly disrupt genes due to their position being at or close to the breakpoint for example 
t(1;17) reciprocal translocations have been characterised in neuroblastomas that lead to 
the dysregulation of a number of tumour suppressor genes found at the breakpoints 
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including the NF1 gene on chromosome 17 (Laureys et al. 1995).   In some instances 
translocations relocate genes close to or away from transcription enhancers leading to 
gene dysregulation for example the t(8;14) that causes the c-MYC oncogene to be 
overexpressed due to the neighbouring immunoglobulin enhancer previously described in 
section 1.1.1 (Joos et al. 1992).  
 
1.2.3   Chromosomal translocations used to identify candidate cancer genes 
Although many translocations have been detected in cancers it is important to 
determine which are primary and therefore disease causing aberrations and which are 
secondary aberrations. Translocations involved in disease initiation can be used to 
identify candidate disease genes which could become potential therapeutic targets. One 
method is to identify recurrent genomic aberrations found in particular cancers. Key 
genes within these regions can then be identified through breakpoint characterisation 
using techniques such as FISH and array-based profiling (see sections 1.2.4 and 1.2.5). 
Once a specific gene or a number of genes have been ascertained further investigation on 
copy number changes, mutation analysis, epigenetic changes and expression alterations 
can be undertaken in a larger sample cohort to determine if the genes are potentially 
disease causing, this method is outlined in Figure 1.4 (Albertson et al. 2003; Strefford et 
al. 2009). Common translocations in cancer syndromes have been used to identify 
candidate cancer causing genes for example the acquired t(5;12) is a rare translocation 
found in some cases of chronic myelomonocytic leukaemia (CMML) a myelodysplastic 
syndrome that often progresses to acute myeloid leukaemia. The t(5;12) was shown to 
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produce a fusion protein involving the PDGFR and TEL genes (Golub et al. 1994). This 
identification of PDGFR-TEL helped discover that TEL was also an important candidate 
gene in childhood acute lymphoblastic leukaemia where it often forms a fusion protein 
with AML1 (Golub et al. 1995).  
 
Familial constitutional translocations that correlate with a specific cancer can be 
used to determine candidate genes that may also play a role in the sporadic forms of that 
particular cancer, for example constitutional chromosomal aberrations involving 13q 
including translocations and deletions were shown to occur in a number of familial cases 
of retinoblastoma (Bunin et al. 1989). The 13q region was later revealed to contain the 
RB1 gene, shown to be disrupted in all sporadic and familial retinoblastoma cases 
(Horsthemke 1992).  
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Figure 1.4 Identifying cancer genes from disease associated translocations. 
A schematic diagram outlining one method to identify cancer causing genes 
from cancer associated translocation (Strefford et al. 2009). 
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1.2.4  FISH based cytogenetic techniques to detect chromosomal abnormalities 
There has been significant progress in cytogenetic analysis over the last decade 
which has allowed fast and accurate detection of structural aberrations using high 
resolution techniques. Although conventional techniques such as karyotyping and 
chromosome banding are still used today their detection is limited to the identification of 
microscopic structural abnormalities along with numerical abnormalities including 
aneuploidy and polyploidy (Sandberg 1985).  New high resolution methods have now 
been developed which allow detection of submicroscopic cytogenetic aberrations. These 
new techniques were initiated from the development of FISH (fluorescence in situ 
hybridisation) in the 1980s which involves designing specific fluorescently labelled DNA 
probes that are used to bind complementary target sequences often on metaphase spreads 
(Bauman et al. 1980). To label whole chromosomes for the detection of aberrations such 
as translocations, chromosome painting was introduced which utilises whole 
chromosome specific DNA probes as opposed to region specific probes (Cremer et al. 
1988). Since then a number of techniques have been developed that apply similar 
methods to the FISH technique while using different probes and/or target sequences, for 
example oligonucleotide probes have been used to increase resolution in oligonucleotide-
based high resolution FISH and chromatin fibres have been used instead of condensed 
chromosomes as target sequences in fibre-FISH methods (Yamada et al. 2011; Heng & 
Tsui 1998). Other FISH modified techniques allow detection of abnormalities on a whole 
genome scale for example comparative genome hybridisation (CGH) can be used to 
detect copy number differences between two genomes as well as multipoint-FISH and 
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SKY (spectral karyotyping) which allow detection of more complex rearrangements by 
labelling all chromosomes thus allowing identification of cytogenetic aberrations with no 
prior knowledge (Darai-Ramqvist et al. 2006; Schröck et al. 1996). Although useful in 
determining chromosomal aberrations at a higher resolution than chromosome staining 
these FISH based techniques are still restricted due to the use of chromosomes as target 
sequences (Scouarnec & Gribble 2012).  
 
1.2.5   Array based cytogenetic techniques to detect chromosomal abnormalities 
Array-based technologies involve the immobilisation of nucleic acid probes such 
as oligonucleotide probes which function as the arrays. RNA or DNA targets are then 
directed to the array surface where they hybridise to the complementary probes thus 
allowing for increased sensitivity and resolution as the targets can represent thousands of 
regions within the genome. Array-CGH is one of the more widely used array techniques 
and though originally the arrays consisted of large BAC (bacterial artificial 
chromosomes) clones they have recently been modified to consist of small 
oligonucleotide probes increasing resolution to up to a few kilobases (Fiegler et al. 2003; 
Barrett et al. 2004). Array-CGH enables the detection of deletions and amplifications 
allowing identification of unbalanced translocations though they cannot detect balanced 
aberrations such as inversions and reciprocal balanced translocations (Scouarnec & 
Gribble 2012).  Array painting is a relatively new technique that combines the methods of 
chromosome painting and CGH-arrays to allow fine mapping of chromosomal 
breakpoints. The technique initially involves the separation and isolation of the derivative 
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chromosomes involved in the translocation by flow sorting. The flow-sorted derivative 
chromosomes are then amplified using techniques such as whole genome amplification 
and are labelled with fluorescent dyes then co-hybridised onto a high-resolution 
oligonucleotide array (Gribble et al. 2009). These high-resolution techniques allow more 
precise breakpoint characterisation and have enabled sequencing of exact breakpoint 
positions (Gribble et al. 2007) (Figure 1.5). 
  
The development of next-generation sequencing allows the sequencing of the 
whole human genome which can now be completed in a few days at a much lower cost 
(Coffey et al. 2011). This technique could now be utilised to determine chromosome 
aberrations by sequencing isolated chromosomes or derivative chromosomes which when 
aligned to the reference genome could be used to detect all types of chromosome 
aberrations including deletions, duplications, insertions, balanced/unbalanced 
translocations and inversions, thus providing a more rapid and accurate method to 
determine cytogenetic abnormalities (Scouarnec & Gribble 2012).  
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Figure 1.5 Array painting used to map chromosomal translocations. 
Diagram of the main steps involved in oligonucleotide array painting involving 
separation and amplification of the derivative chromosomes which are then 
fluorescently labelled with cyanine 5 (cy5) or cy3 and co-hybridised to the 
oligonucleotide array (to the right) and a schematic illustration of the processed array 
data showing the change in cy5 (red)/ cy3 (green) ratio at the breakpoint position 
(yellow) (to the left) (Gribble et al. 2009). 
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1.3     Renal cell carcinoma 
Renal cell carcinoma (RCC) attributes for approximately 85% of all renal cancers 
and 3% of total adult malignancies (Bodmer et al. 2002). It is a heterogeneous disease 
with varying histopathology based on the cell type and location in the nephron. Clear cell 
RCC (ccRCC) is the most common form of RCC and accounts for 60-80% of all sporadic 
renal carcinomas. Other histopathologies include papillary types I and II (10-15%), 
oncocytomas (~5%) and chromophobe tumours (~5%). ccRCC and papillary RCC 
originate from the epithelial cells of the proximal part of the renal tube and 
chromophobes and oncocytomas originate from the collecting tubule of the nephron 
(Oosterwijk et al. 2011). A number of newly identified RCCs were recently recognised 
which contribute to <1% of RCCs including translocation-linked carcinoma that arises 
from the proximal tubule and results in the MiTF/TFE fusion genes, mucinous tubular 
and spindle cell carcinoma both originating from the loop of Henle and tubulocystic 
carcinomas that develop from the collecting tubule (Argani & Ladanyi 2005; Yang et al. 
2010; Deshmukh et al. 2011). RCCs can be further classified due to marked (cyto)genetic 
differences associated with each histopathology, this was originally demonstrated by the 
Mainz classification in 1986 and the Heidelberg classification of renal tumours in 1997 
(Thoenes et al. 1990; Kovacs et al. 1997). More recently a renal cell tumour classification 
was proposed by the World Health Organization (WHO) in 2004, and updated in 2009, 
which is summarised in Table 1.1 (Lopez-Beltran et al. 2006; Lopez-Beltran et al. 2009).  
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RCC subtype Clear cell Papillary Chromophobe Collecting 
ducts of 
Bellini 
Medulary Multilocular 
cystic 
Xp11 
translocation 
After 
neuroblastoma 
Mucinous 
tubular and 
splindle cell 
 
Unclassified 
 
Incidence 
 
75% 
 
10% 
 
5% 
 
1% 
 
Rare 
 
Rare 
 
Rare 
 
Rare 
 
Rare 
 
4-6% 
Development Solitary, rare 
multicentric or 
bilateral 
Multicentric, 
bilateral or 
solitary 
Solitary Solitary Solitary Solitary, rare 
bilateral 
Solitary Solitary Solitary Solitary 
Cell/tissue 
characteristics 
clear 
cytoplasm; 
cells with 
eosinophilic  
cytoplasm 
occasionally 
Type 1 
(basophilic) or 
type 2 
(eosinophilic) 
Pale or 
eosinophilic 
granular 
cytoplasm 
Eosinophilic 
cytoplasm 
Eosinophilic 
cytoplasm 
clear 
cytoplasm, 
small dark 
nuclei 
Clear and 
eosinophilic 
cells 
Eosinophilic cells 
with oncocytoid 
features 
Tubules, 
extracellular 
mucin and 
spindle cells 
Variable, 
sarcomatoid 
Growth 
pattern 
Solid, tubular, 
cystic, rare 
papillae 
Tubulo-
papillary, solid 
Solid Irregular 
channels 
Reticular 
pattern 
Cystic, no 
solid 
component 
Tubulo-
papillary 
Solid Solid Solid 
Prognosis Aggressiveness 
according to 
grade, stage 
and 
sarcomatoid 
change 
Aggressiveness 
according to 
grade, stage 
and 
sarcomatoid 
change 
10% mortality Aggressive, 
2/3 of 
patients die 
within two 
years 
Mean 
survival of 
15 weeks 
after 
diagnosis 
No 
progression or 
metastases 
Indolent Related to grade 
and stage 
Rare 
metastases, 
High 
mortality 
Somatic 
genetic 
changes 
−3p, +5q22, 
−6q, −8p, −9p, 
−14q,  VHL 
gene mutation 
+3q, +7, +8, 
+12, +16, +17, 
+20, −Y 
−1, −2, −6, 
−10, −17, −21, 
hypodiploidy 
−1q, −6p, 
−8p, −13q, 
Unknown VHL gene 
mutation 
t (X; 1) 
(p11.2; q21), t 
(X; 17) 
(p11.2; q25), 
Other 
Allelic imbalance 
at 20q13 
−1, −4, −6, 
−8, −13, 
−14, +7, 
+11, +16, 
+17 
Unknown 
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1.3.1   Familial RCC 
Although familial RCC accounts for only ~2% of all RCCs it is the study of these 
inherited forms which has provided important clues into the pathogenesis of the more 
common sporadic forms of the disease.  Familial RCCs often present at an earlier age 
than sporadic RCCs and are frequently caused by inherited syndromes that predispose to 
RCC. VHL (Von Hippel-Lindau) disease is the most common cause of familial RCC and 
is characterised by a predisposition to the development of ccRCC (>70% lifetime risk), 
haemangioblastomas of the central nervous system, renal, pancreatic and epidydmal cysts 
and pancreatic islet cell tumours (Maher et al. 1990). It was found to be caused by 
disruptions in the VHL tumour suppressor gene (Latif et al. 1993). Following its 
identification the VHL gene was subsequently shown to be mutated in up to 70% of 
sporadic clear cell RCCs (Crossey et al. 1994; Gnarra et al. 1994). Other inherited 
syndromes that predispose to RCC include Birt-Hogg-Dubé syndrome caused by 
disruptions in the folliculin (FLCN) gene, hereditary leiomyomatosis and renal cancer 
associated with mutations of the fumarate hydratase (FH) gene, hereditary 
pheochromocytoma-paraganglioma syndromes are caused by mutations in the subunits of 
succinate dehydrogenase (SDHB, SDHC and SDHD) and Hereditary Papillary RCC 
syndrome correlating with mutations in the proto-oncogene c-MET (Maher 2011) (Table 
1.2). In nonsyndromic cases of familial RCC the genetic basis of the disease is often 
unknown although in some cases germline mutations of FLCN and SDHB have been 
Table 1.1 Known clinico-pathological and genetic features of sporadic RCC tumours. 
Table adapted from Lopez-Beltran et al. 2009. 
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detected with no clinical evidence of the RCC susceptibility syndromes (Silva et al. 2003; 
Woodward et al. 2008; Ricketts et al. 2008). 
 
Constitutional chromosome 3 translocations have been shown to be associated 
with nonsyndromic familial RCCs in a small number of cases. The first was a 
constitutional t(3;8)(p14;q24) translocation found in a large family, with ten family 
members developing RCC, while RCC did not develop in non-translocation carriers (A. 
J. Cohen et al. 1979). Since then 6 more constitutional translocations involving 
chromosome 3 have been associated with familial RCC these include t(2;3)(q35;q21), 
t(3;6)(q11.2;q13), t(2;3)(q33;q21), t(1;3)(q32;q13.3), t(3;8)(p13;q24) and  
t(3;8)(p14;q24.1) (Koolen et al. 1998; Kessel et al. 1999; Bonne et al. 2007; Podolski et 
al. 2001; Kanayama et al. 2001; Meléndez et al. 2003; Poland et al. 2007). A number of 
RCC cases that involve single individuals with chromosome 3 constitutional 
translocations have also been reported; t(3;12)(q13.2;q24.1), t(3;6)(p13;q25.1), 
t(3;4)(p13;p15), t(3;15)(p11;q21), t(3;6)(q22;q16.2) and t(3;4)(q21;q31)  (Kovacs & 
Hoene 1988; Kovacs et al. 1989; Kessel et al. 1999; Bonne et al. 2007; Foster et al. 2007; 
Kuiper et al. 2009).  
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Syndrome Gene Tumour 
   
Von Hippel-Lindau (VHL) VHL (3p25) Clear cell 
Tuberous Sclerosis TSC1, TSC2 Angiomyolipoma, clear 
cell, other 
Constitutional chromosome 3 
translocation 
Responsible gene not 
found* 
Clear cell 
Familial renal carcinoma Gene not identified (rare 
FLCN, SDHB) 
Clear cell 
Hereditary PRCC MET Papillary type 1 
Birt-Hogg-Dube (BHD) FLCN Chromophobe** 
Familial oncocytoma Partial or complete loss 
of multiple chromosome 
Oncocytoma 
Hereditary leiomyoma-RCC FH Papillary type 2 
Hereditary pheochromocytoma-
paraganglioma syndromes 
SDHB, SDHC, SDHD Clear cell 
 
 
Table 1.2 Inherited syndromes and known genes that predispose to familial RCC. 
*VHL gene mutated in some families. **Renal oncocytomas, hybrid oncocytic and clear 
cell carcinomas may occur. RCC = Renal cell carcinoma; PRCC = Papillary RCC 
(Lopez-Beltran et al. 2009) 
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1.3.2   Familial constitutional translocations used to identify candidate RCC genes 
Loss of heterozygosity of 3p in sporadic ccRCC has been reported by numerous 
groups with not all demonstrating a loss or aberration of the VHL locus 3p25, thus 
suggesting other important tumour suppressor genes, apart from VHL, reside within the 
3p region (D Bodmer et al. 1998; Martinez et al. 2000). Other common deleted 3p 
regions include 3p12, 3p14.2, 3p21.3 and studies involving chromosome transfer of 
3p12-p21, 3p14-p21, and 3p21-p22 fragments into sporadic RCC cell lines demonstrated 
significant tumour suppression and rapid cell death (Killary et al. 1992; Sanchez et al. 
1994). Non ccRCCs are rarely associated with 3p deletions or VHL aberrations and rare 
kindreds with familial non-VHL ccRCC have been detected, thus evidence suggests there 
are VHL-independent pathways involved in RCC tumourigenesis (Woodward et al. 2000; 
Woodward et al. 2008).   The characterisation of translocation breakpoints associated 
with RCC has helped to identify a number of candidate tumour suppressor genes, many 
found within the 3p region, involved in sporadic RCC. 
 
The t(3;8)(p14.2;q24.1) was found in a family with a number of cases of familial 
RCC (Cohen et al. 1979). The breakpoint was cloned and it was determined that the 
FHIT gene on chromosome 3p14.2 and the TRC8 gene on chromosome 8q24.1 were 
disrupted producing a fusion gene (Poland et al. 2007). One sporadic RCC was found to 
carry a TRC8 mutation and TRC8 was shown to inhibit growth of cancer cell lines and 
directly interact with VHL (Gemmill et al. 1998; Gemmill et al. 2002; Gemmill et al. 
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2005). FHIT is a TSG found on the chromosme 3p arm that is often deleted in ccRCC 
and was shown to be methylated in >50% of ccRCC (Sükösd et al. 2003; Kvasha et al. 
2008).  A t(1;3)(q32.1;q13.3) breakpoint was identified in a family with four cases of 
ccRCC. The breakpoint was cloned which led to the identification of breakpoint spanning 
genes NORE1 at 1q32.1 and LSAMP at 3q13.3. Both genes were found to be 
epigenetically inactivated in a number of sporadic ccRCCs and further research identified 
them to have tumour suppressing properties (Chen et al. 2003). Recently the 
characterisation of a t(3;4)(q21;q31) found in one individual with RCC allowed the 
identification of a disrupted gene, FBXW7, a known tumour suppressor gene found to be 
disrupted in other cancers (Welcker & Clurman 2008). FBXW7 is part of an E3 ubiquitin 
ligase complex involved in the proteasomal degradation of several oncogenic proteins 
involved in growth and cell cycle progression including mTOR and cyclin E1 (Zhang & 
Koepp 2006; Akhoondi et al. 2007; Mao et al. 2008). FBXW7 has subsequently found to 
be mutated in a small number of sporadic RCC (Kuiper et al. 2009; Guo et al. 2011). 
Other potential candidate genes found to be disrupted at translocation breakpoints 
associated with RCCs include DIRC3 and HSPBAP1 in a t(2;3)(q35;q21) translocation 
and KCNIP4 in a t(3;4)(p13;p15) translocation (Bodmer et al. 2003; Bonne et al. 2007)  
 
In some cases there are no candidate genes found within the vicinity of the 
breakpoints of associated familial RCC translocations and in these cases a ‘three hit’ 
model has been proposed; the initial translocation increases chromosome instability of 
the derivative chromosome involving chromosome 3, this increased instability ultimately 
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leads to the loss of the derivative containing part of the chromosome 3 arm which also 
includes one of the VHL alleles, the third hit involves the disruption of the second VHL 
allele leading to tumourigenesis (Clifford et al. 1998; Bodmer et al. 1998; Meléndez et al. 
2003). A recent population study has shown that there is little increased risk of 
developing RCC in chromosome 3 translocation carriers with no family or personal 
history of RCC (Woodward et al. 2010). This suggests that where there is an association 
with RCC it is likely that the breakpoints have disrupted gene(s) critical in 
tumourigenesis of RCC thus the positioning of the chromosome 3 translocation 
breakpoints are important.  
 
1.3.3  Sporadic RCC 
The majority of RCCs (98%) are sporadic and although VHL was found to be 
mutated >70% of sporadic clear cell RCCs (ccRCC), other familial RCC associated genes 
were found to be rarely disrupted in the sporadic forms. Loss of genetic material leading 
to inactivation of TSGs is often detected in sporadic renal cancers (Wilhelm et al. 2002). 
In ccRCC after the deletion of 3p, the most common chromosomes to exhibit loss of 
heterozygosity (lOH) with deletions detected in 20-40% of ccRCC include 6, 8, 9 and 14. 
Less frequent chromosome deletions have also been detected in chromosomes 18q, 17p, 
13q, 10q, 4 and 1 (Cairns 2010). A small number of known TSGs reside in these deleted 
regions including p53 on 17q, PTEN on 10q, Retinoblastoma (RB) on 13q and CDKN2A
 
on 9p. Point mutations of p53 and RB are very rare in RCC and a small number of 
homozygous deletions of both CDKN2A and PTEN have been detected in sporadic 
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ccRCC, therefore these TSGs are only disrupted in a minority of sporadic ccRCC 
(Vignoli & Martorana 1997; Cairns et al. 1995; Brenner et al. 2002). Tumour suppressor 
genes have thus far not been identified that reside in the more commonly deleted regions 
6q, 8p or 14q in ccRCC. In 2011 a whole exome sequencing project identified PBRM1 
gene complex truncating mutations in 92/227 (41%) of sporadic ccRCC and in 88/257 of 
non clear cell RCC thus suggesting PBRM1 is a major sporadic RCC candidate gene 
(Varela et al. 2011).  PBRM1 is a component of the SWI/SNF chromatin-remodeling 
complex and the same study identified RCC mutations in other components of the 
complex including ARID1A and ARID5B, though at much smaller frequencies. An earlier 
exome sequencing study reported histone modification genes MLL2, JARID1C, UTX and 
SETD2 to be mutated in 12-17% of ccRCC. Thus suggesting chromatin remodeling and 
histone modification pathways play an important role in ccRCC (Dalgliesh et al. 2010).  
 
The MET proto-oncogene functions as a receptor tyrosine kinase that becomes 
activated when its ligand, the hepatocyte growth factor, binds. Germline activating point 
mutations within the tyrosine kinase domain of MET were found to cause hereditary 
papillary RCCs (Schmidt et al. 1997). MET was found to be mutated in a small number of 
sporadic papillary RCCs with one study showing activating mutations in 17/129 (13%), 
though germline MET mutations were later detected in 8 of the 17 cases even though no 
family history was present (Schmidt et al. 1999). The MET gene resides on chromosome 
7 and most papillary RCCs demonstrate trisomy 7 without MET mutations, thus although 
this may not be as oncogenic as activating mutations, the increased expression of MET 
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may present a growth advantage (Zhuang et al. 1998). Other common events in papillary 
RCC include trisomy 17 and loss of chromosome Y in men. Chromosomes 6, 8 and 14 
have also demonstrated LOH in papillary RCC, which interestingly are the same 
chromosomes to show LOH in ccRCC, other than 3p (Kovacs et al. 1991). 
 
Chromophobe RCCs often (75-100%) exhibit monosomy of multiple 
chromosomes including 1, 2, 6, 10, 13, 17, and 21. Deletions of 9p, 8p and 3p have also 
been detected in 25% of Chromophobe RCCs (Speicher et al. 1994). Although folliculin 
(FLCN) mutations are found in the inherited Birt-Hogg-Dube (BHD) syndrome that 
predisposes to RCCs including chromophobe RCC (23%) and chromophobe RCC with 
oncocytoma (67%), FLCN mutations are rarely found in sporadic chromophobe RCCs 
(Toro et al. 2008; Nagy et al. 2004). However p53 point mutations have been reported in 
24-30% of sporadic chromophobe RCCs (Contractor et al. 1997; Gad et al. 2007). 
 
Excluding VHL, most known familial RCC genes have not been shown to be 
associated with the sporadic forms of the disease. Although a number of candidate RCC 
genes have been found many of these genes are often only disrupted in the minority of 
cases, thus it is essential that new candidate genes are identified to allow deeper insight 
into the mechanisms of RCC tumourigenesis which could lead to improved therapeutic 
outcomes. 
 
 57 
 
1.3.4  Epigenetics in RCC 
VHL was among the first TSGs to be shown to be epigenetically silenced via 
promoter methylation in RCCs (Herman et al. 1994). Since then over 60 TSGs have been 
shown to be dysregulated in RCCs due to promoter methylation including the RASSF1 
TSG which maps to the 3p21 loci often deleted in RCCs as well as other cancers (Mark R 
Morris & Eamonn R Maher 2010). Mutations in RASSF1 are rarely found in cancers thus 
epigenetic silencing was shown to be the major mechanism of RASSF1 gene inactivation 
with promoter methylation occurring in approximately 51% of RCC cases and often as 
biallelic inactivation or as a second hit after 3p deletion (Morrissey et al. 2001; Lusher et 
al. 2002). RASSF1 methylation is thought to be an early initiation event in RCC 
tumourigenesis as analysis of normal kidney tissue adjacent to the tumour showed 
aberrant RASSF1 methylation which was not detected in kidney tissue further away from 
the tumour (Costa et al. 2007). Thus epigenetic inactivation of TSGs in RCC could be an 
important initiation event suggesting both genetic and epigenetic analysis are necessary 
in identifying important candidate cancer genes.  
 
Activation of the Wnt pathway leads to cell proliferation and survival and thus 
contains a number of oncogenes often activated in cancers (Vincan 2004). Inhibitors of 
this pathway have been shown to be hyper-methylated in a number RCCs including the 
SFRP (Secreted Frizzled-Related Proteins) proteins (47-73%) which prevent Wnt 
signalling by binding to the Wnt protein and the DKK (Dickkopf) proteins (44-58%) 
which bind to the Wnt receptor (Morris & Maher 2010). A number of these Wnt pathway 
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inhibitors shown to be methylated RCCs have been investigated as potential RCC 
prognostic biomarkers for example SFRP1 methylation showed a negative correlation 
with RCC patient survival in two independent studies and both DKK1 and DKK2 
methylation were shown to positively correlate with pathological grade (with high graded 
tumours often correlating with poor prognosis) (Dahl et al. 2007; Awakura et al. 2008; 
Hirata et al. 2009; Hirata et al. 2011). Further identification of novel methylated TSGs in 
RCC could potentially help to identify novel pathways involved in RCC tumourigenesis 
and lead to new therapeutic targets. 
 
1.3.5  VHL substrates and RCC treatment 
30% of RCC cases present with metastatic RCC which is often highly resistant to 
conventional chemotherapy, and immunotherapy produces modest results. The 5 year 
survival rate is less than 10% of patients with advanced RCC (Cáceres & Cruz-Chacón 
2011).  Studies into the function of the VHL protein as well as other RCC candidate 
genes have helped identify new therapeutic targets leading to the development of RCC 
targeted therapy. 
 
The VHL protein was shown to be part of an E3 ubiquitin ligase multiprotein 
complex (including elongins B and C, cullin-2, and the RBX-1 proteins) involved in the 
ubiquitination of specific target proteins (Conaway et al. 1998). VHL has two functional 
domains, the α domain which interacts with elongin C in the complex while the β domain 
acts as a substrate receptor recruiting target proteins into the complex including the HIFα  
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subunit (Ohh 2006). HIF is a transcription factor consisting of α and β subunits. The β 
subunit is constitutively expressed whereas the α-subunit is regulated depending on the 
oxygen level of the cell (Semenza 2001). When oxygen levels are adequate the HIFα 
subunits undergoes prolyl-hydroxylation via a prolyl hydroxylase (PHD) and is recruited 
to the VHL β domain in the ubiquitin complex and is degraded through ubiquitylation 
and proteasomal degradation (Ohh et al. 2000). In hypoxic conditions the HIFα subunit 
does not undergo prolyl-hydroxylation and therefore does not bind to VHL and instead 
heterodimerizes with the β subunit in the nucleus and binds to hypoxia response elements 
(HREs) promoting the transactivation of hypoxia-inducible genes (Semenza 2001). 
Inactivation of the VHL gene leads to a similar outcome as hypoxic conditions, thus the 
HIFα subunit can no longer bind to VHL and is therefore not degraded leading to the 
expression of HIFα target genes such as VEGF (Maxwell et al. 1999). Other substrates of 
the VHL ubiquitin complex that have been identified and include VHL-interacting de-
ubiquitinating enzyme (VDU1), atypical protein kinase C (aPKC) and substrates of RNA 
polymerase II (POLR2G) (Li et al. 2002; Okuda et al. 1999; Na et al. 2003; Cockman et 
al. 2000). There are over 60 hypoxia-inducible genes transactivated by HIF including 
platelet-derived growth factor (PDGF) a known oncogene, vascular endothelial growth 
factor (VEGF) involved in angiogenesis promotion and the transforming growth factor α 
(TGFα) which activates the epidermal growth factor receptor (EGFR) (Dibb et al. 2004; 
Veikkola & Alitalo 1999; Ananth et al. 1999). The functions of these hypoxia-inducible 
genes have been shown to be involved in the development of cancer thus making the α-
subunits of HIF (HIF1α and HIF2α) the most likely VHL-ubiquitin complex substrates to 
 60 
 
play a vital role in the development of ccRCC (Maynard & Ohh 2007). It has also been 
demonstrated the majority (>50%) of ccRCCs show up-regulation of HIF target genes 
including VEGF. 
 
 Bevacizumab is a recombinant human monoclonal anti-VEGF antibody capable 
of neutralizing VEGF isoforms (Presta et al. 1997). Bevacizumab combined with IFN-α 
was used in a phase III trial with ccRCC patients, and showed increased progression free 
survival time compared to a placebo (Escudier et al. 2007). TGF-α is a ligand for the 
EGF receptor (EGFR) which activates a number of pathways including the MAPK 
pathway and AKT pathways that can lead to cell proliferation. Gefitinib, an EGFR 
inhibitor, has been tested in an RCC phase II trial with patients showing disease stability 
(Dawson et al. 2004). Multikinase inhibitors are a group of therapeutics that inhibit the 
downstream effects of growth factors. A number of multikinase inhibitors were found to 
show positive effects in the treatment of RCC, for example Sorafenib, originally found as 
a Raf inhibitor, was shown to also inhibit other kinases including VEGFR and PDGF-β 
(S. M. Wilhelm et al. 2004). Sorafenib has shown positive effects in a phase II trial with 
metastatic RCC patients showing tumour shrinkage and increased progression free 
survival time (Ratain et al. 2006). Other multikinase inhibitors which have been used in 
RCC treatment trials include Sunitinib, Pazopanib and Axitinib which have all shown 
increased progression free survival and/or disease stability in clinical trials (Motzer et al. 
2007; Sonpavde et al. 2008; Rini et al. 2009). HIF protein translation (along with many 
other proteins) is regulated via the mTOR pathway. Temsirolimus an inhibitor of mTOR 
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activity was used in a large trial with untreated RCC patients and showed increased 
progression free survival and over-all survival time (Hudes et al. 2009).  
 
 These new biological agents have shown positive effects in the treatment of RCC 
such as increased progression free survival, improvements in quality of life and increased 
survival time. In fact it has been estimated that targeted RCC therapies have increased the 
overall survival of metastatic RCC from 10 months to 40 months with an average 
progression-free survival of 27 months (Sun et al. 2010). Yet there is still no curative 
treatment for metastatic RCC. The discovery of other important pathways involved in 
RCC tumourigenesis could lead to better understanding of the molecular events driving 
RCC initiation and progression which could eventually lead to the development of new 
biological agents that further improve the survival rate of RCC patients. Due to the clonal 
diversity within a tumour it is likely that a cocktail of therapeutic agents that target the 
key pathways involved in RCC would be the most effective method to eradicate the 
cancer, as the use of single targeted therapeutic agents inevitably leads to the outgrowth 
of resistant sub-populations within the tumour, due to selective pressure (Greaves & 
Maley 2012). Therefore it is important that further research is undergone to understand 
the key mechanisms that lead to the initiation and progression of RCC.   
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1.4    The ubiquitin pathway  
Ubiquitin is a small, 8.5KDa protein that is ubiquitously expressed in eukaryotic 
organisms and is highly conserved between species. Ubiquitin is attached to protein 
substrates (termed substrate ubiquitylation) within the cell and labels them for a specific 
fate, for example to be degraded by the proteasome (Herrmann et al. 2007). These 
ubiquitin tags essentially direct proteins to different locations within the cell thereby 
controlling the fate of many proteins. There are many ubiquitin pathways in human cells 
that are involved in the ubiquitylation of specific protein substrates producing a highly 
effective mechanism for the regulation of almost all cellular biology. Ubiquitin is a 
member of a highly conserved family of proteins termed the ubiquitin-like proteins 
(UBLs) that include SUMO, ISG15, NEDD8, URM1, FAT10, ATG8, ATG12, FUB1, 
UFM1 and UBL5, these ubiquitin-like proteins function as tags that can be attached to 
substrate proteins and control the protein fate via a number of mechanisms depending the 
type of ubiquitn-like molecule attached  (Welchman et al. 2005). The major steps in the 
ubiquitin pathways involve the activity of a ubiquitin-activating enzyme (E1), a 
ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3) (Herrmann et al. 2007). In 
the human genome two E1 enzymes have been identified which produce a thioester bond 
between their active cysteine (Cys) residue and the carboxy terminus of ubiquitin in an 
ATP dependent reaction. Ubiquitin is then transferred from the E1 to the active Cys 
residue in the ubiquitin-conjugating domain (UBC) of an E2 enzyme which would then 
engage an E3 enzyme to undergo substrate ubiquitylation (Schulman & Harper 2009). 
E3s bring the specific protein substrate and the ubiquitin charged E2 together which 
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initiates the ligation of the ubiquitin to a specific lysine (Lys) residue in the substrate 
(Yihong & Rape 2009) (Figure 1.6). E3s are categorized into three main groups: RING-
finger-type, HECT-type and U-box-type. RING-finger-type E3s are subdivided into 
families including the cullin-based E3s which are one of the larger classes of E3s (Ardley 
& Robinson 2005).  There are at least 38 active E2 enzymes and up to 1000 E3 enzymes 
in the human genome thus often a single E2 enzyme is able to interact with several E3s 
(Yihong & Rape 2009). 
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Figure 1.6 The ubiquitin pathway 
Schematic illustration of the ubiquitin pathway involving the ubiquitylation of protein 
substrates via a hierarchical group of three enzymes: a ubiquitin-activating enzyme (E1), 
a ubiquitin-conjugating enzyme (E2) and a ubiquitin ligase (E3). E1s are loaded with 
ubiquitin (Ub) through an ATP dependent mechanism. Ub is transferred to an E2 enzyme 
bound by a thioester linkage on an active cys residue found in the E2 ubiquitin binding 
domain. E3 enzymes are often complexes containing a number of enzyme components 
that bind specific substrates as well as the loaded E2s. The Ub is transferred from the E2 
to specific Lys residues found on the substrates. The E2 is then reloaded with Ub and the 
cycle starts again (image adapted from Ye & Rape 2009). 
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  The number of ubiquitin molecules and type of linkages within a ubiquitin chain 
attached to a substrate has been shown to affect substrate outcome, for example substrate 
proteins can be attached with a single ubiquitin protein on one (monoubiquitylation) or 
many (multi-monoubiquitylation) Lys residues (Pickart & Fushman 2004). 
Polyubiquitylation involves the addition of a chain of ubiquitin molecules which are 
linked to each other via one of seven Lys (K) residues within ubiquitin (K48, K63, K11, 
K6, K27, K29 or K33) or the amino terminus ( Li & Ye 2008). Branches of ubiquitin 
molecules extending from ubiquitin chains as well as multiple ubiquitin chains have been 
detected on substrates though the significance of these is unknown (Kim et al. 2007). 
Ubiquitylated substrates are then recognised by a number of proteins all containing types 
of ubiquitin-binding motifs, for example ubiquitin-associated domains (UBA) and 
ubiquitin-interacting motifs (UIM), often these ubiquitin binding proteins show a 
preference to specific ubiquitin conjugates such as ubiquitin chains linked together via a 
specific lys residue i.e. Lys48-ubiquitin chains attract proteins that chaperone the 
substrates for proteasomal degradation (Dikic et al. 2009; Richly et al. 2005). Ubiquitin 
binding proteins often bind downstream components of signalling pathways thus 
combining ubiquitylation with a specific biological effect for example NEMO (NF-
kappaB essential modulator) a protein that binds lys63-ubiquitin chains has been shown 
to facilitate NFκB (nuclear factor κB) activation (Hadian et al. 2011) (Figure 1.7).  
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Figure 1.7 Ubiquitin chains and substrate outcomes 
Schematic representation of the known Ubiquitin (Ub) modifications along with their 
known and predicted functional outcomes. A single Ub can be attached to a substrate 
(monoubquitylation) or as a chain of multiple ubs (polyubiquitylation) attached via 5 
different lysine (lys) residues (Lys48, lys11, lys63, lys6, lys27, lys29 or lys33). In some 
cases ub molecules can also be attached via their amino terminus (N). (Yihong & Rape 
2009).  
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1.4.1    Ubiquiting conjugating enzymes (E2s) – not just ubiquitin carriers 
E2 enzymes are distinguished by a conserved 150-200 amino-acid ubiquitin-
conjugating domain (UBC) which contains the catalytic active cysteine that binds 
ubiquitin via a thioester bond (Wijk & Timmers 2010). E2 enzymes can bind a number of 
E3s thus affecting substrate ubiquitylation however the rules defining how an E2 chooses 
which E3 it binds to and when is a question for future research, though it is known that 
E3 binding motifs within the E2 proteins contain slight variations leading to specific E3 
binding (Zheng et al. 2000). E2-E3 interactions are usually very weak this is thought to 
be due to the fact that the E2 regions used to bind E3s overlap with the regions used to 
interact with E1s. This suggests an E2 cannot be charged with a ubiquitin by an E1 while 
still bound to an E3, thus instead must undergo numerous cycles of E3 binding and 
dissociation to recharge during ubiquitin chain formation (Yihong & Rape 2009). As E3 
enzymes bind specific substrates they were originally seen as the sole enzymes that 
brought substrate specificity to the ubiquitin cascade with E1 and E2 enzymes described 
simply as ubiquitin carriers. Recent research has indicated that E2s play an important role 
in the biological outcome of a substrate as the length and type of ubiquitin chains 
assembled by the E2 can affect the fate of the substrate (Li & Ye 2008). 
 
It has been demonstrated that the choice of whether or not a lys residue in the 
substrate and/or ubiquitin will receive the next ubiquitin is made by the E2s as recent 
research has shown specific E2s are involved in ubiquitin chain initiation while others are 
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involved in chain elongation (Windheim et al. 2008). Ubiquitin chain assembly is often 
initiated by the binding of a single ubiquitin to the lys residue on a substrate protein. This 
first mono-ubiquitin initiation step is often carried out by a specific E2 which is then 
replaced by a different E2 that carries out ubiquitin chain elongation, for example the 
APC/C E3 complex uses the Ubc4 E2 to initiate ubiquitin chain formation while the E2 
Ubc1 is then used to extend Lys-48 ubiquitin chains (Rodrigo-Brenni & Morgan 2007; 
Jin et al. 2008). Ubiquitin chain elongation E2s most often lack the ability to initiate 
chain formation themselves for example the UBE2N and UBE2V1 lys-63 specific E2s 
and the UBE2S lys11 specific E2 are unable to initiate ubiquitin chain formation and are 
therefore chain elongation specific E2s (Windheim et al. 2008). Substrates can attach 
ubiquitin on a number of lys residues, some initiation E2s can bind ubiquitin non-
specifically to any lys residue allowing them to initiate ubiquitylation on many substrate 
types using numerous E3s (Kirkpatrick et al. 2006). Other E2s appear to be selective and 
only transfer ubiquitin to particular lys residues on substrates by recognising certain 
residues in close proximity to the lys residue thus providing specificity, for example 
UBE2T only mono-ubiquitylates specific lys residues on the substrate FANCD2 and is 
unable to catalyse ubiquitin chain extension (Alpi et al. 2008). E2 enzymes have 
therefore been shown to provide another level of substrate specificity, alongside the 
substrate receptor E3s, within the ubiquitin pathway cascade. 
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1.5    The ubiquitin pathway in cancer 
 Ubiquitylation of substrate proteins via the ubiquitin pathway can affect the 
substrates in a number of ways including protein stability, interactions and localisation. 
This in turn can lead to global cell signalling variations in pathways involved in 
proliferation, apoptosis, DNA repair and the cell cycle (Kirkin & Dikic 2007). 
Dysregulation of these cell signalling pathways can provide an advantage to cancerous 
cells leading to tumourigenesis, thus it is not surprising that defects in the ubiquitin 
machinery have been detected in a number of cancers (Kirkin & Dikic 2011).   
 
1.5.1   Ubiquitin ligase enzymes (E3s) and their involvement in cancers 
Many types of E3 ligases are involved in the regulation of oncogene and/or 
tumour suppressor gene expression levels within human cells including the SCF (SKP1–
CUL1–F-box), ECV (Elongin B/C-cullin 2-VHL) and APC/C (anaphase-promoting 
complex/cyclosome) E3 complexes, see Figure 1.8 (Kitagawa et al. 2009). These three 
E3 complexes are structurally very similar, consisting of four specific subunits including 
a RING-finger protein, scaffold protein, adaptor protein and a substrate specific subunit 
(Nakayama & Nakayama 2006). VHL  is the only identified substrate specific subunit for 
the ECV complex whereas the SCF and APC/C complexes have a number of substrate 
specific subunits including more than 70 F-box proteins that bind the SCF complex and  
CDC20 and CDH1 that bind the APC/C complex (Jin et al. 2004; Kraft et al. 2005). 
Various substrates have been identified for all three E3 complexes as shown in Figure 
1.8. 
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Figure 1.8 The structure and substrates of the SCF, EVC and APC/C ubiquitin ligase 
complexes  
SCF, ECV and APC/C E3 ligases are comprised of similar components including a 
RING-finger protein: RBX1 or APC11 (an RBX1-related protein), a scaffold protein: 
cullin-1/2 or APC2 ( a CUL1- related protein), an adapter protein SKP1 and elongin (the 
adapter protein is unknown for the APC/C complex) and finally a receptor protein 
responsible for substrate specificity: >70 F-box proteins act as receptor proteins for the 
SCF complex including SKP2, FBXW7 and β-TRCP whereas the ECV complex only 
recruits one receptor protein, VHL, and the APC/C complex recruits two, CDC20 or 
CDH1.  A number of known substrates are shown for each complex (Nakayama & 
Nakayama 2006). 
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 There are three major substrate recognition F-box proteins that become part of the 
SCF complex to regulate a number of cell cycle control proteins; FBXW7 (F-box and 
WD-40 domain protein 7), SKP2 (S-phase kinase-associated protein 2) and β-TRCP (β-
transducin repeat-containing protein) (Nakayama & Nakayama 2006). FBXW7 has been 
shown to initiate the degradation of a number of oncogenes including Notch-1, Notch-4, 
JUN, c-MYC, Cyclin E and mTOR and has therefore been described as a tumour 
suppressor (Welcker & Clurman 2008; Tan et al. 2008). Mutations in FBXW7 have been 
identified in numerous cancers including hereditary colorectal cancer, ovarian cancer and 
lymphoma (Miyaki et al. 2009; Kwak et al. 2005; Song et al. 2008). FBXW7 gene 
deletions have also been detected in cancers including gastric cancer and colorectal 
cancer (Milne et al. 2010; Iwatsuki et al. 2010). Conversely it has been demonstrated that 
SKP2 has oncogenic potential with many of its targets functioning as tumour suppressors 
including p27, p21 and p57 (Kitagawa et al. 2009; Lin et al. 2010; Bretones et al. 2011). 
SKP2 expression has been shown to negatively correlate with p27 levels and poor 
prognosis in several cancers (Wang et al. 2012). β-TRCP has numerous substrates which 
can regulate various pathways leading to complex outcomes, for example β-TRCP targets 
cell cycle regulators EMI1/2, CDC25A/B and WEE1A for degradation as well as β-
catenin, an essential component of the Wnt pathway and IκB an inhibitor of the NFκB 
pathway (Winston et al. 1999; Margottin-Goguet et al. 2003; Watanabe et al. 2004; 
Uchida et al. 2011). Thus β-TRCP appears to inhibit proliferation via degradation of cell 
cycle regulators and inactivation of the Wnt pathway yet activates the NFκB pathway 
inhibiting apoptosis and promoting cell proliferation. Therefore it is not surprising that β-
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TRCP is deregulated in what appear to be opposing methods depending on the type of 
cancer, for example it has been shown to be mutated in cancers such as gastric cancers, 
yet in others such as colorectal cancer it is shown to be overexpressed (Kim et al. 2007; 
Ougolkov et al. 2004). Although E2 enzymes have been shown to provide a degree of 
specificity to the ubiquitination of E3 substrates (see section 1.4.1) there has only been a 
few reports relating E2 enzyme overexpression to cancer development (Okamoto et al. 
2003; Roos et al. 2011). 
 
1.5.2   The ubiquitin pathway in kidney cancer 
As already stated in section 1.3.3 VHL is mutated in up to 70% of sporadic 
ccRCCs and is part of the ECV ubiquitin ligase complex consisting of elongins B and C, 
Cullin-2 and RBX-1. A number of other components of the ubiquitin pathways have been 
shown to be mutated in a small number of sporadic kidney cancers including the tumour 
suppressor gene BAP1 which functions as a de-ubiquitin enzyme involved in cell 
proliferation regulation, CUL7 part of a novel SCF-like E3 ligase that potentially 
regulates cell growth through binding IRS-1 (insulin receptor substrate-1) and p53, β-
TRCP and FBXW7 which are both substrate recognition components of the SCF-
complex that regulate a number of known oncogenes (see section 1.5.1 for detail) and 
TRC8 which was revealed to be an E3 ubiquitin ligase (Guo et al. 2011; Yu et al. 2010; 
Sarikas et al. 2008; Kuiper et al. 2009; Gemmill et al. 2005). E2-EPF a ubiquitin 
conjugating enzyme involved in targeting VHL for proteasomal degradation has also 
been shown to be upregulated in papillary type RCCs (Roos et al. 2011).  
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Known familial RCC genes (VHL, FLCN, FH, SDH, MET) have all been shown 
to play a role in the mTOR, HIF or Wnt pathways shown to be involved in RCC 
tumourigenesis (Baldewijns et al. 2010) . Many of the disrupted ubiquitin pathway 
components found in sporadic RCCs, including VHL, are regulators of the mTOR and/or 
HIF pathway; for example FBXW7 found to be disrupted in a familial RCC case and 
mutated in a single sporadic RCC case, targets mTOR for proteasomal degradation and 
disruptions in the SCF/FBXW7 E3 ligase cause increased activation of the mTOR 
pathway (Mao et al. 2008), CUL7 found to be mutated in 3% of sporadic RCCs targets 
IRS-1 for proteasomal degradation; IRS-1 is activated by the insulin receptor and 
instigates the activation of the mTOR pathway thus mutations in CUL7 prevent 
degradation of IRS-1 and lead to increased activation of the mTOR pathway (Guo et al. 
2011; Xu et al. 2008). Wnt/β-catenin pathway activation has been detected in a number of 
RCC cases and is thought to be involved in RCC tumourigenesis (Saini et al. 2011). VHL 
has also been shown to target the β-catenin oncogene for proteasomal degradation thus 
linking both the HIF and Wnt/β-catenin pathways in RCC (Peruzzi & Bottaro 2006). β-
TRCP, shown to be mutated in ~2% of sporadic RCCs, acts as a substrate receptor for the 
SCF E3 ligase and has been shown to target β-catenin for ubiquitylation and proteasomal 
degradation (Guo et al. 2011; Liu et al. 2004) (Figure 1.9). 
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Figure 1.9  Ubiquitin pathways involved in RCC tumourigenesis 
Overview of the signalling pathways involved in RCC including the HIF and mTOR 
(green/purple circles) and Wnt/β-catenin pathways (red circles) showing the components that 
are often disrupted in RCC within these pathways (* known RCC causative genes). A number of 
ubiquitin systems regulate the HIF, mTOR and Wnt/β-catenin pathways by binding specific 
components and targeting them for proteasomal degradation, within these ubiquitin pathways 
the substrate receptor subunit of the E3 ligases (orange boxes) have been shown to be 
deregulated in sporadic and/or familial RCC. VHL is part of the ECV E3 complex that has been 
shown to target both the HIFα subunit and β-catenin regulating both the HIF and Wnt pathways. 
The SCF complex has been shown to be involved in RCC tumourgenesis via deregulation of two 
different substrate receptor subunits; FBXW7 shown to target mTOR and β-TRCP shown to 
target β-catenin for proteasomal degradation. CUL7 is a substrate receptor subunit of an SCF-
like E3 ligase known to target IRS1 for degradation, deregulating the mTOR pathway. Thus the 
ubiquitin system plays an important role in RCC tumourigenesis (Baldewijns et al, 2010; 
Linehan et al, 2010; Guo et al, 2011; Mao et al. 2008). IGF = insulin growth factor; IR = 
insulin Receptor; PI3K = Phosphatidylinositol 3-kinases; Akt = serine/threonine kinase; FLCN 
= folliculin; TSC = Tuberous sclerosis protein; mTOR = mammalian target of rapamycin; HGF 
= hepatocyte growth factor; MET = hepatocyte growth factor receptor (proto-oncogene); FH = 
fumarate hydratase; SDH = succinate dehydrogenase; PHD = prolyl hydroxylase. 
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The ubiquitin system consists of numerous ubiquitin pathways that regulate many 
signalling cascades. A small number of these ubiquitin pathways, including the SCF and 
ECV cascades, appear to play an important role in the development of both familial 
and/or sporadic RCCs and are often involved in the regulation of the mTOR, HIF and 
wnt/β-catenin signalling cascades. Although a number of components of the SCF/ECV 
pathways, other than VHL, have been shown to be disrupted in sporadic RCCs, these 
only account for a small percent of sporadic RCCs (1-3%). It is likely that there are other, 
not yet detected, candidate sporadic RCC genes that are involved in the mTOR, HIF and 
wnt/β-catenin signalling pathways. One of the most prominent ways to regulate these two 
pathways is through the ubiquitin system as a number of the pathway components are 
regulated through ubiquitylation, thus there maybe novel RCC genes within the ubiquitin 
system yet to be found. Further elucidation of these ubiquitin cascades and the signalling 
pathways they regulate could help to identify novel RCC components, thus increasing 
current knowledge of RCC tumourigenesis and allowing the development of new 
therapeutic targets. 
 
 76 
 
Chapter Two: Methods 
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2.1    Materials 
2.1.1   Companies purchased from 
Company names and local branch locations are shown in the table below: 
 
Company name Address 
Abcam Cambridge, UK 
Appleton Woods Birmingham, UK 
Applied Biosystems Warrington, UK 
Bioline London, UK 
Biorad Hemel Hempstead, UK 
Cell signaling Hitchin, UK 
Clontech Saint-Germain-en-Laye, France 
Corning High Wycombe, UK 
New England Biolabs Hitchin, UK 
European Cell and Culture Collection Porton Down, UK 
Fermentas (Thermo Scientific) St. Leon-Rot, Germany 
Fisher Loughborough, UK 
GE Healthcare Amersham, UK 
Integrated DNA Technologies  Glasgow, UK 
Invitrogen Paisley, UK 
MRC-Holland  Amsterdam, Netherlands  
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PAA Laboratories Yeovil, UK 
Promega Southampton, UK 
Qiagen Crawley, UK 
Roche Welwyn Garden City, UK 
Sigma-Aldrich Poole, UK 
Stratagene Cambridge, UK 
 
2.1.2    General chemicals and equipment 
 Isopropanol, ethanol and methanol were purchased from Fisher. Phosphate 
Buffered Saline (PBS) tablets from Thermo scientific. Agarose was purchased from 
Bioline and DNA ladders from Fermentas. The Polyvinylidene difluoride (PVDF) 
membrane was purchased from GE Healthcare. Tissue culture flasks and dishes were 
purchased from Corning and pipettes from Appleton Woods. All other general chemicals 
were purchased from Sigma-Aldrich unless specified. 
 
2.2   Sequencing 
2.2.1   PCR 
Polymerase chain reaction was used to amplify specific DNA fragments for 
sequencing or cloning. A list of the primers used in the PCR reactions are shown in 
appendix 8.1.1, 8.1.2 and 8.1.3.  The reaction components are shown on the next page. 
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PCR reactions were carried out in a thermal cycler with a heated lid at the 
conditions shown on the next page. 
Reaction components* 1 x Volume 
10x PCR reaction buffer with 20mM Mgcl2 2.5µl 
2mM dNTP mix (1:1:1:1) 2.5µl 
GC-RICH Solution, 5x conc. 5.0µl 
Forward primer 20µM 1µl 
Reverse primer 20µM 1µl 
Fast start taq DNA polymerase 5U/µl 0.2µl 
dH2O Up to 25µl 
DNA** / 
* 10x reaction buffer, 5x GC-rich solution and fast start taq polymaerase were 
purchased from Roche. dNTPs were purchased from Fermentas. 
**10-200ng genomic DNA or 1-10ng bacterial DNA or 0.1-1ng plasmid DNA 
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Step Temperature Duration Cycles 
Hot start: 
For heat activated 
enzymes. 
95˚C 5 minutes / 
Denaturation step: 
Separation of DNA 
strands to produce single 
stranded DNA 
95˚C 30-45s 
Cycle 25 – 35x 
depending on the 
amount of starting 
DNA and amount 
of product needed 
Annealing step: 
Anneal primers to single 
stranded DNA 
Primer  annealing 
temperature 
(50-65˚C) 
30-45s 
Extension step: 
Synthesis of new DNA 
strands complementary to 
DNA template 
72˚C 
Depends on length 
of DNA template 
(~1 minute per kb) 
Final extension step: 72˚C 10 minutes / 
 
2.2.2   Agarose gel electrophoresis 
Agarose gels were used to analyse PCR products used for sequencing and 
cloning. 
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The percentage of the agarose gels ranged from 1% to 2.5% depending on the 
DNA fragment size. For example a 1% agarose gel was made by mixing 1% w/v agarose 
powder with 1X TBE buffer (90mM Tris-base, 90mM boric acid and 2mM EDTA. 
pH8.0) and dissolved by heating in a microwave. Once the agarose had cooled ethidium 
bromide was added to make a final concentration of 0.25µg/ml. The gel was poured into 
the casting tray with a comb and left to solidify at room temperature. Once solid, the 
comb was removed and the gel was placed in an electrophoresis chamber containing 
1XTBE buffer. DNA samples were added along with 2x loading dye (50% glycerol, 
2mM EDTA and 0.1% orange G). DNA ladders were added as size standards and the gels 
were run at 180 Volts for as long as needed.  
 
2.2.3   EXOSAP reaction 
The PCR products were cleaned using exonuclease I and alkaline phosphatase 
treatment. Single stranded DNA is digested by the exonuclease I enzyme into free 
dNTPs. The dNTPS are then inactivated by the antartic phosphates by removing the 
dNTP phosphate groups. The EXOSAP reaction conditions are shown on the next page. 
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Reaction components* 1x Volume 
FastAP thermosensitive alkaline phosphatase 
1u/µl 1 µl 
10X FastAP buffer 1 µl 
Exonuclease I 20u/µl 1 µl 
PCR product 5µl 
dH2O Up tp 10µl 
* FastAP alkaline phosphatase, fastAP buffer and exo I were purchased 
from Fermentas. 
 
 
The reaction components were mixed well then incubated at 37˚C for 30 minutes 
then at 85˚C for 20 minutes to inactivate the reaction. 
 
2.2.4    Sanger sequencing reaction 
EXOSAP treated PCR products were used as the template for the terminator cycle 
sequencing reaction (Sanger sequencing). Terminator cycle sequencing involves the 
incorporation of fluorescent labelled dideoxynucleotides also known as dye terminators. 
Four different dyes are used to represent each of the four bases A, T, G and C. Each 
sample was sequenced bi-directionally therefore the forward and reverse primers are 
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added to separate PCR reactions for each sample. The terminator cycle sequencing 
reaction components and conditions are shown below. 
 
Reaction components* 1X volume 
BigDye Terminator v1.1/3.1 Sequencing Buffer 5x 2.0 µl 
BigDyeTerminator v3.1** 0.75 µl 
Primer forward or reverse 20µM 1.0 µl 
Purified DNA 5 µl 
dH2O Up to 10 µl 
* Big dye terminator and big dye terminator buffer were purchased from applied 
biosystems. ** The BigDye terminator Cycle Sequencing Kit includes dye 
terminators, deoxynucleoside triphosphates, AmpliTaq DNA Polymerase, FS, 
rTth pyrophosphatase, magnesium chloride, and buffer. 
 
Step Temperature Duration 
Denaturation 95˚C 25s 
Annealing 50˚C 25s 
Extension 60˚C 4 minutes 
 
The reaction was carried out in a thermocycler with a heated lid for 28 cycles. 
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2.2.5   Sequencing Precipitation  
The sequencing products were cleaned from impurities such as excess fluorescent 
ddNTPs and enzymes from the sequencing reaction. Precipitation buffer was prepared 
using 0.5M EDTA and 3M NaAc in a 1:1 ratio. The samples to be precipitated were 
prepared in a 96 well plate with a sealing lid. Three and a half µl of precipitation buffer 
was added to each of the samples to be sequenced. One hundred µl of 100% ethanol was 
then added to the sample which was then centrifuged at 4000rpm for 15 minutes at 4˚C to 
pellet the DNA. After the spin, the sealing lid was removed and the plate was spun upside 
down at 400rpm for 1 minute. Two hundred µl of 70% ethanol was then added to the 
sample, to wash the pellet, and was centrifuged at 4˚C for 10 minutes at 4000rpm. The 
plate was then spun upside down at 400rpm again and the wash step was repeated. The 
plate was then spun upside down for a final time and was then left on the worktop until 
all the residual ethanol had evaporated. 10µl of formamide (Hi-Di, Applied Biosystems) 
was added to the DNA sample which was then denatured on a heating block set at 95˚C 
for 5 minutes. The plate was then placed on ice before loading on to the sequencer.  
 
2.2.6   Sequencing analysis 
The plate containing the denatured DNA was placed on a AB3730 capillary 
sequencer (Applied Biosystems), and analysed using Bioedit V7.1.3 
(www.mbio.ncsu.edu/bioedit/bioedit.html).  
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2.3    Cloning 
2.3.1   Plasmid constructs 
 Plasmid maps can be found in section 8.2. UBE2QL1 expression constructs were 
made by cloning the full length human coding region into the EcoR1-BamH1 sites of 
pcDNA3.1 (Invitrogen), pFLAG-CMV4 (Sigma-Aldrich) and pCMV-myc (Clontech) 
vectors. All three FBXW7 isoform constructs were kindly given to us by Markus 
Welcker. The FBXW7 coding regions were cloned into p3XFLAG-myc-CMV-24 
(Sigma-Aldrich) at the following sites; FBXW7α in Hind3-EcoRI, FBXW7β in EcoRI-
Xba1 and FBXW7γ in Hind3-Xba1. Stop codons were included in the FBXW7 coding 
regions therefore the myc tag was not incorporated. The Hisx6-Ubiquitin vector was 
kindly given to us by Dirk Bohmann. Plasmids were verified by sequencing. 
 
2.3.2   Designing cloning primers 
Primers were designed to contain specific restriction enzyme sites to produce the 
correct sticky ends for ligation into the vector. It was important to design the forward 
primers so the open reading frame (ORF) of the gene was in frame with the epitope tags 
within the vector. The ORF sequence was run through the webcutter 2.0 software, 
accessed online, to identify any restriction endonuclease sites within the sequence 
(www.na.lundberg.gu.se/cutter2). The restriction sites that were chosen for each ORF were 
ones which would be in the correct orientation for the vector and were not found within the 
ORF. Forward primers were made to include the initiation (ATG) codon and reverse primers 
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were made to include the stop codons as all tags used were at the N-terminus of the gene. 
Primer sequences are shown in appendix 8.1.4. 
 
2.3.3   PCR (pfu taq) 
PfuUltra II fusion HS DNA polymerase was used to amplify the open reading 
frames of genes to be used for expression cloning. Pfu polymerase possesses 3’ to 5’ 
proof reading properties and therefore ensures accuracy, preventing the insertion or 
deletions of incorrect bases during the reaction. The PCR components using pfu DNA 
polymerase are shown below. 
 
Reaction components* 1 x Volume 
10x PfuUltra II reaction buffer 5µl 
2mM dNTP mix (1:1:1:1) 5µl 
Forward primer 20mM 2µl 
Reverse primer 20mM 2µl 
PfuUltra II fusion HS DNA 
polymerase 
1µl 
dH2O Up to 50µl 
cDNA** / 
* PfuUltra II DNA polymerase and buffer were 
purchased from stratagene, dNTPs were purchased from 
Fermetas.**100ng genomic DNA 
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Pfu DNA polymerase PCR reactions were carried out in a thermal cycler with a 
heated lid at the following conditions. 
 
Step Temperature Duration Cylces 
Hot start: 95
o
C 5 minutes 
1x 
Denaturation step: 95
o
C 30s 
35-45 x 
Annealing step: 
Touchdown starting at 4
 
o
C above annealing 
temperature.* 
30s 
Extension step: 72
 o
C 
Depends on 
length of DNA 
template 
(~1 minute per 
kb) 
Final extension 
step: 72
 o
C 10 minutes 
1x 
* Touchdown annealing steps were used to avoid amplifying non-specific 
sequence. This involves 5 cycles at 4
 o
C above annealing temperature, 5 cycles 
at 2
 o
C above annealing temperature then 35 cycles at annealing temperature. 
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2.3.4   Site directed mutagenesis 
C88A and C88S UBE2QL1 mutants were generated by PCR-based site-directed 
mutagenesis using the QuikChange Lightning Site-Directed Mutagenesis Kit following 
manufacturer’s instructions. This allows the generation of site-specific mutations using 
almost any double stranded plasmid as the template. Complementary primers were 
designed containing the desired nucleotide change along with 12 correct base pairs either 
side, the primers anneal to the same sequence on opposite strands of the plasmid. Primer 
sequences are shown in appendix 8.1.5. The mutant strand synthesis PCR reaction 
components were as follows: 
 
Reaction components* 1 x Volume 
10× QuikChange reaction buffer 2.5µl 
dsDNA template (plasmid)** 
 
1µl 
Forward primer 20mM 1µl 
Reverse primer 20mM 1µl 
2mM dNTP mix (1:1:1:1) 0.5µl 
QuikSolution reagent 0.75µl 
QuikChange® Lightning Enzyme 0.5µl 
ddH2O Up to25µl 
* Quickchange reagents were from the QuikChange Lightning 
Site-Directed Mutagenesis kit from Stratagene, dNTPs were 
purchased from Fermetas.**100ng plasmid DNA 
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The mutant strand synthesis PCR reaction was carried out in a thermal cycler with 
a heated lid with the following conditions. 
 
Step Temperature Time Cycles 
Hot start: 95˚C 2 minutes / 
Denaturation step: 95˚C 20s 
18x 
Annealing step: 60˚C 10s 
Extension step: 68˚C 
30 
seconds/kb of 
plasmid 
length* 
Final extension 
step: 68˚C 5 minutes / 
 
The PCR product is then treated with 2µl of DpnI endonuclease (Stratagene) as 
this specifically digests methylated DNA and as almost all E. coli strains contain DNA 
that is dam methylated the Dpn I digest only digests the parental DNA template therefore 
selecting for the newly synthesised mutated DNA. PCR products were incubated with 
DpnI for 5 minutes at 37˚C.  DpnI treated plasmid DNA was then transformed into XL-1 
 90 
 
Blue competent cells (Stratagene), see section 2.3.9. Plasmids were verified by 
sequencing (section 2.2). 
 
2.3.5  Gel extractions 
DNA fragments of correct size were extracted from agarose gels using the 
QIAquick gel extraction microcentrifuge protocol (Qiagen). The DNA was eluted in 30μl 
of dH2O.  
 
Briefly, the DNA band was excised from the gel over a UV light using a sharp 
scalpel. After weighing the gel fragments, 3 volumes of buffer QG was added to 1 
volume of gel in a 1.5ml microcentrifuge tube. The tubes were incubated at 50˚C until the 
gel had dissolved then 1 gel volume of isopropanol was added. QIA-quick spin columns 
were placed in 2ml collection tubes and the samples were applied to the columns. 0.5ml 
of buffer QG was added to the columns which were then centrifuged for 1 minute at 
13,000xg, removing any agarose in the sample. 0.75ml of buffer PE was added to the 
column which was centrifuged again for 1 minute. The column was centrifuged for an 
additional minute to remove any residual ethanol. The column was then placed in a 1.5ml 
microcentrifuge tube and the DNA was eluted in 30µl of dH2O, the column was left for 1 
minute before centrifuging at maximum speed for 1 minute. 
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2.3.6   Restriction enzyme digest 
 The UBE2QL1 PCR inserts and vectors were restriction digested with restriction 
enzymes EcoRI and BamHI to create complementary sticky ends. Plasmids were also 
digested with the same restriction enzymes; these included PCDNA3.1 (Invitrogen), 
pFLAG-CMV4 (Sigma) and pCMV-myc (Clontech). The restriction digest reaction 
components are shown below. 
 
Reaction components* Insert Vector 
EcoRI 12u/µl 2µl 2µl 
BamHI 10u/µl 2µl 2µl 
10x Buffer E 5µl 3µl 
DNA 30µl of PCR product 1µg 
10 x BSA (N,O 
bis(trimethylsilyl)acetamide) 
1x 1x 
H2O Up to 50µl Up to 30µl 
* All reagents were purchased from Promega. 
 
Reactions were incubated at 37 ˚C for 2 hours. 
 
2.3.7  Ligation reaction 
The digest reaction products were run out on a 1.5% agarose gel and extracted 
using the QIAquick gel extraction microcentrifuge protocol and eluted in 30 µl of H2O. 
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The products of the gel extraction were then run out again on a 1.5% agarose to 
determine the amount of insert and vector. This was done by running out 5 µl of the 
insert and 1 µl of the vector next to 0.5 µg of fermentas generuler 100bp ladder. By 
comparing the brightness of the bands the estimated concentration (ng) of the vector and 
insert could be determined and used to estimate the amount needed for a 3:1 ratio using 
the following equation: 
 
Insert length (bp) x Vector mass (ng) / vector length (bp) = Insert mass (ng) 1:1   
         Insert mass (ng) 1:1 ratio x 3 = 3:1 insert:vector ratio  
 
For example 1µl of vector was estimated to be ~100ng by comparing the vector 
band on an agarose to the bands on the ladder of known concentration. The vector size 
was 6,300bp and the insert size was 495bp, therefore using the equation: 
 
 495bp x 100ng / 6,300bp = 8ng of insert. 
 
5µl of the insert was estimated to be about 40ng therefore 8ng per 1µl. Therefore 
3µl of insert was added to 1µl of vector for a 3:1 ratio. T4 DNA ligase was used for the 
ligation reaction. The reaction conditions are shown on the next page. 
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Reaction 
components* 1x Volume 
10X ligation buffer 1μl 
Plasmid 3:1 ratio 
(plasmid:insert) Insert 
T4 DNA ligase 100u 1μl 
dH2O Up to 10μl 
* The T4 DNA ligase and 10x ligation buffer were 
purchased from Promega. 
 
The ligation reaction was left at 4˚C overnight.  
 
2.3.8   pGEM-T easy vector ligation 
The pGEM-T easy vector system was used to clone modified DNA PCR products 
for sequencing and methylation analysis. Taq DNA polymerase adds single 3’ A-
deoxynucleotide to double stranded DNA. These A tails allow the PCR products to be 
cloned into the pGEM vector (promega). The pGEM vector was already linearized with 
EcoRV and a T base is added to the 3’ ends.  
 
The PCR products were run out on a 2% gel and gel extracted using the QIAquick 
gel extraction microcentrifuge protocol described in section 2.3.5. The ligation reactions 
were then set up as follows on the next page. 
 94 
 
 
Reaction components 1xVolume 
2x rapid ligation buffer 5 µl 
pGEM T Easy Vector (50ng) 1 µl 
PCR product 3 µl 
T4 DNA ligase 1 µl 
dH2O Make Up to 10 µl 
 
The reaction was mixed by pipetting up and down and then incubated at 4˚C 
overnight.  
 
2.3.9  Transformation 
Plasmids were transformed into α-select chemically competent cells (DH5α) 
according to manufacturer’s instructions (Bioline). 
 
 Briefly, 100μl of DH5α cells were added to 10μl of ligation reaction which were 
then incubated on ice for 30 minutes. The cells were heat shocked at 42
o
C for 45 seconds 
promoting the uptake of the plasmid, then placed on ice for 2 minutes. 2ml of pre- 
warmed L-Broth was added to the cells which were then incubated in a rotating incubator 
set at 220rpm at 37
o
C for 1 hour. 200μl of cells were spread onto LB agar plates 
 95 
 
containing either 100µg/ml ampicillin or 25µg/ml of kanamycin. These were then 
incubated overnight at 37
o
C.   
2.3.10  Minipreps 
Colonies were then selected off agar plates and picked off using a pipette tip 
which was added to 2ml of LB-broth containing either 100µg/ml ampicillin or 25µg/ml 
of kanamycin.  This was then left in a rotating incubator set at 220rpm at 37
o
C overnight. 
Plasmid DNA extractions from DH5α cells were performed using the Wizard plus SV 
miniprep protocol (Promega). The DNA was eluted in 50μl of dH2O. 
 
1ml of the culture was pelleted by centrifugation at 15000rpm for 15secs. The 
pellet was resuspended in 250µl of cell resuspension solution. Two hundred and fifty µl 
of cell lysis solution was added and the cell suspension which was left until clear. Ten µl 
of alkaline protease solution was then added and the lysate was incubated for 5 minutes at 
room temperature. Three hundred and fifty µl of neutralization solution was applied and 
the lysate was then centrifuged for 10 minutes at 14000xg. The cleared lysate was then 
added to a spin column which was centrifuged at 14000xg for 1 minute. The column was 
then washed twice with 750µl of diluted column wash solution and then centrifuged for 1 
minute at 14000xg. The column was then centrifuged for 2 minutes at 14000xg. The 
column was placed in a 1.5ml centrifuge tube and the DNA was eluted with 50µl of 
nuclease free water by centrifuging at 14000xg for 1 minute.   
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2.3.11  Maxipreps 
The plasmids were extracted and purified using QIAfilter plasmid Maxi kits 
(QIAGEN 2005).  
 
Briefly, 200ml of bacterial cultures were left overnight in a rotating incubator set 
at 220rpm and 37
o
C. All of culture was centrifuged at 6000rpm for 10mins. The pellet 
was resuspended in 10ml of buffer P1 solution. 10ml of lysis buffer (buffer P2) was 
added to the cell solution and mixed thoroughly; this was then left for 5 minute 
incubation at room temperature. 10ml of neutralization buffer (buffer P3) was added to 
the cell solution and the lysate was decanted into the QIAfilter cartridge and incubated at 
room temperature for 10 minutes. Qiagen-tips were equilibrated by applying 10ml of 
equilibration buffer (buffer QBT) and allowing the column to empty by gravity flow. The 
nozzle cap from the QIAfilter cartridge was removed and the plunger was inserted into 
cartridge filtering the cell lysate into a 50ml tube. The cell lysate was applied to the 
equilibriated QIAGEN-tip and was left to enter by gravity flow. Two x 30ml of wash 
buffer (buffer QC) was applied to the Qiagen-tip. The DNA was eluted in 15ml of elution 
buffer. Ten ml of isopropanol was added to precipitate the DNA, this was centrifuged at 
6000rpm for 60 minutes at 4
o
C. The DNA pellet was washed using 70% ethanol and 
centrifuging for 10 minutes at 11,000rpm. The pellet was left to dry and then resuspended 
in 500µl dH2O.  
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2.3.12  Glycerol stocks 
Glycerol stocks were made from DH5α cell colonies known to contain the correct 
plasmid and insert. Two hundred µl of 100% glycerol was added to 800µl of cell culture 
in a 1.5ml microcentrifuge tube, therefore using a 1:4 ratio. These were then frozen at -
80˚C. 
 
2.3.13  DNA quantification 
DNA concentration and quality was determined by measuring the absorbance at 
260nm and 280nm in a spectrophotometer. DNA was diluted in sterile RNase and DNase 
free water, therefore a reading of 1 unit at 260nm corresponds to 50µg of DNA per ml. 
DNA of good quality was determined by having a 260nm/280nm absorbance ratio value 
between 1.8 and 2. The calculation used to determine DNA concentration is shown 
below. 
 
[DNA] µg/µl = 50 x Absorbance at 260nm x Dilution factor 
                            1000 
 
2.4   DNA Methylation analysis 
 
2.4.1  Bisulphite DNA modification 
DNA methylation occurs on cytosine residues on CpG dinucleotides in regions 
with a GC content of >55% known as CpG islands. These CpG islands are found at the 
regulatory regions of gene promotors. One way to determine the methylation status of 
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genes is to use sodium bisulfite treatment of DNA. This causes the conversion of 
unmethylated cytosine residues to uracil residues and the methylated cytosines stay 
unchanged. Therefore the DNA sequence will be different depending on the DNA being 
methylated or unmethylated.  The epitect bisulfite kit (QIAGEN) was used for the 
conversion of tumour DNA as it provides fast and efficient DNA modification starting 
with DNA amounts as small as 1ng. An example of how bisulfite treated DNA enables to 
distinguish between methylated and unmethylated DNA is shown below. 
 
Non-treated DNA Bisulfite Treated DNA 
Origional DNA sequence Methylated DNA Unmethylated DNA 
C-G-N-N-C-G-N-N-C-G C-G-N-N-C-G-N-N-C-G U-G-N-N-U-G-N-N-U-G 
 
DNA was modified using the epitect sodium bisulfite modification kit, the DNA 
was eluted in 40µl of buffer EB (QIAGEN). 
 
Briefly, the bisulfite mix was prepared by adding RNase free water and vortexing 
until dissolved. Eighty-five µl of the bisulfite mix was added to ~1µg of DNA in 200µl 
PCR tubes. Thirty-five µl of DNA protection buffer was added to the reaction and the 
reaction volume was made up to 140µl using RNase-free water. The bisulfite DNA 
conversion step was performed using a thermal cycler following the conditions shown on 
the next page. 
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Step Temperature Time 
Denaturation 99˚C 5s 
Incubation 60˚C 25s 
Denaturation 99˚C 5s 
Incubation 60˚C 85s 
Denaturation 99˚C 5s 
Incubation 60˚C 175s 
Hold 20˚C Indefinite 
 
Once the bisulfite conversion step was complete, the reaction mixtures were 
transferred to 1.5ml tubes and 560µl of buffer BL with 10µg/ml of carrier RNA was 
added to the reactions which were then transferred to an Epitect spin column. The column 
was centrifuged for 1 minute at 15,000xg and DNA was then washed using 500µl of 
buffer BW and centrifuged again. Five hundred µl of buffer BD was then added to 
desulfonate the DNA and was centrifuged for 1 minute. The wash step with buffer BW 
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was then repeated and the column was centrifuged for 1 minute to remove any residual 
liquid. The column was placed in a new 1.5ml centrifuge tube and 40µl of buffer EB was 
added to the membrane. DNA was eluted by centrifuging at 15,000xg for 1 minute. 
 
2.4.2  Designing non bias primers for methylated and unmethylated DNA 
To determine if the CpG island of UBE2QL1 was methylated in cell lines and 
tumour samples the COBRA technique was used. Primers needed to be designed, to 
amplify the CpG island from bisulfite modified DNA, that bound specifically to modified 
DNA and to not show any bias towards the methylation status. As bisulphite modified 
DNA converts all non-methylated cytosines (C) to thymines (T) all the C were 
substituted for T in the primer providing they were not next to guanines (G). Any C next 
to G in the primer that could not be avoided were substituted for a Y in the forward 
primer meaning the base could be a C or T and an R in the reverse primer meaning the 
base could be an A or G. UBE2QL1 COBRA primers can be found in appendix 8.1.6. 
 
2.4.3  COmbined Bisulphite Restriction Analysis (COBRA) 
COBRA was used to determine DNA methylation at the UBE2QL1 promoter 
CpG island and consists of sodium bisulfite PCR treatment followed by a restriction 
digest to identify methylated CpGs. 
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2.4.3.1 CpG amplification PCR conditions 
The first PCR reaction included 2µl of bisulfite modified DNA and the UBE2QL1 
COBRAF primer and the UBE2QL1 COBRA OR primer. Two µl of PCR product from 
this reaction was then used in a second round of nesting PCR using the same forward 
primer and the inner reverse primer (UBE2QL1 COBRA IR). This was to ensure the 
correct product was amplified. The PCR reactions were set up using the same reagents 
and concentrations as standard PCR as described in section 2.2.1. The PCR conditions are 
shown below. 
 
Step Temperature Duration 
Hot start: 95˚C 5 minutes 
Denaturation step: 95˚C 30s 
Annealing step: 
Touchdown decreasing 2˚C 
every 2 cycles from 62˚C – 
58˚C 
Then 56˚C for 35 cycles*. 
30s 
Extension step: 72˚C 45s 
Final extension step: 72˚C 10 minutes 
* The PCR machine was set to 56˚C for 40cycles after the touchdown in the second 
round. 
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2.4.3.2 Restriction Digest 
The restriction enzyme BstII cuts at the recognition site shown below: 
 
5’ CGCG 3’ 
3’ GCGC 5’ 
 
As only methylated C will stay as C and not be converted to T, the enzyme will 
only cut at methylated CpGs. Therefore after running the digest products on an agarose 
gel it was possible to determine which samples had methylated UBE2QL1 CpG islands. 
The digest reactions are shown below. 
 
Reaction components* 1x volume 
BstUI  (Bsh1236I) 10u/µl 0.5µl 
1x buffer R 2µl 
DNA (PCR product) 12µl 
dH2O Make up to 20µl 
* Bsh1236I and 1xbuffer R were purchased from 
Fermentas. 
 
The digest reaction was incubated at 37˚C for 2 hours. A control plasmid with 
known CGCG sites was also digested at the same time to ensure the digestion was 
successful. The digested products were then run out on a 2% agarose gel for analysis.  
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2.4.3.3 COBRA analysis 
Bisulfite modified UBE2QL1 promoter PCR products, from each tumour, were 
transformed into DH5α cells as in section 2.3.9. As the PCR products were bisulfite 
modified, sequencing each of the clones allowed detection of methylated CpGs within the 
promoter region. Eight to 12 colonies were picked for each tumour using a pipette tip and 
were placed in 5µl of dH2O of which 2µl was used in a PCR reaction (section 2.2.1) with 
plasmid specific primers to amplify the plasmid inserts. PCR products for each tumour 
were then sequenced and analysed (see section 2.2). UBE2QL1 CpG diagrams were 
produced using CpGviewer (http://dna.leeds.ac.uk/cpgviewer/) to demonstrate the 
number of CpGs methylated in each of the clones from each tumour. 
 
2.5   DNA deletion analysis 
 
2.5.1   Multiplex Ligation-dependent Probe Amplification (MLPA) 
MLPA is a multiplex PCR method which allows detection of abnormal copy 
numbers of genomic DNA or RNA sequences. MLPA probes contain primer sequences at 
the 5’ and 3’ ends that allow a single pair of PCR primers to be used for MLPA 
amplification, see Figure 2.1. The probes hybridise to their target sequence and the 
primers allow amplification of the probe sequence. Probe binding only occurs if the target 
sequence is an exact match, differences in one or more nucleotides of the target sequence 
can affect binding. MLPA has five major stages; DNA denaturation and probe 
hybridisation, ligation reaction, PCR reaction, separation of products by electrophoresis 
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and data analysis. All reagents unless specified were purchased from MRC-holland, the 
reference kit used was SALSA MLPA kit P300-A1 human DNA reference-2.  
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Figure 2.1 schematic diagram of Multiplex Ligation-dependent Probe Amplification 
(MLPA) Probes. 
MLPA probes consist of two separate oligonucleotides named the left probe oligo (LPO) 
and the right probe oligo (RPO). The LPO consists of the left hybridising sequence 
(LHS) at its 3’ end which binds to the target sequence, an optional stuffer sequence and 
the forward primer sequence at its 5’ end. The RPO contains the right hybridising 
sequence (RHS) at its 5’ end, an optional stuffer sequence and the reverse primer 
sequence at its 3’ end. The RPO is modified with a 5’ phosphate to allow ligation of the 
RPO and LPO during the ligation reaction. 
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2.5.1.1 Designing MLPA probes 
Custom designed probes for UBE2QL1 are shown in Appendix 8.1.7. Probes were 
designed using MRC-holland guidelines (www.mrc-holland.com) and the probe 
designing program alleleID 7 (Premier Biosoft). Probes were designed within the two 
UBE2QL1 exons as well as upstream and downstream of each exon. Care was taken to 
design probes in regions with no known polymorphisms as determined using the single 
nucleotide polymorphism database from NCBI. 
 
2.5.1.2 Denaturation and hybridisation reaction 
Reactions were carried out in a thermal cycler with a heated lid. DNA was diluted 
to 50-100ng in 2.5μl of buffer TE which was then denatured by heating to 98˚C for 5 
minutes. The DNA was then cooled to 25˚C and 0.75μl of MLPA buffer, 0.5μl of SALSA 
probe mix and 0.25μl of custom designed probes were added to each tube. Tubes were 
incubated for 1 minute at 95˚C followed by 16 hours at 60˚C to allow the hybridisation of 
probes to their target sequence.  
 
2.5.1.3 Ligation reaction 
The samples were cooled to 54˚C and 1.5μl of ligase-65 buffer A, 1.5μl of ligase-
65 buffer B and 25μl of dH2O were added to each tube. Samples were then incubated for 
15 minutes at 54˚C to allow ligation of the RPO and LPO probes. The samples were then 
heated to 98˚C for 5 minutes to inactivate the ligation reaction.  
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2.5.1.4 PCR reaction 
Polymerase mix was made up in new tubes by adding 1μl of SALSA PCR-
primers, 1μl of SALSA enzyme dilution buffer, 2.75μl of dH2O and 0.25μl SALSA 
polymerase. Two μl of SALSA PCR buffer and 13μl of dH2O were added to tubes 
containing 5μl of the ligation reaction.  The tubes were placed in a thermal cycler and 
heated to 60˚C, while at 60˚C 5μl of the polymerase mix was added to each tube. The 
following PCR program was then used to amplify the probe products.  
 
Step Temperature Duration Cycles 
Denaturation step: 
Separation of DNA strands to produce 
single stranded DNA 
95˚C 30s 
Cycle 35x  
Annealing step: 
Anneal primers to single stranded DNA 
 60˚C 30s 
Extension step: 
Synthesis of new DNA strands 
complementary to DNA template 
72˚C 1 minute  
Final extension step: 72˚C 20 minutes / 
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2.5.1.5 Electrophoresis 
The amplification products were separated by electrophoresis using a 3730 DNA 
analyzer (Applied Biosystems). 1μl of the PCR products were added to a 96 well plate 
along with 0.2μl of labelled size standard (LIZ-500, applied biosystems) and 9μl of 
formamide (Hi-Di, applied biosystems). 
 
2.5.1.6 MLPA data Analysis 
MLPA data was analysed on Genemapper V3.5 (Applied Biosystems) to visually 
examine the peak profiles and to calculate the peak area and peak height for each probe. 
Further calculations were carried out in an excel spreadsheet. Analysis involved block 
normalisation of all probes by dividing the peak area of each probe by the total peak area 
of the control reference probes. Further normalisation was achieved by dividing the 
normalised peak areas with the average of all the normalised peak areas for that probe in 
control samples. Normalised probe signals that deviated from their neighbouring 
reference probes by ≥25% were highlighted. An average deviation of ≥30% from 
adjacent reference probes for all UBE2QL1 probes or single exon probes indicated a gene 
or exon deletion, respectively. 
 
2.5.2  Loss of heterozygosity (LOH) 
Microsatellites are segments of DNA, often in non-coding regions, that contain a 
repeated sequence such as a mono or di nucleotide tract e.g. CACACACA . If an 
individual is heterozygote for a particular microsatellite marker this can be informative. 
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Large deletions of DNA often occur in tumours and these can be detected by comparing 
microsatellite markers in corresponding normal (CN) DNA and tumour DNA. If the 
marker is heterozygote in the CN but homozygote in the tumour, this suggests that 
particular locus has been deleted in the tumour. If the CN is homozygote this is said to be 
non-informative. 
 
2.5.2.1 Microsatellite Markers  
Microsatellite markers within the 3p15 locus were found using the NCBI map 
viewer (www.ncbi.nlm.nih.gov/projects/mapview/). Microsatellite markers within the 
3p15 locus with a known heterozygosity of >0.5, thus likely to be informative, were 
searched for. Primers were produced to amplify microsatellite markers D5S2505 and 
D5S2054 both found within the same chromosomal locus as UBE2QL1, specifically 
3p15. The primers used are shown in appendix 8.1.8. 
 
2.5.2.2 LOH PCR 
PCR was used to amplify the microsatellite markers with the conditions shown on 
the next page. 
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Reaction components* 1 x Volume 
10x PCR reaction buffer 1.5µl 
2mM dNTP mix (1:1:1:1) 1.5µl 
MgCl 1.5µl 
Forward primer 20µM 1µl 
Reverse primer 20µM 1µl 
Thermoprine taq DNA polymerase 5U/µl 0.1µl 
dH2O Up to 15µl 
DNA** / 
* 10x reaction buffer, MgCl and thermoprime taq polymaerase were purchased 
from Thermo scientific. dNTPs were purchased from Fermetas. 
**10-200ng genomic DNA 
 
LOH PCR conditions are shown below. 
Step Temperature Duration Cycles 
Hot start: 95˚C 5 minutes / 
Denaturation step: 95˚C 30s 
Cycle 30x Annealing step: 58˚C 30s 
Extension step: 72˚C 45s 
Final extension step: 72˚C 10 minutes / 
 
 111 
 
Five µl of PCR products were run on a 2% agarose gel to confirm the PCR 
reaction produced the correct sized products. The PCR products were then diluted 1 in 
10. A master mix containing 500µl of HiDi and 5µl of LIZ-500 (Applied Biosystems) 
size standard was prepared. One µl of diluted PCR product was added to 9µl of master 
mix. The amplification products were separated by electrophoresis using a 3730 DNA 
analyzer. 
 
2.5.2.3  LOH Data analysis 
Data was analysed using Genemapper 4.0 (Applied biosystems). To establish 
possible LOH candidates the following equation was used: 
 
Determine peak height ratio of tumour or CN: 
(Peak area of allele 1 / peak area of allele 2). 
 
LOH was established by dividing the tumour peak height ratio by the CN peak height 
ratio. A number ≤0.5 is due to LOH. 
 
2.6    RNA analysis 
2.6.1   RNA quantification 
RNA concentration and quality was determined by measuring the absorbance at 
260nm and 280nm in a spectrophotometer. RNA was diluted in sterile RNase and DNase 
free water, therefore a reading of 1 unit at 260nm corresponds to 40µg of RNA per ml. 
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RNA of good quality was determined by having a 260nm/280nm absorbance ratio value 
between 1.8 and 2. The calculation used to determine RNA concentration is shown 
below. 
 
[RNA] µg/µl = 40 x Absorbance at 260nm x Dilution factor 
                            1000 
 
2.6.2   Reverse transcription cDNA synthesis 
cDNA was produced from 1µg of RNA using superscript II RT and random 
hexamers following manufacturer’s instructions (Invitrogen, 2003).  The reaction mixture 
is shown below. 
 
Reaction components* 1x Volume [Final] 
Random Hexamers 0.5µg/µl 0.5µl 0.25µg 
2mM dNTP (1:1:1:1) 2µl 0.25mM 
1µg RNA / / 
 RNase free dH2O Make up to 12µl / 
* All reagents were used from the superscriptII reverse transcriptase kit 
purchased from Invitrogen. 
 
The reaction mixture was heated for 65
o
C for 5 minutes and quickly placed on 
ice. The following mixture was then added shown on the next page. 
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Reaction component 1x Volume [Final] 
5 x First Strand Buffer 4µl 1x 
0.1M DTT 2µl 10mM 
 
The reaction mixture was mixed gently using a pipette and then incubated at  
25˚C for 2 minutes. Then 1µl of superscript II RT enzyme was added to the reaction. The 
following conditions were set in a thermal cycler with a heated lid. 
 
Step Temperature Time 
Primer annealing 25
o
C 10 minutes 
Extension 42
o
C 90 minutes 
Inactivation of reaction 70
o
C 15minutes 
 
The cDNA was stored at -20
o
C. 
 
2.6.3   Reverse transcription PCR (RT-PCR) 
RT-PCR was used to measure gene expression by showing the amount of gene 
specific RNA in a sample in a semi-quantitative manner. The RT-PCR products are run 
on an agarose gel and viewed under UV light. The strength of the band signal on an 
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agarose gel was used to determine if there was a loss of gene expression compared to a 
control. 
 
cDNA was produced using 1µg of RNA from samples of interest. The cDNA was 
used in a standard PCR reaction to amplify the gene of interest for each sample. GAPDH 
primers were used as a control to make sure each reaction contained equal amounts of 
cDNA. RT-PCR reaction components and reaction conditions are shown below and on 
the next page. 
 
Reaction components* 1 x Volume 
10x PCR reaction buffer with 20mM Mgcl2 2.5µl 
2mM dNTP mix (1:1:1:1) 2.5µl 
GC-RICH Solution, 5x conc. 5.0µl 
Forward primer 20µM 1µl 
Reverse primer 20µM 1µl 
Fast start taq DNA polymerase 5U/µl 0.2µl 
dH2O Up to 25µl 
cDNA 1 µl 
* 10x reaction buffer, 5x GC-rich solution and fast start taq 
polymaerase were purchased from Roche applied science. dNTPs were 
purchased from Fermetas. 
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Step Temperature Duration 
Hot start: 95˚C 5 minutes 
Denaturation step: 95˚C 30s 
Annealing step: 58˚C 30s 
Extension step: 72˚C 45s 
Final extension step: 72˚C 10 minutes 
 
Ten µl of the RT-PCR products were run out on a 2% agarose gel and analysed 
under ultraviolet light. 
 
The primers were designed to bind to two separate exons to prevent the 
amplification of any genomic DNA contaminating the sample, as this would contain an 
intron between the two exons. All primers used in RT-PCR reactions are shown in 
Appendix 8.1.9. 
 
2.6.4   Quantitative Real time-PCR 
Taqman oligonucleotide probes were used to determine gene expression in real 
time. Each probe has a fluorescent reporter 6-Carboxyfluorescein (FAM) at the 5’ end 
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and a 3’ quencher Tetramethyl-6-Carboxyrhodamine (TAMRA). The probes are designed 
to bind specifically to RNA/cDNA as they bind within the boundary of two exons, 
therefore amplification of DNA contamination is avoided. Primers bind to the 
complementary sequence either side of the probe and taq polymerase extends the primers 
across the gene of interest. The probe is degraded due to the 5’ endonuclease activity of 
taq polymerase and the fluorescent reporter is released from the quencher emitting 
fluorescence. Fluorescence is then detected per cycle of PCR allowing quantification of 
gene expression in real time.  
 
 Taqman assays containing probes and primers for UBE2QL1 and β-actin along 
with taqman universal master mix II were purchased from Applied Biosystems.  cDNA 
samples  (1 – 100ng) were loaded in triplicate on a 96 well plate with negative controls 
containing no cDNA.  β-actin probes were used as internal controls and were loaded in 
triplicate on the same plate for each sample. The reaction components are shown below. 
 
Reaction component* Volumes per reaction Final concentrations 
Taqman Universal Master Mix II 10 µl 1X 
Taqman assay, 20x 1 µl 1X 
RNase free dH2O 9 µl 1 – 100ng 
Total volume 20 µl / 
* All reagents were purchased from Applied Biosystems. Universal Master Mix includes 0.05 u/µl Taq 
DNA Polymerase, reaction buffer, 4mM MgCl2 and 0.4mM of each dNTP 
 
A 7500 real-time PCR system (Applied Biosystems) was used set to the following 
conditions shown on the next page. 
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Step Temperature Duration Cycles 
Hot start: 95˚C 10 minutes / 
Denaturation step: 95˚C 15s 
Cycle 40x 
Annealing step: 60˚C 1 minute 
 
2.6.4.1 QRT-PCR analysis 
The 7500 fast real-time PCR system (Applied Biosystems) was used to analyse 
the QRT-PCR data. A threshold is set at a point where PCR products were produced 
exponentially. Number of PCR cycles undertaken up until the threshold is known as the 
Ct value. Normalisation of samples is carried out by calculating the ∆Ct, which involves 
subtracting the Ct of the internal control (β-actin) from the Ct of the gene of interest 
(GOI). Gene expression in tumours was compared to gene expression in corresponding 
normals (CN) through calculating the ∆∆Ct (∆Ct for GOI – ∆Ct for CN).  To determine 
tumour gene expression relative to the CN the following equation was used 2
-∆∆ct
, 
presuming the PCR product doubles in log phase. 
 
2.7    Tissue culture 
2.7.1   Cell lines and clinical samples 
An EBV-transformed lymphoblastoid cell line was established from the index 
case of the family with the t(5;19)(p15.3;q12) by European Cell and Culture Collection. 
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RCC cell lines used in this study included KTCL 26, SKRC45, SKRC54, Caki-1, 786-0, 
KTCL 140, RCC4, SKRC39, SKRC47, SKRC18, UMRC3, RCC48, RCC1, RCC12, 
A498, ACHN, 769P and CAL 54. 
 
 
2.7.2   Culture conditions 
Cells were grown in 75cm
3 
flasks with Dulbecco’s modified eagle medium 
(DMEM) containing 10% V/V FBS, 1% L-Glutamine, 1% Penicillin/streptomycin (100 
units/ml penicillin, and 100µl/ml streptomycin) (invitrogen) and 1% MEM non-essential 
amino acids (all reagents purchased from Sigma unless specified). The t(5;19)(p15.3;q12) 
EBV-transformed lymphoblastoid cell line was maintained in RPMI 1640 (Invitrogen) 
supplemented with 10% V/V FBS and 1% Penicillin/streptomycin.  Cells were incubated 
at 37˚C and 5% CO2. 
 
2.7.3   Transfections  
The day before transfection media was removed and the cells were washed with 
Phosphate buffered saline (PBS) before treatment with 0.25% trypsin (Invitrogen) to 
resuspend the cells. A haemocytometer was used to count the cells and a cell 
concentration 3.0 x 10
5
 cells was added to a 6 well dish. A confluency of >80% was 
achieved overnight. For each transfection 2µg of plasmid DNA was added to 100µl of 
Opti-MEM medium (Invitrogen). Fugene HD transfection agent (Roche) was then added 
at a ratio of 2:6 or 2:8 (µg DNA: µl Fugene) depending on the cell line and the 
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transfection reagent:DNA complex was incubated at room temperature for 15 minutes. 
The transfection complex was added to the 6 well dish containing the cells, which was 
then gently rocked to ensure efficient mixing of the transfection complex. Cells were then 
incubated for 48 hours at 37˚C before protein extraction. 
 
2.7.4   Colony formation assays and stable clones 
Cells were transfected with either Flag-empty vector or flag-UBE2QL1. The 
pFLAG-CMV4 (Sigma-Aldrich) plasmid contains the neo gene from Tn5 which allows 
resistance to G418. Transfected cells were grown in 10cm
3
 dishes with 10ml of DMEM 
and 10% FBS plus 1mg/ml G418 an aminoglycoside antibiotic (PAA). Once non-
transfected control cells had all died from exposure to G418, transfected cells were 
seeded in serial dilutions. After 21 days from the initial seeding, the surviving colonies 
from the colony assays were stained with 0.4% crystal violet (Sigma) in 50% methanol. 
Replica assays were set up at the same time to produce UBE2QL1 stably expressing 
clones. Once colonies were visible by eye at 21-28 days each colony was removed by 
pipetting up the colony using a p200 pipette and adding the cells to a 6 well dish 
containing 2ml of DMEM with 10% FBS supplemented with G418.  Once cells became 
>80% confluent they were transferred to a 25ml flask. Protein was extracted from all 
clones and western blot analysis was used to verify UBE2QL1 stable expression.  
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2.7.5   Soft agar colony assays 
Soft agar colony assays can be used to determine the ability of a cell line to 
undergo anchorage independent growth, thus the ability to proliferate suspended in agar. 
The assays were carried out in 6-well plates and involved adding 2mls of base layer 0.7% 
agar to each well and then leaving the plates at room temperature to set. Once solidified 
the agar is placed in a 37˚C incubator to equilibrate. SKRC47 flag-UBE2QL1 or flag-
empty vector stable clones were counted and prepared to contain ~ 2x10
4
 cells per 100µl. 
A middle layer of 1ml 0.35% agar was combined with 100µl of prepared cells and added 
to the base agar and allowed to set at room temperature. Once set 2ml of a final layer of 
0.7% agar was then added on top of the middle agar layer and allowed to set at room 
temperature. As soon as the final layer was set the plates were placed in a 37˚C incubator 
for 28 days and were maintained by applying 200µl of DMEM supplemented with 10% 
FCS and 1mg/ml of G418 (PAA) weekly. Each experiment was undertaken 6x 
simultaneously. Colonies measuring ≥100µm were manually counted under a 
microscope. Details of the components of 2xDMEM, 1xDMEM, 0.7% agar and 0.35% 
agar are shown in the tables on the next page. 
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2X DMEM 
Reaction 
components 
Volumes Final  % 
FCS     50ml 20 
Penicillin-
Streptomycin 
5ml 2 
L-Glutamine 5ml 2 
10x DMEM* 50ml 20 
7.5% sodium 
bicarbonate*   
25ml 10 
G418  50mg/ml 1ml 0.4 
dH2O Up to 250ml  
*10x DMEM and 7.5% sodium bicarbonate were both purchased from 
Sigma. 
 
1X DMEM 
Reaction 
components 
Volumes Final % 
FCS     10ml 10 
Penicillin-
Streptomycin 
1ml 1 
L-Glutamine 1ml 1 
10x DMEM 10ml 10 
7.5% sodium 
bicarbonate   
5ml 5 
dH2O Up to 100ml  
 
0.7% and 0.35% agar solutions were made up combining different ratios of 1x DMEM, 
2x DMEM and 1.4% noble agar (Sigma), as shown in the tables on the next page. 
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0.7% agar 
Reaction 
components 
Volumes 
(150ml total) 
Final % 
2xDMEM 75ml 50 
1.4% agar 75ml 50 
2xDMEM : 1.4% noble agar = 1:1 ratio 
 
0.35% agar 
Reaction 
components 
Volumes 
(80ml total) 
Final % 
2xDMEM 20ml 25 
1.4% agar 20ml 25 
1X DMEM 40ml 50 
2xDMEM : 1.4% noble agar: 1xDMEM = 1:1:2 ratio 
 
2.8 Protein Analysis 
2.8.1   Antibodies 
The following antibodies were used in this study; Monoclonal anti-FLAG M2 
(1:2,000 dilution; Sigma), monoclonal anti- β-actin (1:10,000 dilution; Sigma), 
monoclonal anti-tubulin (1:10,000 dilution; Sigma), anti-C-Myc (1:1,000 dilution; 
Sigma), anti-6xHis (1:1,000 dilution; Abcam), anti-RBX1 (1:1,000 dilution; Cell 
Signalling), anti-mtor (1:1,000 dilution; Cell signaling), anti-cyclin E1 (1:1,000 diltuion; 
Abcam). 
 
2.8.2   Protein extraction from cells 
Cells were grown in either 6 well dishes or 10cm
3
 dishes until confluent, they 
were then washed twice with PBS and 150µl – 1ml (depending on the amount of cells) of 
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lysis buffer* was added. Cells were scraped off into the lysis buffer which was pipetted 
into 1.5ml tubes and incubated on ice for 20minutes. They were then centrifuged at 
15,000 x g for 15 minutes and the supernatant containing the protein was transferred to a 
clean tube. 
 
*  RIPA buffer (50 mM Tris-HCl pH8, 150 mM NaCl, 1 mM EDTA, 1% nonidet 
NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS)  was used for proteins extracted for 
standard western blot analysis, NETN buffer (50mM Tris-HCl at pH7.5, 150mM NaCl, 
1mM EDTA, 1% Nonidet P-40) was used in Co-Immnoprecipitation experiments and His 
pulldown lysis buffer (50mM Na-phosphate at pH8, 300mM NaCl, 0.01% Tween-20, 1% 
Triton X-100) was used in Hisx6 pulldown experiments. In all protein extractions a 
complete mini protease inhibitor cocktail tablet (Roche) was added per 10ml of lysis 
buffer. 
 
2.8.3   Determining Protein concentration  
Protein concentrations were determined using the DC protein assay following 
manufacturer’s instructions (Bio-Rad).  
 
Briefly, 20µl of reagent S was added to every ml of reagent A (an alkaline copper 
tartrate solution). Protein standards were prepared, 0.2mg/ml – 1.4mg/ml, using BSA 
(Bovine serum albumin, Invitrogen) in RIPA buffer. Five µl of standards and protein 
samples were added in duplicate to a 96 well-plate. Twenty-five µl of reagent A (+ 
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reagent S) was added into each of the wells along with 200µl of reagent B (a dilute folin 
reagent) making sure each of the wells were thoroughly mixed. After 15 minutes at room 
temperature the OD was measured at 690nm on a Wallac Victor3 fluorometer (Perkin 
Elmer). A calibration graph was produced from the readings of the protein standards and 
the regression equation from the graph was used to calculate the concentration of the 
protein samples. 
 
2.8.4   Western Blot analysis 
2.8.4.1 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel (SDS-PAGE) electrophoresis is 
used to separate proteins according to their size. Proteins are denatured and given a 
negative charge due to the SDS detergent. The negative charge per unit mass is identical 
for each protein; thus once the proteins have been separated on a polyacrylamide gel in 
an electrical field, specific proteins can be detected due to their size. A protein ladder is 
run with the samples to determine the size of the protein bands.  
 
  The acrylamide gel construct was produced using 0.75mm or 1.5mm glass plates 
which were assembled and placed in a gel stand. The stacking and resolving mixtures 
were then prepared, see table on the next page. 
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Reagents Stacking Resolving  
Acrylamide/ Bis 30% (W/V) 4% 
9 -15%  
(depending on size of 
protein) 
0.5M TRIS ph 6.8 HCL 1.5ml - 
1.5M TRIS ph8.8 HCL - 2.5ml 
dH2O Make up to 7.5ml Make up to 10ml 
10% SDS (Sodium Dodecyl 
Sulfate) 
60µl 100µl 
10% APS (Ammonium 
persulfate) 
50µl 50µl 
TEMED 
(Tetramethylethylenediamie) 
10µl 10µl 
 
The resolving gel mix was poured between the glass plates this was then covered 
with 1ml of dH2O to make sure the top edge of the gel layer set straight. Once the 
resolving layer had set the water was drained off and the stacking mix was poured on top 
of the resolving gel and the comb was inserted between the glass plates. After the gel had 
fully set it was clipped into a gel running tank and 1X SDS running buffer (25 mM Tris, 
192 mM glycine, 0.1% w/v SDS, pH 8.3) was poured between two sets of plates and the 
combs were removed carefully. Five X SDS gel loading buffer (10% w/v SDS, 10mM 
beta-mercapto-ethanol, 20% v/v glycerol, 0.2M Tris-HCL pH6.8 and 0.05% w/v 
Bromophenol blue) was added to 10 µg - 30µg of each protein sample which was then 
loaded onto the gel. Five µl of Fermentas Plus Prestained Protein Ladder was also loaded 
onto the gel. The gel was electrophoresed at 120V for as long as needed. 
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2.8.4.2 Wet transfer and blocking 
A wet transfer involves the gel and membrane being sandwiched between sponge 
and paper. Four pieces of filter paper (9cm x 6cm ) and two sponges per gel were soaked 
in transfer buffer (25mM Tris, 192mM Glycine and 20% MeOH). The Polyvinylidene 
Fluorid (PVDF) membrane was cut to the size needed and activated in 100% methanol (as 
methanol is a low surface tension liquid it displaces the air in the pore structure of the membrane) 
and then soaked in transfer buffer. The gel was removed from the tank carefully and the 
wells cut off using a plastic cutter. The membrane was placed carefully over the gel and 
both were moved onto the clamping devise where the membrane was clamped between 
filter paper and sponges in the following order; sponge, 2 filter papers, gel, membrane, 2 
filter papers, sponge.  All were clamped tightly together ensuring no air bubbles formed 
between the membrane and gel. The sandwich was then submerged in a tank of transfer 
buffer. An electrical field was then applied at 100V for 1 hour or 50V overnight at 4˚C. The 
negatively charged proteins travel towards the positive electrode therefore the proteins move 
towards the membrane and binds. To prevent the primary antibody binding to regions of 
the membrane not bound by proteins, after transfer the membrane was blocked for 45 
minutes in 5% w/v dried skimmed milk in PBS or 5% w/v BSA in TBS-T ( 50M Tris 
pH7.6, 150mM NaCl, 0.05% Tween 20) depending on the primary antibody.  
 
2.8.4.3 Immunodetection 
The primary antibodies were diluted in 5% w/v dried milk in PBS or 5% w/v BSA in 
TBS-T and incubated with the membrane for 1 hour at room temperature or overnight at 4˚C. 
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Membranes were then washed in PBS or TBS-T 3 x 5 minutes. Secondary-Horse radish peroxide 
(HRP) antibodies were diluted in the same buffer used for the primary and incubated with the 
membrane for 1 hour at room temperature. Amersham ECL western blotting detection agents 
(GE healthcare) were applied to the membrane making sure the solution was applied 
evenly across the membrane. This was incubated at room temperature for 5 minutes. The 
excess solution was drained off the membrane which was then wrapped in cling film 
making sure no air bubbles were trapped, and was taped onto a film cassette. In the dark 
room photographic film (Kodak) was exposed to the membrane for as long as required. 
The film was developed using a SRX-101A medical film processor (Konica Minolta). 
 
2.8.4.4 Membrane stripping  
Membranes were stripped of primary and secondary antibodies by boiling in 
water for 5 minutes. Blocking was repeated to prepare the membrane for further blotting. 
 
2.8.5  Protein synthesis using a Coupled reticulocyte lysate system 
UBE2QL1 and UBE2QL1
C88A 
proteins were synthesised and labelled with [35S]-
methionine using the TNT Coupled Reticulocyte Lysate System following 
manufacturer’s instructions (Promega). TNT lysate reactions were set up as shown on the 
next page. 
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Reaction components* 1 x Volume 
TNT Rabbit Reticulocyte Lysate 25μl 
TNT Reaction Buffer 2μl 
TNT RNA Polymerase (SP6, T3 or T7) 1μl 
Amino Acid Mixture, Minus Leucine, 1mM 1μl 
Amino Acid Mixture, Minus Methionine, 1mM 1μl 
[35S]methionine (1,000Ci/mmol at 10mCi/ml) 2μl 
RNasin Ribonuclease Inhibitor (40u/μl) 1μl 
DNA Template(s) ** 1μl 
Nuclease-Free Water to a final volume Up to 50μl 
* All components were purchased from Promega unless stated otherwise. 
[35S]methionine was purchased from Perkin Elmer. ** 0.5μg/μl of 
PCDNA3.1 vector (Invitrogen) containing either UBE2QL1 or UBE2QL1
C88A
  
were used. 
 
Reactions were incubated at 30°C for 90 minutes. 5µl of reaction mixture was applied 
to SDS-PAGE and analysed using autoradiography (see sections 2.8.4). 
 
2.9 Pulldowns and Immunprecipiations 
 
2.9.1   Hisx6 ubiquitin pulldown 
Pulldowns of Hisx6 tagged ubiquitin were carried out using Dynabeads His-tag 
isolation and pulldown (Invitrogen). The Dynabeads are coated in a cobalt-based 
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immobilised metal affinity chromatography chemistry which allows the binding of 
histidine-tagged proteins.  
HEK293 cells were seeded in 10cm
3
 dishes and transfected with either flag tagged 
UBE2QL1, UBE2QL1
C88A
 or UBE2QL1
C88S
 along with Hisx6-tagged ubiquitin or Hisx6 
empty vector control (sections 2.8.2 and 2.7.3). Cells were lysed with 1x binding/wash 
buffer (50mM Na-phosphate at pH8, 300mM NaCl, 0.01% Tween-20) containing 1% 
Triton X-100. The whole-cell lysates obtained by centrifugation for 15 minutes at 
12,500rpm, were incubated with 2mg of His tag Isolation and Pulldown Dynabeads 
(Invitrogen) for 1h at 4°C. The protein bound beads were placed on a magnet and the 
supernatant was removed.  The beads were washed with 1X Pull-down buffer (3.25mM 
Na-phosphate at pH7.4, 70mM NaCl, 0.01% Tween-20) four times and the bound 
proteins were then eluted with 50μl of His elution buffer (300mM Imidazole, 50mM Na-
phosphatase pH8.0, 300mM NaCl, 0.01% Tween-20). Laemmli sample buffer was added 
to the elutes with or without β- mercaptoethanol (a reducing agent) and applied to SDS–
PAGE and western blot analysis (section 2.8.4). 
2.9.2   Antibody binding 
Dynabeads with protein G coupled to their surface (Invitrogen) were used for Co-
immunoprcipitations. The Protein G Dynabeads bind a number of mammalian 
immunglobulins including strong binding of human IgGs. As the beads are magnetic the 
beads along with the bound proteins can be separated from the solution using a magnetic 
block. To bind the antibody to the beads 50µl of suspended protein G Dynabeads were 
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added to a 1.5ml tube placed on a magnetic tube rack. The supernatant was removed and 
the beads were washed twice with Citrate Phosphate Buffer (24.5 mM Citric Acid and 
51.7 mM Dibasic Sodium Phosphate, pH=5.0). Ten - 20µg of antibody was diluted in 
100µl of PBS then added to the dry beads and incubated for 1 hour. The supernatant was 
removed and the beads were washed three times with Citrate Phosphate Buffer. The 
beads were re-suspended in 50µl of PBS and stored at 4˚C until required. 
 
2.9.3   Co-immunoprecipitation 
Protein was extracted from transfected HEK293 cells grown in 6 well plates 
(sections 2.8.2 and 2.7.3). Each transfection was repeated in 3 wells and the lysate from 
all 3 replica wells was combined and added to 50µl of dry antibody bound protein G 
Dynabeads and was incubated on a roller for 2 hours at 4˚C. Twenty µl of the complete 
lysate was removed before adding to the beads to verify the input. The supernatant was 
removed from the bead-protein complex using the magnetic rack and the beads were 
washed 3 times with 200µl of PBS. The beads were re-suspended in PBS one more time 
and were transfered to a clean 1.5ml tube. The PBS was removed and 30µl of 2x Lamelli 
sample loading buffer (62.5 mM Tris-HCl pH6.8, 25% Glycerol, 2% SDS, 0.5 % β-
Mecaptoethanol, 0.5% Bromophenol blue) was added and the sample was boiled for 10 
minutes. The samples were run on a SDS-PAGE gel to undergo western blot analysis 
(section 2.8.4). 
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2.10 Immunoflouresence 
Immunofluorescence was used for protein localisation experiments in HeLa cells.  
2.10.1 Cell fixing 
 Cover-slips were sterilised by dipping them in 70% ethanol and leaving them to 
dry on a sterile tissue. Once the ethanol dried, 4 cover-slips were placed in each well of a 
6 well plate. HeLa cells were then trypsinized and 3 x 10
5
 cells were seeded into the 6 
well dishes and left overnight. Cells were transfected the next day with the appropriate 
plasmid following the trasfection protocol in section 2.7.3. 
 
After 48 hours media was removed using a vacuum pump, and cells were washed 
in PBS 3 times. Cells were fixed by adding 2ml of previously chilled 100% methanol to 
the cells which were then incubated at -20˚C for 10 minutes. The cover-slips were 
washed 3 times with PBS and were blocked by incubating them with 1% BSA in PBS for 
30 minutes, this minimises non-specific adsorption of the antibodies to the cover-slips.  
 
2.10.2 Cell staining 
The 1% BSA in PBS was removed from the coverslips with a vacuum pump and 
using tweezers each cover-slip was transferred to a single well in a 24 well dish, making 
sure the cell side was facing up.  Primary antibodies were diluted by the correct amount 
to a final volume of 1ml. One hundred µl of the diluted antibodies were pipetted onto the 
cover-slips, which were then incubated for 1 hour at room temperature. Cover-slips were 
washed 3 times in PBS and 100µl of the diluted secondary antibody was added to each 
 132 
 
cover-slip, which were further incubated for 1 hour at room temperature. Cover-slips 
were then washed for a final time in PBS.  
 
Microscope slides were labelled and 3 separate drops of 4'-6-Diamidino-2-
phenylindole (DAPI) nucleic acid stain (invitrogen) were dropped on each slide. Cover-
slips were removed from the 24 well dish using tweezers and placed cell side down onto 
the drops of DAPI. Slides were placed in a slide holder covered in tinfoil and left 
overnight. The next day cells were viewed using a fluorescence light microscope, 
Axiovert 200 (Zeiss). Secondary antibodies used were goat anti-mouse IgG Alexa Fluor 
594 and goat anti-rabbit IgG Alexa Fluor 488 purchased from Invitrogen. 
 
2.11   Protein degradation assay 
 Cycloheximide (CHX) is an antibiotic that inhibits protein translation in 
eukaryotic cells and therefore can be used to determine a proteins half life when added to 
cells in a time-course experiment.  
 
HeLa and SKRC47 cells were transfected with either myc-UBE2QL1 or myc-
empty vector (EV) (section 2.7.3). At 24 hours post-transfection cells were treated with 
100μg/ml of cyclohexamide (Sigma-Aldrich) and collected at specific time intervals. 
Cells were lysed and whole-cell extracts were prepared (section 2.8.2). The protein 
concentration for each sample was determined (section 2.8.3) and 10μg of protein were 
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analysed by SDS-PAGE and immunoblotting with the indicated antibodies (section 
2.8.4). 
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Chapter Three:  
Characterisation of the 
t(5;19)(p15.3;q12) breakpoints 
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3.1   Introduction: A novel familial constitutional translocation, 
t(5;19)(p15.3;q12), associated with RCC 
A constitutional translocation, t(5;19)(p15.3;q12), was found to be associated with 
a familial predisposition to RCC  in one family. No mutations were detected in known 
RCC genes VHL and FLCN. The index case developed both oncocytoma and 
chromophobe RCC at age 35 years and her sister presented with clear cell and 
chromophobe RCC at age 36 years and then developed multiple oncocytomas at age 38 
years. The t(5;19)(p15.3;q12) was shown to be present in both sisters. Their maternal 
aunt was reported to have died from an RCC, age unknown and their deceased mother 
was reported to have developed a carcinoid tumour at age 44 years. The 
t(5;19)(p15.3;q12) was not detected in the two brothers of the index case and they have 
not developed RCC or any other cancer type. As the t(5;19)(p15.3;q12) positively 
segregated with the emergence of RCC within this family, it was deduced that the 
translocation was responsible for the onset of RCC tumourigenesis. It was decided that 
further characterisation of the t(5;19)(p15.3;q12) breakpoints and investigation of the 
surrounding genes was necessary to establish the cause of RCC within this family and 
potentially identify a novel RCC candidate gene  (Figure 3.1).  
 
3.1.1   Aims 
Characterisation of the t(5;19)(p15.3;q12) breakpoint region was carried out to 
determine the exact breakpoint position on both derivative chromosomes and to elucidate 
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the genetic consequences of the breakpoint i.e. if there was loss or gain of genetic 
material within the breakpoint regions. Candidate RCC genes within the breakpoint 
regions could then be identified and investigated further. 
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Figure 3.1 Pedigree of family with a constitutional t(5;19)(p15.3;q13.1) and 
predisposition to renal cell carcinoma (RCC). 
Affected family members with the constitutional t(5;19)(p15.3;q13.1) and RCC (or 
carcinoid) are indicated as shown in the figure legend. Females are illustrated by a 
circle and males by a square and deceased individuals are indicated by a diagonal line 
across the respective symbols. III:1 represents the index case. 
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3.2    Results  
 
3.2.1   Mapping of the t(5;19)(p15.3;q12) breakpoint region 
CGH arrays were undertaken by the Wellcome Trust Sanger Institute and 
Nimblegen prior to the start of this project. Initially, an EBV-transformed lymphoblastoid 
cell line was established from the index case of the family with the t(5;19)(p15.3;q12) by 
the European Cell and Culture Collection. To map the t(5;19)(p15.3;q12) breakpoints, 
derivative (der) chromosomes extracted from the lymphoblastoid cell line were separated 
by flow cytometry and hybridised onto a whole genome tiling path array at the Wellcome 
Trust Sanger Institute, which allowed mapping of the breakpoints to within a few 
megabases (Fiegler et al. 2003). Data from the whole genome arrays showed the 
breakpoint spanning clone on der(5) was chr5tp-10A3 that corresponded to chromosome 
region 6,580,618bp and the breakpoint spanning clone on der(19) was chr19tp-1B2 that 
corresponded to position 35,029,739bp (hg18). Breakpoints were then further refined by 
Nimblegen where the derivative chromosomes where hybridised onto a custom designed 
oligonucleotide CGH array that spanned the region of the predicted breakpoint from the 
whole genome tiling array (Figure 1.5). Using the raw data from the oligonucleotide 
arrays from Nimblegen the breakpoint positions were predicted to be where the Cy5/Cy3 
ratio changed from positive to negative (or vice versa), thus showing an intermediate 
ratio. The probes that showed an intermediate ratio were at 34,971,050bp for der(19) and 
6,509,950bp for der(5) and thus were  predicted to be where the translocation breakpoints 
occurred (hg18) (Figure 3.2). 
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3.2.2  Sequence of t(5;19)(p15.3;q12) derivative breakpoints 
DNA was extracted from the t(5;19)(p15.3;q12) lymphoblastoid cell line and 
primers were designed 500bp either side of the predicted breakpoint positions as 
determined by the CGH array. The breakpoints were then amplified using PCR and 
subsequently sequenced to determine the exact breakpoint positions of the derivative 
chromosomes. Sequences revealed the chromosome 19 breakpoint positions to be at 
30,279,438bp on der(19) and at 30,279,436bp on der(5) and the chromosome 5 
breakpoint at 6,456,990bp on der(19) and at 6,456,998bp on der(5) (hg19). The origin of 
four bases, CCTG, on the der(19) breakpoint could not be assigned as they were common 
to both the chr19q and chr5p breakpoint regions. Depending on the origin of the four 
common bases chr19 showed a duplication of either GGACCTG or GGA and chr5 
displayed a deletion of either CAGGGCT or GCT (Figure 3.3).  
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Figure 3.2 Custom designed oligonucleotide array painting of der(5) and der(19) 
The fluorescent profiles of both der(5) (A) and der(19) (B) from the t(5;19)(p15.3;q12) 
are shown. The Y axis represents cy5/cy3 ratio and the X axis shows genome position. 
Breakpoint positions are indicated by the arrow and estimated breakpoint positions (bp) 
determined from the array raw data are shown (figure supplied by Nimblegen). 
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Figure 3.3 Characterisation of the t(5;19) breakpoints. 
Nimblegen oligonucleotide array data was used to design primers 500bp either side of the 
predicted breakpoint positions. A, Products of der(5) and der(19) breakpoint 
amplification from PCR (–ve control contains no DNA). PCR products were gel extracted 
and sequenced using Sanger sequencing. B, Illustration of the der(19) chromosome with 
the sequence of the der(19) breakpoint below.. C, Illustration of the der(5) chromosome 
with the sequence of the der(5) breakpoint below. Bases originating from chr19 are shown 
in black and from chr5 in blue. It was not possible to ascribe the chromosomal origin for 
four bases shown in pink, (CCTG). Depending on the origin of the four common bases a 
duplication of either GGACCTG (30,279,436-30,279,442) or GGA (30,279,436-
30,279,438) occurred on chr19 and a deletion of either CAGGGCT (6,456,991-6,456,997) 
or GCT (6,456,995-6,456,997) occurred on chr5.  (-) = DNA reverse strand (+) = DNA 
positive strand. 
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3.2.3   Map of genes within breakpoint vicinity 
Once the breakpoint had been sequenced a map of the genes within the vicinity of 
the breakpoint could be established using the Ensemble Genome Browser 
(www.ensembl.org) (Figure 3.4). The der(5) breakpoint was shown to disrupt the only 
intron of an uncharacterised gene, UBE2QL1. The 5’ end, including exon 1, and part of 
the intron of UBE2QL1 were translocated onto der(19); no genes on chromosome 19 
were disrupted. The 3’end of UBE2QL1, including exon 2 and part of the intron 
remained on der(5). No other genes were in the breakpoint vicinity for 23.5kb on der(5) 
and 73kb on der(19) thus UBE2QL1 was the only candidate gene within the breakpoint 
region (Figure 3.5). 
 
3.2.4   Existing knowledge on UBE2QL1 
Research was carried out to determine any existing knowledge on UBE2QL1 
using a number of distinguished scientific websites including Ensemble Genome 
Browser: www.ensembl.org/index.html, National Center for Biotechnology Information 
(NCBI): www.ncbi.nlm.nih.gov/, Exome Variant Server: evs.gs.washington.edu/EVS/, 
Catalogue Of Somatic Mutations In Cancer (COSMIC): 
www.sanger.ac.uk/genetics/CGP/cosmic/ and PubMed: www.ncbi.nlm.nih.gov/pubmed. 
There were six main elements that were researched for up to date knowledge on 
UBE2QL1: genomic structure of the gene, predicted protein size, gene homology, 
evolutionary conservation, expression data and published literature. 
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 UBE2QL1 can be found at position  6,448,736-6bp-6,495,022bp (hg19) on the 
chromosome 5 forward strand in humans. It consists of two exons separated by a large 
intron of 41,969bp. Exon 1 consists of 118aa and exon 2 of 43aa contributing to the full 
sized protein of 161aa (see appendix figure 8.3) with a predicted molecular weight of 
18KDa, which was confirmed in this study. UBE2QL1 is highly homologous to the E2 
ubiquitin conjugating family 1 (see section 6.1 for detail) thus is named UBE2QL1 
(Ubiquitin-Conjugating Enzyme E2Q family-Like 1) due to this homology. UBE2QL1 is 
highly conserved throughout evolution with 100-99% sequence alignment with primates, 
99% sequence alignment with chicken, mouse, rat and guinea pig and 91-95% sequence 
alignment with zebrafish, fugu and xenopus (see appendix figure 8.4). Human UBE2QL1 
also exhibits high intra-species conservation as little genetic variation has been detected 
within the protein coding regions or splice sites, with no UBE2QL1 nonsynonymous 
single nucleotide polymorphisms (SNPs) and only 3 rare synonymous SNPs been 
detected by dbSNP, 1000 genomes and variant server (see appendix figure 8.5). Very 
recently data for UBE2QL1 in COSMIC (Catalogue Of Somatic Mutations In Cancer) has 
become available with 2 UBE2QL1 mutations detected; one synonymous mutation in a 
breast cancer tissue:  c.C480T, p.D160D, and one nonsynonymous mutation in an 
endometrium cancer tissue: c.C400A, p.R134S. No further functional data was carried 
out to determine if these mutations affected UBE2QL1 protein function and if they were 
involved in cancer initiation and/or progression. UBE2QL1 expression data from 
RNAseq (Illumina Body Map 2.0) consisting of expression data from a number of human 
tissues demonstrated high UBE2QL1 expression in the brain, heart muscle, skeletal 
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muscle and thyroid, medium expression in the colon, kidney, liver, lung, adipocyte, 
adrenal gland, breast, ovary, testis and prostate and low expression in white blood cells. 
No expression was detected in the bone marrow, spleen, thymus, small intestine, 
pancreas, skin, uterus and cervix. A literature search identified only one peer reviewed 
paper on UBE2QL1 research which identifies a number of gene promoter regions that are 
rich in short tandem repeats (STR) and that lack the conventional motifs for the TATA, 
and TATA-less promoters, and thus suggests these novel rich STR promoters may 
possess functional roles in gene expression (Darvish et al. 2011). No published studies or 
data on UBE2QL1 protein function were found thus UBE2QL1 was an uncharacterised 
protein at the start of this study. 
 
3.2.5   Loss of UBE2QL1 second allele 
To ascertain if UBE2QL1 functions as a TSG the Knudson ‘two hit’ model of 
tumourigenesis was applied (see section 1.1.2), thus if the second allele of UBE2QL1 was 
disrupted in the tumours (the first allele being disrupted by the t(5;19)(p15.3;q12) ) this 
would suggest UBE2QL1 was a likely RCC TSG candidate. MLPA was used to 
investigate if the second UBE2QL1 allele had been deleted in the t(5;19)(p15.3;q12) 
tumours with probes being designed within each exon and at the 5’ and 3’ ends of each 
exon (six probes in total). MLPA confirmed an intragenic deletion of UBE2QL1 exon 1 
in an oncocytoma from patient III:2 with exon 1 probes showing an average loss of peak 
area by 31% compared to an unrelated normal renal DNA sample. Exon 1 probe 
deviation from reference probes within the same sample was shown to be significant   
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using the two tailed t-test (P<0.01) confirming a UBE2QL1 exon deletion in patient III:2 
(Figure 3.6). As both UBE2QL1 alleles were shown to be disrupted in patient III:2 thus 
complying with Knudson’s TSG two-hit model, UBE2QL1 was hypothesised to function 
as a potential RCC TSG. 
 
 146 
 
Figure 3.4 Derivative chromosome breakpoint maps 
Schematic breakpoint maps of der(5) and der(19) from the t(5;19)(p15.3;q12) created 
using ensemble genome browser (www.ensembl.org). Red lines indicate the breakpoint 
positions. Scale is shown in megabases(Mb). der(19) demonstrates no genes within the 
vicinity of the breakpoint for 73kb (upper panel) and der(5) breakpoint demonstrates 
disruption of UBE2QL1 (lower panel). 
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Figure 3.5 t(5;19)(p15.3;q12) derivative breakpoints 
Schematic illustration of t(5;19)(p15.3;q12) derivative breakpoints. Chromosome material 
originating from chromosome 19 is shown in red and from chromosome 5 in blue. 
UBE2QL1 on chromosome 5p was disrupted by the translocation leaving exon 2 and part of 
the intron on der(5) and exon 1 and part of the intron translocated to der(19). There were 
no other genes within the vicinity of the breakpoint for 23.5kb on der(5) and 73kb on 
der(19). Arrows within the chromosomes indicate the normal direction of transcription. 
Breakpoint positions are indicated in the diagram. 
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Figure 3.6 MLPA deletion analysis of UBE2QL1 exon 1 in t(5;19) patient III:II 
A, MLPA (Multiplex Ligation-dependent Probe Amplification) trace for 6 UBE2QL1 
probes. All 3 UBE2QL1 exon 1 probes show an average loss of 31% (arrowed) in a 
t(5;19)(p15.3;q13.1) associated oncocytoma from patient III:2 as compared with unrelated 
normal renal tissue, NN1. UBE2QL1 probe locations: Ex1/2 = within exon, Ex1/2+ =3’ of 
exon, Ex1/2- = 5’ of exon. Reference probes are labelled. B, UBE2QL1 MLPA probe 
deviation from reference probes for exons 1 and 2. Deviation of exon 1 probes is 
significant indicating a deletion of exon 1. Unpaired t test, P=0.0048, Error bars= SEM, 
**= P<0.01. 
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3.2.6   Expression analysis of HIF-1/2 targets in t(5;19)(p15.3;q12) renal tumours 
As explained in section 1.3 VHL-associated renal tumourigenesis involves the 
deregulation of HIF and subsequently HIF target genes. To investigate if UBE2QL1 RCC 
tumourigenesis was associated with HIF deregulation, expression analysis of the HIF-1 
and HIF-2 target genes; carbonic anhydrase 9 (CA9) and Cyclin D1 (CCND1) 
respectively, was undertaken. Immunohistochemical staining of three t(5;19)(p15.3;q12) 
associated renal tumours from individuals III:1 and III:2 (two oncocytomas and one 
chromophobe RCC) for HIF target genes CA9 and CCND1 was kindly undertaken by Dr 
Anne-Bine Skytte.  None of the tumours displayed up-regulation of CA9 or CCND1 
when compared to sporadic ccRCCs with known HIF deregulation, thus if UBE2QL1 
does function as an RCC TSG than it likely causes RCC tumourigenesis via novel 
mechanisms (Figure 3.7). 
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Figure 3.7  HIF-1/2 target gene immunohistochemistry on t(5;19)(p15.3;q13.1) 
tumours carried out by Anne-Bine Skytte 
Immunohistochemistry (IHC) of HIF targets on three t(5;19)(p15.3;q13.1) associated 
renal tumours. A, Carbonic anhydrase (CA9) IHC in a t(5;19)(p15.3;q13.1) 
oncocytoma. B, Carbonic anhydrase (CA9) IHC in a t(5;19)(p15.3;q13.1) 
chromophobe renal tumour. Both A and B show no CA9 up-regulation as compared 
to C, CA9 up-regulation shown in a sporadic clear cell RCC through IHC. D, IHC of 
cyclin D1 (CCND1) in a t(5;19)(p15.3;q13.1) chromophobe renal tmour showing no 
up-regulation compared to E, a sporadic chromophobe RCC showing up-regulation 
of CCND1. 
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3.3    Conclusion 
 Characterisation of the t(5;19)(p15.3;q12) breakpoint region allowed the 
identification of a disrupted uncharacterised gene UBE2QL1. As the t(5;19)(p15.3;q12) 
was associated with RCC in one family and a UBE2QL1 exon 1 deletion was detected in 
an oncocytoma in one of the t(5;19)(p15.3;q12) patients, this suggested UBE2QL1 could 
be the causative gene within this family following Knudsons two hit model. As 
UBE2QL1 possibly functions as a novel RCC TSG it was essential to determine if 
UBE2QL1 functioned within the same pathway as VHL thus initiating RCC 
tumourigenesis through the same means. VHL-dependent RCCs (and familial RCC 
associated with FH and SDHB) are caused by the dysregulation of HIF-1/2 leading to 
upregulation of HIF-1/2 target genes, therefore VHL-dependent RCCs show a dramatic 
increase in expression of HIF-1/2 target genes such as CA9 and CCND1 on 
immunohistochemistry. t(5;19)(p15.3;q12) oncocytoma and chromophobe slices showed 
no upregulation of HIF targets CA9 and CCND1 thus suggesting UBE2QL1 
tumourigenesis initiation may function through an alternative pathway to that of VHL.  
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Chapter Four: Genetic and 
epigenetic analysis of UBE2QL1 in 
RCC  
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4.1   Introduction: Is UBE2QL1 inactivated in other familial and 
sporadic RCCs? 
UBE2QL1 was the only gene within the vicinity of the t(5;19)(p15.3;q12) 
breakpoints and a second hit in the wildtype (wt) UBE2QL1 allele was identified in a 
t(5;19)(p15.3;q12) associated tumour. This suggested UBE2QL1 maybe a novel TSG 
responsible for RCC tumourigenesis in the t(5;19)(p15.3;q12)  family.  It was therefore 
necessary to identify if UBE2QL1 is a novel RCC TSG in other familial and/or sporadic 
RCC cases. There are a number of mechanisms including chromosomal translocations 
that can lead to the deregulation of TSGs in cancers; gene mutations, gene deletions and 
promoter methylation (see section 1.1.2 for details). All three mechanisms of TSG 
inactivation were investigated for UBE2QL1 in sporadic RCCs to determine if, like VHL, 
UBE2QL1 was important for the tumourigenesis in both sporadic and familial cases. 
 
4.1.1   Aims 
UBE2QL1 mutation, promoter methylation and gene deletion analysis were 
undertaken in sporadic RCC cell line and tumour samples to determine if UBE2QL1 gene 
deregulation was occurring in other RCC cases.  
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4.2   Results 
 
4.2.1  UBE2QL1 mutation analysis in RCCs 
Mutation analysis of the exons and exon/intron boundaries of UBE2QL1 was 
undertaken by direct sequencing in (i) 116 sporadic RCC tumours; (ii) 17 RCC derived 
cell lines; and (iii) lymphocyte derived DNA from 71 individuals with a genetic 
predisposition to the development of RCC, the nature of which is not known. No 
mutations or polymorphisms were detected. As no polymorphisms were detected in the 
protein coding region or splice sites and only 3 rare synonymous polymorphisms have 
been detected by dbSNP, 1000 genomes and variant server (see section 3.2.4), it was 
deduced that UBE2QL1 is a highly conserved gene. This therefore suggests there is 
strong negative selection during UBE2QL1 evolution due to functional constraint, thus 
any harmful variants of UBE2QL1 would diminish an individual’s capacity to succeed 
reproductively thus causing removal of deleterious alleles from the population, this is 
also known as purifying selection. It was also shown in section 3.2.4 that UBE2QL1 has 
remained highly conserved during its evolution, thus evidence suggests UBE2QL1 may 
be an important gene in organism viability, though further studies in animal models 
would need to be carried out to test this hypothesis.  
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4.2.2    UBE2QL1 CpG island 
CpG islands can be identified as a 200bp stretch of DNA with GC content of 
≥50% and an observed CpG/expected CpG (ObsCpG/ExpCpG) ratio of ≥0.60.  The 
(ObsCpG/ExpCpG) ratio is calculated using the following formula: number of (CpGs/ 
(number of Cs x number of Gs)) x total number of nucleotide (Han & Zhao 2009). To 
determine if UBE2QL1 contains a promoter CpG island and therefore could undergo 
deregulation via promoter hyper-methylation in tumours the promoter and 5’ UTR of 
UBE2QL1 was examined using the UCSC genome browser (http://genome.ucsc.edu/). A 
250bp region 5’ to the transcription start of UBE2QL1 showed a CpG content of 66% and 
a (ObsCpG/ExpCpG) ratio of 0.8 suggesting UBE2QL1 transcription could be regulated 
by promoter methylation (Figure 4.1).  
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Figure 4.1 UBE2QL1 CpG island 
UBE2QL1 CpG island found on Chr5:6,448,710-6,449,006bp (hg19). Forty-seven CpG 
dinucleotides  within the amplified region are labelled 1-47. The transcriptional start site 
is highlighted grey and the transcription direction is shown by the full arrow. Sequences 
of the nesting primers used for COmbined Bisulphite Restriction Analysis (COBRA) are 
shown with half arrows. 
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4.2.3   UBE2QL1 expression and methylation analysis in RCC cell lines  
RT-PCRs (reverse transcriptase-PCR) were carried out to determine if UBE2QL1 
expression was deregulated in RCC cell lines. Complete loss of UBE2QL1 expression 
was shown in 11/18 RCC cell lines thus suggesting UBE2QL1 may be deregulated 
(Figure 4.2). Promoter methylation is a common mechanism of TSG inactivation in many 
cancers including RCC (see section 1.1.4). One method to detect gene inactivation due to 
promoter methylation within cell lines is to extract protein from the cell lines before and 
after incubation with the de-methylating agent 5-Aza-2’-deoxycytidine (5-Aza). 5-Aza is 
a nucleoside anaolog which becomes incorporated into the cell’s DNA, it inhibits 
methyltransferases due to stable complexes forming between the 5-Aza residues in the 
DNA and the methyltransferases. mRNA expression analysis pre and post 5-Aza can help 
determine if a gene has been inactivated due to promoter methylation as it would show 
loss (or reduced) expression pre 5-Aza and increased expression post 5-Aza due to the 
inhibition of promoter methylation within the cells. RCC cell line mRNA was extracted 
pre and post 5-Aza treatment courtesy of Dr. Mark Morris. Eleven RCC cell lines showed 
decreased UBE2QL1 mRNA expression via RT- PCR. After 5-Aza treatment re-
expression of UBE2QL1 was observed in 6/11 RCC cell lines suggesting epigenetic 
silencing of UBE2QL1 by promoter methylation was taking place in these cell lines 
(Figure 4.2). 
 
To confirm UBE2QL1 promoter methylation within the RCC cell lines, COBRA 
(COmbined Bisulfite Restriction Analysis) was undertaken. COBRA involves the 
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bisulfite modification of the cell line DNA leading to changes in the DNA sequence 
depending on whether the DNA is methylated or unmethylated. Methylated cytosines 
remain as cytosines and unmethylated cytosines become thymines. A restriction enzyme 
(BstUI) that recognises the restriction site ‘CGCG’ can then be used in a digest reaction 
to cut any CpGs within the amplified promoter region. Only methylated CpGs will be cut 
and therefore only methylated UBE2QL1 promoter regions will show digested products 
when run on an agarose gel, see section 2.4 for details. UBE2QL1 methylation was 
confirmed by COBRA in 5/5 RCC cell lines that showed reduced expression (Figure 
4.2). 
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Figure 4.2 UBE2QL1 expression, pre and post 5-aza and methylation results in RCC 
cell lines 
A, Reverse transcriptase (RT) – PCR shows complete loss of UBE2QL1 expression in 
11/18 RCC cell lines (upper band). GAPDH expression levels are shown to verify the 
same amount of RNA was used for each RCC cell line (lower band). –ve = negative 
control with no RNA added to the RT-PCR reaction. B, RT-PCR of RCC cell lines grown 
without 5-aza (-) and with 5-aza (+).  5 RCC cell lines that showed increased expression 
of UBE2QL1 post 5-Aza are presented (upper band) along with the GAPDH expression 
levels shown as a positive control (lower band). C, Bisulphite modified DNA was used to 
amplify the UBE2QL1 CpG island and subsequently used in a BstUI digest reaction. The 
PCR products are shown with no BstUI added (-) and with BstUI added (+). 
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4.2.4   Expression and methylation analysis of UBE2QL1 in sporadic RCCs 
As UBE2QL1 was shown to be regulated by promoter methylation in RCC cell 
lines this suggested it may also be deregulated in RCC sporadic tumours. Expression 
analysis of UBE2QL1 was undertaken in 28 sporadic RCC tumours compared to 
corresponding normal kidney tissue from the same patients by quantitative real-time PCR 
(QRT-PCR). UBE2QL1 demonstrated reduced mRNA levels (>40% loss) in 22/28 
(78.6%) sporadic RCCs compared to the corresponding normals (CN) (Figure 4.3). Both 
promoter methylation and UBE2QL1 exon deletions had previously been detected as 
mechanisms of UBE2QL1 gene deregulation, it was therefore  deduced these mechanisms 
were likely the cause of UBE2QL1 decreased expression in sporadic RCCs.  
 161 
 
Figure 4.3 Expression analysis of UBE2QL1 in sporadic RCCs 
Quantitative Real-Time PCR (QRT-PCR) results showing the mean values of UBE2QL1 
expression for 28 sporadic RCCs compared with matched corresponding normal (CN) 
renal tissue. 1= 100% expression compared to CN. All samples were normalised to β-
actin. n = 3 independent assays run in triplicate for all samples. Error bars represent ± 
standard error of the mean (SEM). 
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 As UBE2QL1 showed decreased mRNA expression in RCC tumours COBRA 
analysis was undertaken to determine if CpG island promoter methylation was the 
mechanism for this deregulation in expression. UBE2QL1 promoter methylation was 
detected in 14/66 (21.2%) sporadic RCC tumours. CNs from the same patient and 5 
unrelated normal renal tissues did not show promoter methylation (Figure 4.4). 
UBE2QL1 QRT-PCR data was available for 8 of the methylated sporadic RCCs (1T, 2T, 
5T, 13T, 17T, 18T, 20T and 22T) (no RNA was available for the other sporadic RCC 
cases) all demonstrating a ≥60% decrease in expression compared to matched CNs 
(Figure 4.3). To determine the extent of promoter methylation within the sporadic RCC 
tumours the methylation index (MI) was calculated. This involves calculating the total 
methylated CpGs and dividing by the total number of CpGs sequenced. Single UBE2QL1 
alleles were cloned and sequenced by cloning the bisulfite modified UBE2QL1 CpG 
island into pGEM-T vectors and extracting the DNA from positive clones which were 
subsequently sequenced. Each RCC tumour had 8-12 clones sequenced to determine the 
extent of UBE2QL1 methylation within the tumour. Forty-seven CpGs were identified 
within the UBE2QL1 CpG island and were labelled 1-47 (Figure 4.1 ). The sequencing 
data from each clone was used to produce representative UBE2QL1 CpG island figures 
showing both methylated and unmethylated CpGs for all the clones for each tumour. 
Four/eleven UBE2QL1 methylated RCC tumours showed an MI of >40% and were 
therefore determined to be hypermethylated, a further 6/11 showed an MI of 10-40% 
suggesting partial promoter methylation. One tumour presented an MI of <10%. MI 
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analysis was not carried out for 3 tumours due to lack of DNA from these tumours 
(Figure 4.5).  
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Figure 4.4 BstU1 digest of bisulphite modified UBE2QL1 CpG island in sporadic 
RCCs. 
BstU1 digests of bisulphite modified UBE2QL1 CpG island for 14 sporadic RCCs that 
showed promoter methylation. Eight tumours (T) with matched corresponding normals 
(N) (top panel) and 6 tumours without Ns (bottom left panel) are shown. Six normal renal 
tissues (NN) demonstrate no promoter methylation (bottom right panel). The PCR 
products are shown with no BstUI added (-) and with BstUI added (+). BstUI digested 
products signify promoter methylation.  Negative control (-ve) = no DNA template added 
and positive control (+ve) = PCDNA3.1 plasmid to demonstrate the digestion reaction 
worked. 
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Figure 4.5 Schematic diagram representing UBE2QL1 CpG island clones for 4 
sporadic RCCs. 
Bisulfite modified UBE2QL1 CpG islands were cloned for 11/14 methylated sporadic 
RCCs.  The analysed CpG dinucleotides are number 1-47 and are represented as 
individual circles as shown on the top panel. Each horizontal line of 47 CpG 
dinulceotides represents one clone for that particular sporadic RCC. Black circles 
signify methylated CpGs and white circles unmethylated CpGs. Four sporadic RCCs 
(2T, 20T, 22T and 29T) that demonstrated hypermethylation with an MI >40% are 
shown. MI is calculated as a percentage of total methylated CpGs for one RCC tumour 
/ total number of CpGs sequenced for the same tumour. 
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4.2.5  LOH (Loss of heterozygosity) of 5p15.3 in sporadic RCCs 
Microsatellite marker analysis is a technique used to determine if a region within 
the genome has undergone loss of heterozygosity (LOH). Microsatellites are short 
tandem repeat sequences that can be from 2-7 nucleotides, for example the dinucleotide 
repeat CACACA. The number of repeat sequences within a microsatellite can be highly 
variable, resulting in different length microsatellites. Allelic variation of microsatellite 
lengths can be highly informative when determining LOH of chromosomal regions when 
comparing tumour DNA and CN DNA.  NCBI map viewer 
(http://www.ncbi.nlm.nih.gov/projects/mapview/) was used to identify known, 
characterised microsatellite markers found within the same chromosomal band as 
UBE2QL1, specifically 5p15.3, with a known LOH frequency of >60%.  Two 
microsatellite markers were identified that met the correct criteria; D5S2505 (5,869,996 -
5,870,453bp) and D5S2054 (5,944,886 – 5,945,198bp) (hg19) both found within the 
5p15.3 chromosomal band. Primers were designed to amplify the microsatellite markers 
by PCR and products were separated by electrophoresis. Markers that were heterozygous 
for an individual in the CN were labelled as informative as a loss of heterozygosity in the 
tumour could be identified by a loss of one of the markers. Homozygote markers are non-
informative as a loss of one allele cannot be detected. To establish possible LOH 
candidates, the peak height ratio was calculated for both the matched CN and tumour 
using the following equation: Peak area of allele 1 divided by peak area of allele 2. The 
peak height ratio of the tumour was then divided by the CN peak height ratio and a 
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number ≤0.5 was concluded to be due to LOH of that particular allele. The microsatellite 
marker D5S2505 was found to have LOH in 3/28 informative sporadic RCC tumours. 
LOH was confirmed in two of these tumours with the D5S2054 marker while the third 
tumour was non-informative for this marker (Figure 4.6). 
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Figure 4.6 Microsatellite marker analysis for 5p13.3 in sporadic RCC tumours 
Microsatellite traces for 3 tumours (16T, 24T and 25T) showing loss of marker D5S2505 
and 2 tumours (16T and 24T) showing loss of D5S2054, both markers reside at 
chromosome position 5p15.3. T = Tumour, N = normal kidney tissue from the same 
individual, NI = non-informative due to homozygosity of marker. The peak height ratio 
for the tumour and normal was calculated (Peak Height (PH) of allele 1 / PH of allele 2) 
and loss of heterozygosity was established by dividing the tumour peak height ratio by the 
normal peak height ratio. A number ≤0.5 was due to LOH. 
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4.2.6   Multiplex Ligation-dependent Probe Amplification (MLPA) of UBE2QL1 in 
sporadic and familial RCCs 
As the microsatellite marker analysis suggested there was LOH of 5p15.3 for 3 
sporadic RCC tumours this suggested UBE2QL1 could be deleted presuming the entire 
chromosomal band was lost. Smaller gene deletions can also occur in tumours leading to 
the complete or partial deletion of TSGs (see section 1.1.2). To analyse if UBE2QL1 was 
deleted in the tumours showing 5p15.3 LOH and if smaller gene deletions of UBE2QL1 
had also occurred in sporadic RCCs, specific UBE2QL1 probes were designed for MLPA 
analysis. MLPA allows the detection of abnormal copy numbers of very small targets 
(50-70 nucleotides) thus allowing the detection of single exon aberrations within a gene 
(for details see section 2.5.1). Probes were designed for UBE2QL1 with exons 1 and 2 
and both 5’ and 3’ of each of the exons making a total of 6 probes. Peak heights of 
UBE2QL1 probes were compared to control reference probes for each sample and an 
average deviation of ≥30% from adjacent reference probes were regarded for all 
UBE2QL1 probes or single exon probes indicating a whole gene or exon deletion 
respectively. UBE2QL1 deletions were demonstrated in 8/49 (16.3%) sporadic RCC 
tumours with confirmed UBE2QL1 deletions in the three tumours that demonstrated LOH 
of 5p15.3, see section 4.2.5   (Figure 4.7).  
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Figure 4.7 UBE2QL1 deletion analysis via MLPA in sporadic RCCs 
A, MLPA (Multiplex Ligation-dependent Probe Amplification) traces of 3 sporadic renal 
tumours (20T, 25T and 29T) compared to a normal renal tissue (NN1).  Probe loss 
indicating UBE2QL1 deletions are shown by an arrow. 20T showed an average peak loss 
of 30.5% across all the UBE2QL1 probes, 25T an average peak loss of 32.3% and 29T an 
average peak loss of 35.7%. UBE2QL1 probe locations: Ex1/2 = within exon, Ex1/2+ 
=3’ of exon, Ex1/2- = 5’ of exon. Reference probes are labelled.  B, Total UBE2QL1 
probe deviations from reference probes for 8 sporadic RCCs. All tumours show a 
significant deviation of all UBE2QL1 probes compared to reference probes  signifying a 
complete gene deletion of UBE2QL1 (unparied t test). Error bars = SEM, * = P<0.05, 
**= P<0.01, ***= P<0.001. 
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4.3    Conclusion 
 UBE2QL1 was shown to be disrupted in sporadic RCC by promoter 
hypermethylation and LOH of the UBE2QL1 locus with UBE2QL1 deregulation 
demonstrating in 37% of sporadic RCCs. One sporadic tumour (20T) was confirmed to 
have both UBE2QL1 with both promoter methylation and gene loss been detected, thus 
following Knudson’s two hit model, suggesting UBE2QL1 is an important TSG in RCC 
tumourigenesis. 78.6% of sporadic RCCs showed a >40% loss of UBE2QL1 expression 
compared to the CN; therefore not all mechanisms of UBE2QL1 deregulation were 
detected. This suggests other, possibly indirect mechanisms, have led to UBE2QL1 
deregulation including aberrations of regulators of UBE2QL1 or disruptions in pathways 
upstream of UBE2QL1 expression. No intragenic UBE2QL1 mutations were detected, yet 
lack of coding region polymorphisms suggests UBE2QL1 has undergone strong negative 
selection during evolution suggesting it has an important role in organism viability.  
Although no mutations were detected this observation is reminiscent of RASSF1A a TSG 
which is often inactivated by methylation/allele loss in sporadic RCC and intragenic 
mutations are rarely detected (see section 1.3.4). The detection of UBE2QL1 aberrations 
in sporadic cases of RCC has demonstrating that the study of inherited forms of RCC has 
provided important insights into the pathogenesis of the more common sporadic forms of 
RCC. 
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Chapter Five: UBE2QL1 
suppresses RCC cell line 
proliferation and colony formation 
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5.1  Introduction: Does UBE2QL1 functions as a tumour suppressor? 
UBE2QL1 was found to be disrupted by the constitutional t(5;19)(p15.3;q13.1) 
associated with familial RCC and an intragenic deletion of UBE2QL1 exon 1 was 
detected in an oncocytoma of a t(5;19)(p15.3;q13.1) patient (section 3.2).  It was also 
established that UBE2QL1 showed decreased expression of >40% in 78.6% of sporadic 
RCCs compared to CN and in 21.2% and 16.3% of cases this deregulation was due to 
promoter methylation and gene deletions, respectively (section 4.3). This data suggests 
UBE2QL1 was likely to function as a novel RCC tumour suppressor gene as it was found 
to be disrupted in both sporadic and familial RCCs by a number of mechanisms. To 
determine if UBE2QL1 exhibited growth suppressor properties both colony formation 
assays and soft agar growth assays were carried out using UBE2QL1 silenced RCC cell 
lines.  
 
Colony formation assays involve the introduction of a tumour suppressor or 
oncogene into a cell line via plasmid transfection.  Cells containing the plasmid can be 
selected for as the plasmids contain an antibiotic resistance gene such as the neomycin 
resistance gene. Treating cells with Geneticin (G418) an aminoglycoside antibiotic 
similar in structure to neomycin, enables only cells resistant to G418, and therefore 
containing the plasmid, to survive. Control experiments involve the transfection of the 
empty vectors containing only the antibiotic resistant gene. Two weeks after transfection 
surviving cells are seeded for colony formation assays and the number of colonies that 
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have grown to a size ≥100µm after 4 weeks determined. The growth of colonies in the 
presence of a tumour suppressor gene would normally be significantly reduced compared 
to the control. Soft agar growth assays are carried out in a similar manner to colony 
formation assays, the difference being the cells are grown in soft agar as opposed to being 
grown on a tissue culture dish, thus measuring the ability of the cells to grow in an 
anchorage-independent manner. The process of transformation of normal cells to 
neoplastic cells produces a population of cells that proliferate independently of external 
and internal signals that would normally inhibit growth. Anchorage-independent growth 
is the most common method for detecting cell transformation as this measures the ability 
of cells to proliferate in a semisolid culture media (soft agar). Cancer cell lines have 
already undergone this transformation and are often capable of efficiently undergoing 
anchorage-independent growth; the introduction of a tumour suppressor gene into these 
cancer cell lines should therefore hinder their ability of anchorage-independent growth 
thus producing fewer and smaller colonies after the incubation period.  
 
5.1.1   Aims 
Colony formation assays and soft agar growth assays were carried out using a 
naturally occurring UBE2QL1 silenced RCC cell line(s) transfected with either 
UBE2QL1 or empty vector to determine if UBE2QL1 possessed tumour suppressor gene 
properties, such as proliferation and anchorage-independent growth inhibition, thus 
reversing the effects of neoplastic cell transformation. 
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5.2 Results 
 
5.2.1  UBE2QL1 colony formation assays 
To determine if the function UBE2QL1 allowed the suppression of growth of 
RCC cells, the UBE2QL1 silenced RCC cell lines SKRC47 and SKRC39 were 
transfected with FLAG tagged wild-type UBE2QL1 expression plasmids or FLAG empty 
vector plasmids, which after two weeks of selection were subsequently seeded  at varying 
densities to carry out colony formation assays. UBE2QL1 re-expression produced a 
57.5% (P<0.0001, SEM 2.556) and a 54.6% (P<0.0001, SEM 0.87) reduction in colonies 
compared with those transfected with empty vector in SKRC47 and SKRC39 cell lines, 
respectively.  This data suggests UBE2QL1 possesses growth suppressive functions in 
renal cancer cells (Figure 5.1). 
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Figure 5.1 Colony formation assays to assess UBE2QL1 growth suppression function 
in RCC cell lines. 
Equal amounts of G418 resistant empty vector (EV) pFLAG-CMV-4 and pFLAG-CMV-
4-wtUBE2QL1 were transfected into SKRC47 and SKRC39 cell lines which after 2 
weeks of selection and seeding, were incubated in media containing G418.  After four 
weeks plates were stained with 0.4% crystal violet and manually counted blindly using 
an average of 3 counts (n = 3). A, (Top panel) chart demonstrating the percentage of 
SKRC47 colonies (>100µm) for cells expressing UBE2QL1 compared to cells 
expressing EV. Error bars represent standard error of the mean (SEM). (t = 22.5199, 
SEM = 2.556, *** = p<0.0001). B, (Top panel) chart demonstrating the percentage of 
SKRC39 colonies (>100µm) for cells expressing UBE2QL1 compared to cells 
expressing EV. (unpaired t-test: t = 62.5977, SEM = 0.87,  *** = p<0.0001). (Bottom 
Panel) Photographic image of representative plates showing colony growth for 
UBE2QL1 (left) expressing cells compared to EV (right) after 4 weeks for SKRC47 (A) 
and SKRC39 (B) RCC cell lines. 
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5.2.2  Stable UBE2QL1 expressing SKRC47 clones 
To produce SKRC47 clones stably expressing UBE2QL1 or empty vector (EV) 
cells were initially transfected with EV pFLAG-CMV-4 and pFLAG-CMV-4-
wtUBE2QL1. Transfected cells were selected for using G418 antibiotic as plasmids 
contained a neomycin resistant gene. Selected cells were seeded and 12 colonies were 
selected and grown in separate dishes. Western blot analysis was used to determine if 
clones stably expressed Flag-UBE2QL1 after a four week period. One clone was shown 
to stably express Flag-UBE2QL1 and was subsequently used in the soft agar assays 
(Figure 5.2).  
 
5.2.3   UBE2QL1 soft agar assays 
The ability of UBE2QL1 to inhibit anchorage independent growth in soft agar was 
assessed by soft agar growth assays. Flag-UBE2QL1 or Flag-EV stably expressing 
SKRC47 clones were seeded in six well dishes in soft agar and compared following five 
weeks of incubation. There was a statistically significant 77% reduction in colony growth 
(number of colonies ≥100µm) for UBE2QL1 expressing cells compared to EV (p<0.0001, 
SEM 17.252) (Figure 5.2). This result verified the ability of UBE2QL1 to inhibit 
anchorage independent growth and therefore suggests UBE2QL1 potentially inhibits the 
transforming abilities of neoplastic cells by functioning as a tumour suppressor. 
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Figure 5.2 Soft agar growth assays to assess UBE2QL1 inhibition of anchorage 
independent growth. 
Clones of SKRC47-pFLAG-CMV-4-wtUBE2QL1 and empty vector (EV) pFLAG-CMV-4 
were seeded at the same density into soft agar and incubated for five weeks after which 
colonies (>100µm) were blindly counted with a light microscope (n = 6). A, Chart 
demonstrating the number of colonies (>100µm) grown in an anchorage-independent 
manner after 4 weeks for clones expressing UBE2QL1 compared to cells expressing EV. 
Error bars represent standard error of the mean (SEM). (unpaired t-test: t = 9.6319, 
SEM = 17.252, *** = p<0.0001). B, Representative microscope images (x100 
magnification) of clones following five weeks of  incubation expressing either UBE2QL1 
(left) or EV (on the left), showing the difference in number and size of colonies. C, 
Western blot analysis of protein extracted from Flag-UBE2QL1 stably expressing 
SKRC47 clone and Flag-EV clone to confirm expression for soft agar assays. Blots were 
probed with anti-Flag (top panel) and anti-β-actin to confirm equal loading (bottom 
panel). 
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5.3    Conclusion 
 UBE2QL1 re-expression in UBE2QL1 silenced RCC cell lines demonstrated 
significant suppression of colony growth suggesting UBE2QL1 has anti-proliferative 
function thus demonstrating tumour suppressor properties. This was further supported by 
the ability of UBE2QL1 to diminish colony formation of an RCC cell line in soft agar, as 
anchorage independent growth represents a hallmark of tumourigenesis. These results 
along with the genetic and epigenetic evidence of UBE2QL1 dysregulation in sporadic 
and familial RCC, supports the notion that UBE2QL1 is a novel RCC tumour suppressor 
gene. Although components of E3 ubiquitin complexes (e.g. VHL and FBXW7) have 
clearly been implicated in tumourigenesis (see section 1.5) there is very little information 
regarding the potential role of E2 ubiquitin conjugating enzymes, although increased 
expression of some (e.g. UbcH10 and E2-EPF) has been described in some cancers 
(Okamoto et al. 2003b, 2003b; Tedesco et al. 2007; Roos et al. 2011; Seghatoleslam et al. 
2012). Thus it was determined important to investigate the function and role UBE2QL1 
plays in the cell to determine the mechanism of its tumour suppressor properties. 
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Chapter Six: UBE2QL1 ubiquitin 
conjugation, E3 binding partners 
and protein substrates 
 181 
 
 
6.1    Introduction: UBE2QL1 is part of the ubiquitin cascade  
 UBE2QL1 was an uncharacterised protein with an unknown function and 
therefore to understand the mechanism involved that allows UBE2QL1 to function as a 
novel RCC tumour suppressor gene it was important to determine the normal function of 
UBE2QL1 in the cell. The UBE2QL1 amino acid (aa) sequence shows homology to the 
family of ubiquitin conjugating enzymes known as E2 enzymes, these are characterized 
by a ~150aa ubiquitin conjugating domain (UBC) which contains a conserved active-site 
cysteine (C) residue that binds ubiquitin via a thioester bond (see section 1.4.1 for detail) 
(Figure 6.1). E2s form an important component of the ubiquitin cascade as they interact 
with an E3 ubiquitin ligase to ubiquitylate the protein substrate with substrate fate being 
determined by the nature of the ubiquitin chain(s) formed by the E2 enzyme (see section 
1.4). As UBE2QL1 showed homology to the family of E2 enzymes it was necessary to 
determine if UBE2QL1 functioned as an E2 conjugating enzyme. Alignment of 
UBE2QL1 with the UBC domain of E2 conjugating enzymes allowed the identification 
of a possible active cysteine (C88) which could be hypothesised to bind ubiquitin via a 
thioester bond (Figure 6.1). To determine if UBE2QL1 binds ubiquitin at residue C88 
mutant forms of UBE2QL1 that were predicted to affect the binding of ubiquitin were 
created. It has been shown that mutating the active C residue of E2 enzymes to an alanine 
(A) produces an E2 enzyme that lacks the capacity to bind ubiquitin as the thioester bond 
can no longer be formed (Sung et al. 1990).  Point mutations of the active C residues of 
E2 conjugating enzymes to a serine (S) residues have been demonstrated to bind 
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ubiquitin and ubiquitin-like proteins with a much more stable oxy-ester bond as opposed 
to the normal thioester bond (Wada et al. 2000). As the normal thioester created between 
an E2 active C and ubiquitin is often disrupted during normal lysis procedures a C-S 
mutant creating a more stable oxy-ester bond formation would potentially enhance 
ubiquitin binding and allow identification of ubiquitin binding to an E2 in vivo under 
normal lysis conditions (Jin et al. 2007).  Due to the aforementioned properties of E2 
conjugating active cysteine C-A and C-S mutants, UBE2QL1 C88A and C88S mutants 
were created to investigate the potential binding of ubiquitn at the C88 residue and were 
used in subsequent ubiquitin binding assays, along with wild-type UBE2QL1, in vitro 
and in vivo.  
 
Once ubiquitin is bound to an E2 ubiquitin conjugating enzyme the ubiquitin 
protein is transferred to a substrate leading to substrate ubiquitylation. This process is 
often facilitated via an E3 ligase complex which binds both the substrate and E2 enzyme 
(see section 1.4). Initially a yeast-2-hybrid was carried out by the German Cancer 
Research Centre using UBE2QL1 as bait to identify potential E3 protein binding 
partners. Only one potential binding partner was identified which was isolated only once: 
SUGT1 (suppressor of G2 allele of SKP1), yet this interaction could not be confirmed via 
co-immunoprecipition or mass spectrometry and was therefore deduced to be a false 
positive.  The interaction of E2 enzymes and E3 ligases are often weak as this allows for 
efficient E2 dissociation from the E3 enzyme after the transfer of the ubiquitin to make 
way for a new E2-ubiquitin molecule. It is also important to note E3 ligases often only 
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bind to E2 enzymes already thioesterified with ubiquitin, and not to the naked E2 
proteins.  It is often the case that many E2-E3 interactions are not discovered using 
normal methods to detect protein interactions, such as yeast-2-hybrids and pulldown 
assays, this is thought to be because the weak binding of E2 enzymes to E3 ligases is 
often disrupted in the wash steps of such assays, or the input E2 protein is non-
thioesterified with ubiquitin thus would not likely bind to its E3 partner (Deshaies & 
Joazeiro 2009). Although VHL is an E3 ligase enzyme and is the most frequently 
mutated gene in ccRCC, it was determined that it was not likely that UBE2QL1 partners 
with VHL to ubiquitinate VHL substrates, as staining of t(5;19)(p15.3;q12) renal tumours 
showed no HIF target gene deregulation, thus suggesting UBE2QL1 functions in a 
different pathway to that of VHL/HIFα.  
 
As mentioned above following initial failed attempts to identify a UBE2QL1 E3 
ligase binding partner, an in silico search using the full length UBE2QL1 protein 
sequence to identify potential binding motifs within the protein was performed using 
ELM (The Eukaryotic Linear Motif resource for Functional Sites in Proteins). This 
revealed a phosphodegron consensus sequence, VTPPVS at positions 154-159, which 
was proposed to act as an FBXW7 recognition motif (Nash et al. 2001) (Figure 6.2). 
FBXW7 is an F-box protein that provides substrate recognition to the CUL1-SKP1-
RBX1 SCF ubiquitin ligase (SCF
FBXW7
) complex, is inactivated in a variety of cancers 
and was previously found to be disrupted in a case of clear cell RCC associated with a 
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constitutional t(3;4)(q21;q31) (see section 1.5.1 and 1.5.2). Therefore it was important to 
ascertain the possible interaction between UBE2QL1 and FBXW7.  
Figure 6.1 UBE2QL1 amino acid alignment with the ubiquiting conjugating (UBC) 
domain. 
Alignment showing homology of UBE2QL1 and the UBC domain. Homologous amino 
acids are shown in yellow. The UBC domain active cysteine is indicated by an arrow 
showing homology to a C88 on UBE2QL1. 
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Figure 6.2 Schematic illustration of UBE2QL1 protein domains 
UBE2QL1 contains 161 amino acids with a ubiquitin conjugating (UBC) domain at 
residues 1-114aa and an FBXW7 binding domain at residues 154-159aa. Within the UBC 
domain is a potential active cysteine at C88. 
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6.1.1   Aims 
UBE2QL1 plasmid constructs expressing mutants UBE2QL1
C88A
 and 
UBE2QL1
C88S
, were used in an in vitro transcription/translation rabbit reticulocyte lysate 
system that supports ubiquitin conjugation and in His pull down assays, along with wild 
type UBE2QL1, to determine if UBE2QL1 binds ubiquitin at amino acid position C88. 
As UBE2QL1 was shown to contain a consensus sequence proposed to act as an FBXW7 
recognition motif, both immuoprecipitations and co-localisation experiments were 
undertaken with UBE2QL1 and FBXW7α/γ to establish if the proteins interacted in vivo. 
Degradation assays were performed to ascertain if UBE2QL1 re-expression increased the 
rate of FBXW7 substrate degradation. 
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6.2 Results: 
6.2.1   UBE2QL1 ubiquitin binding 
Wild-type UBE2QL1 (wtUBE2QL1) and UBE2QL1
C88A
 were synthesised using 
an in vitro transcription/translation rabbit reticulocyte lysate system that incorporates L-
-[
35
S]-methionine into the proteins. The rabbit reticulocyte lysate contains all the 
machinery for ubiquitylation (E1 ubiquitin-activating enzyme, ubiquitin and ATP) and 
therefore supports ubiquitin conjugation. The reticulocyte UBE2QL1 protein synthesis 
products, when run on an agarose gel and detected using x-ray film, showed 
UBE2QL1
C88A
 migrated to the expected UBE2QL1 size of 18KDa whereas wtUBE2QL1 
migrated to a size of 26KDa. As it was predicted that UBE2QL1 binds ubiquitin at 
residue C88 and ubiquitin itself runs to a size of 8KDa, the results suggest this increase in 
size of wtUBE2QL1 was due to bound monoubiquitin. UBE2QL1
C88A
 was likely unable 
to bind ubiquitin by inhibiting the formation of a thioester bond.  
 
With this indication that UBE2QL1 contains a central active-site cysteine residue 
(C88) involved in ubiquitin binding, it was determined important to investigate whether 
UBE2QL1 binds ubiquitin directly in vivo. HEK293 cells were transfected with 
expression plasmids encoding Hisx6–ubiquitin (His-Ubq) or Hisx6 empty vector (His-
EV) and either wtUBE2QL1, UBE2QL1
C88A 
or UBE2QL1
C88S
. His pull-downs were 
carried out in both the presence and absence of β-mercaptoethanol, which is predicted to 
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reduce thioester bonds thus breaking the bond between E2 enzymes and ubiquitin. In the 
absence of β-mercaptoethanol, wtUBE2QL1 and UBE2QL1C88S were both shown to bind 
ubiquitin with UBE2QL1
C88S
 showing enhanced avidity for ubiquitin relative to 
wtUBE2QL1. In the presence of β-mercaptoethanol, and consistent with observations for 
some other E2 enzymes, wtUBE2QL1 was no longer shown to bind ubiquitin, whilst 
UBE2QL1
C88S
 retained its ability to bind ubiquitin. This is most likely due to the 
reduction of the thioester bond produced between wtUBE2QL1 and ubiquitin. 
UBE2QL1
C88S
 most likely produced an oxy-ester bond with ubiquitin which is a much 
more stable bond able to withstand the reducing abilities of β-mercaptoethanol. 
UBE2QL1
C88A was unable to bind ubiquitin in either the presence or absence of β-
mercaptoethanol as was shown with the reticulocyte lysate protein synthesis kit. In all 
cases of UBE2QL1 binding ubiquitin only the binding of mono-ubiquitin was detected. 
Together these results indicate that UBE2QL1 is monoubiquitinated in vivo at an active-
site cysteine residue C88. 
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Figure 6.3 UBE2QL1 binds ubiquitin via an active cysteine, C88. 
A, wtUBE2QL1 and UBE2QL1
C88A
 were synthesised with the incorporation of [
35
S]-
methionine using an in vitro reticulocyte lysate transcription/translation kit that 
supports ubiquitin conjugation. UBE2QL1
C88A
 migrated to the correct protein size of 
18KDa. wtUBE2QL1 migrated to a size 26KDa. As ubiquitin has a molecular weight of 
8KDa this suggested the increase in size of wtUBE2QL1 was due to mono-
ubiquitylation. B, HEK293 cells were transfected with FLAG-wtUBE2QL1 or FLAG-
UBE2QL1
C88S
 or FLAG-UBE2QL1
C88A
 mutants and Hisx6-ubiquitin or His-EV (as 
indicated). Ubiquitin binding was assessed with His pull-downs using dynabeads in the 
presence (+) and absence (-) of β-mercaptoethanol and probed with anti-FLAG and 
anti-HIS. Input bands were detected at a size of 18KDa (UBE2QL1 Mr = 18KDa). All 
other bands were detected at a size of 26KDa due mono-ubiquitination of UBE2QL1 
and UBE2QL1
C88S
. 
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6.2.2   UBE2QL1 and FBXW7 protein interaction 
As a number of attempts to identify a UBE2QL1 protein binding partner(s), 
including a yeast 2 hybrid carried out by the German Cancer Research Centre and 
immunoprecipitations followed by mass spectrometry, produced no UBE2QL1 binding 
partner candidates, an ELM (Eukaryote Linear Motif) search was undertaken. ELM is an 
open access website (http://elm.eu.org/) that uses a comprehensive database of validated 
motifs to predict functional motifs within a protein of interest, including ligand motifs, 
post-translational modification sites, subcellular targeting sites and cleavage sites. These 
linear motifs are short modules within proteins that allow low-affinity interactions 
providing a level of protein regulation within the cell and are important in targeting 
protein localisation, directing protein turnover and regulating cell signalling (Puntervoll 
et al. 2003; Dinkel et al. 2012). A UBE2QL1 ELM search identified two linear motifs 
outside of the UBC globular domain; globular domain filtering is undergone as functional 
sites must be accessed and therefore don’t often reside in globular domains with most 
true motifs being present in the exposed loops  (Table 6.1). One motif identified was the 
FBXW7 binding motif (Figure 6.2), FBXW7 is one of the many F-box proteins that 
functions as a substrate recognition component for the E3 ligase complex SCF.  In one 
study FBXW7 was found to be disrupted by a familial constitutional translocation 
associated with RCC and was shown to be mutated in small number of sporadic cases of 
RCC, thus suggesting FBXW7 may play a role in RCC tumourigenesis (see section 
1.5.2). FBXW7 has also been shown to regulate the degradation of mTOR and as the 
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mTOR pathway has been demonstrated to be an important pathway in RCC 
tumourigenesis, this along with the aforementioned points indicated it was important to 
determine if UBE2QL1 and FBXW7 interacted in vivo (see section 1.5.1 and 1.5.2). 
 
Table 6.1 Linear motifs identified in the UBE2QL1 protein sequence by ELM 
Linear motifs were detected using the ELM (Eukaryote Linear Motif) website. After 
taxonomic range, cell compartment, structure and globular domain filtering two linear 
motifs were found within UBE2QL1; a phosphothreonine motif that binds FHA domains 
and an FBXW7 phosphodegron motif. Key:  . = any amino acid, [...] = amino acids listed 
are allowed, {min, max} = specified range of amino acids; min required and max 
allowed, (...) = Used to mark positions of specific interest; e.g. the amino acid being 
covalently modified, or used to group parts of the expression. A probability score is 
calculated which is a low number for strictly annotated regular expressions and a high 
number for degenerate ones. This score reflects the probability of the regular expression 
to be found by chance in a given protein sequence and helps limit the number of 
predicted degenerate motif instances. The motif probability cut-off was set to 0.1. 
 
  
 
.
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Elm Name 
Instances  
(Matched 
Sequence) 
Positions 
(aa) 
Elm Description 
Cell 
Compartment 
Motif 
Probability 
score 
LIG_FHA_1 WVTPPVS 153-159 
Phosphothreonine 
motif binding a 
subset of FHA 
domains that 
show a preference 
for a large 
aliphatic amino 
acid at the pT+3 
position. 
nucleus ..(T)..[ILV] 0.0087 
LIG_SCF_FBW7_1 VTPPVS 154-159 
The TPxxS 
phospho-
dependent degron 
binds the FBXW7 
F box proteins of 
the SCF 
(Skp1_Cullin-
Fbox) complex. 
cytosol, 
nucleus 
[LIVMP].{0,2}(T)P..([ST]) 0.0007 
     
 Immunofluorescence studies to determine UBE2QL1 cell expression were carried 
out using both FLAG and MYC tagged UBE2QL1 constructs in HeLa, Hek293 (data not 
shown) and SKRC47 (data not shown) cell lines. As an antibody was not available to 
detect endogenous UBE2QL1 only exogenous expression could be detected using 
expression constructs. UBE2QL1 appears to localise in small clusters within the nucleus 
(Figure 6.4).  From analysing the DAPI (4',6-diamidino-2-phenylindole) stains these 
small clusters do not appear to be in the nucleoli as these are displayed as black spots 
within the nucleus, this is due to little DNA residing within the nucleoli and DAPI only 
binding to double stranded DNA (Figure 6.4). These UBE2QL1 clusters would therefore 
most likely be localised to specific subdomains known as nuclear bodies found within the 
nucleus. There are a number of nuclear bodies that have been characterised including 
Cajal bodies, PML bodies, Gems (gemini of Cajal bodies), cleavage bodies, clastosomes 
and nuclear speckles (Spector 2001; Spector & Lamond 2011; Lafarga et al. 2002). Many 
of these nuclear bodies contain specific machinery for particular tasks within the nucleus, 
for example nuclear speckles are enriched in pre-mRNA splicing factors and clastosomes 
are composed of components of the ubiquitin-proteasome pathway. Further investigations 
using specific nuclear body markers would need to be carried out to confirm which 
nuclear body UBE2QL1 resides in. 
 
 Immunofluorescence and co-immunprecipitation experiments were undertaken to 
determine if UBE2QL1 and FBXW7 interacted within the cell. FBXW7 has three known 
isoforms that are produced by alternative splicing (FBXW7 α, β and γ). The three 
isoforms are differentially regulated and FBXW7α is expressed at much greater levels 
 194 
 
than FBXW7β and FBXW7γ, in most human and primary cell lines (Welcker & Clurman 
2008). All three isoforms have been shown to localise to specific areas within the cell, 
with FBXW7β exhibiting cytoplasmic localisation and both FBXW7γ and FBXW7α 
localising to the nucleus with some clustering to specific domains within the nucleus 
(Welcker & Clurman 2008). Immunofluorescence of FLAG-FBXW7 α, β, and γ in HeLa 
cells demonstrated similar localisation patterns to what has previously been reported, 
suggesting the FBXW7 constructs and immunofluorescence protocol were producing 
normal expression and staining of the FBXW7 proteins (Figure 6.5).  
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Figure 6.4 FLAG and MYC tag UBE2QL1 immunofluorescence  in HeLa cells 
A, HeLa cells were transfected with FLAG-UBE2QL1 and blotted with anti-FLAG 
(mouse)  and anti-α-tubulin (rabbit) and labelled with secondary antibodies anti-mouse 
(red) and anti-rabbit (green). B, HeLa cells were transfected with MYC-UBE2QL1 and 
blotted with anti-MYC (rabbit)  and anti-α-tubulin (mouse) and labelled with secondary 
antibodies anti-mouse (red) and anti-rabbit (green). The nucleus was labelled using the 
nuclear stain DAPI (blue). Both MYC and FLAG labelled UBE2QL1 shows speckeled 
nuclear staining (yellow arrow) suggesting domain localisation within the nucleus. This 
speckled appearance is not due to nucleoli localisation as no UBE2QL1 staining occured 
within any of the nucleoli (white arrow).  scale bars = 13μm. 
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Figure 6.5 FBXW7 α, β and γ isoform localisation staining within HeLa cells. 
Hela cells were transfect with FLAG-FBXW7α (A), FLAG-FBXW7γ (B) and FLAG-
FBXW7β (C). Cells were blotted with anti-FLAG and labelled with anti-mouse (red). 
Both FBXW7α and γ showed nuclear localisation with staining in specific domains within 
the nucleus (white arrows) and FBXW7β displayed cytoplasmic localisation. The nucleus 
was labelled using the nuclear stain DAPI (blue), scale bar = 13μm. 
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As α and γ isoforms of FBXW7 were shown to reside in specific clusters within 
the nucleus similar to that of UBE2QL1, immunofluorescence was undertaken to 
determine if FBXW7 α and/or FBXW7γ co-localised with UBE2QL1. HeLa cells were 
co-transfected with FLAG-FBXW7α/γ and MYC-UBE2QL1 and cells were stained with 
fluorescently labelled anti-MYC and anti-FLAG antibodies as well as DAPI to indicate 
the nucleus. These experiments demonstrated UBE2QL1 and FBXW7 α /γ partially co-
localised within specific clusters in the nucleus of the cell (Figure 6.6), thus suggesting 
an interaction between UBE2QL1 and FBXW7α/γ may occur in vivo. 
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Figure 6.6 UBE2QL1 and FBXW7α/γ co-localisation in HeLa cells 
HeLa cells were transfected with FLAG-FBXW7γ (A) or FLAG-FBXW7α (B) and MYC-
UBE2QL1. Cells were labelled with anti-FLAG (red) and anti-MYC (green) along with 
the nuclear stain DAPI (blue). Both FBXW7α/γ and UBE2QL1 demonstrated staining of 
the same specific domains within the nucleus producing a speckled appearance. Partial 
co-localisation is visualised as a yellow stain due to the overlay of red and green stains 
(white box shows a zoomed in image of co-localisation). Merge = labelled with anti-MYC 
(green) and anti-FLAG (RED), Triple = labelled with anti-MYC (green), anti-FLAG 
(red) and DAPI (blue). Scale bar = 13μm. 
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 Co-immunoprecipitations were undertaken to demonstrate protein binding of 
UBE2QL1 and FBXW7 α/γ. As there were no antibodies available for UBE2QL1 and no 
FBXW7 antibodies that could be used successfully for immunoprecipitations (IPs), all 
IPs were undertaken using tagged expression plasmids. MYC-UBE2QL1 and FLAG-
FBXW7 (α or γ) were transfected into HEK293 cells and IPs were carried out using 
magnetic Dynabeads (Invitrogen) that had been conjugated with either anti-FLAG or 
anti-MYC antibodies. When UBE2QL1 was immunoprecipitated with MYC Dynabeads 
and immunoblotted with anti-FLAG, FLAG-FBXW7 bands were present demonstrating 
protein binding. IPs of FBXW7 isoforms using anti-FLAG Dynabeads also demonstrated 
protein binding with bands present for MYC-UBE2QL1 after blotting with anti-MYC 
(Figure 6.7). Controls transfected with empty vector (EV)-MYC and FBXW7 or EV-
FLAG and MYC-UBE2QL1 showed no bands for MYC-UBE2QL1 or FLAG-FBXW7 
respectively, demonstrating proteins were not binding to the FLAG or MYC tags or 
weren’t binding to the antibody bound dynabeads (Figure 6.7). Thus both 
immunofluorescence co-localisation studies and Co-IP experiments demonstrated 
UBE2QL1 and FBXW7 α/γ interaction in vivo. 
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Figure 6.7 UBE2QL1 and FBXW7α/γ co-immunoprecipitations 
A, HEK-293 cells were transfected with either empty vector (EV)-MYC or MYC-
UBE2QL1 and FLAG-FBXW7α/γ as indicated. Immunoprecipitation (IP) of MYC-
UBE2QL1 followed by immunoblot (IB) analysis with anti-FLAG identified FBXW7α and 
FBXW7γ as UBE2QL1 interacting proteins (right panel). B, HEK-293 cells were 
transfected with either EV-FLAG or FLAG-FBXW7α/γ  and MYC-UBE2QL1 as 
indicated. IP of FLAG-FBXW7α and FLAG-FBXW7γ  followed by IB analysis with anti-
MYC confirmed FBXW7α and FBXW7γ as UBE2QL1 interacting proteins (right panel). 
10μg of cell lysates are shown to indicate input levels of FBXW7α, FBXW7γ and 
UBE2QL1 (A and B left panels). 
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6.2.3   Does FBXW7 target UBE2QL1 for proteasome degradation?  
The FBXW7 recognition motif identified in UBE2QL1 acts as a phosphodegron 
motif that has been demonstrated to target FBXW7 substrates, such as cyclin E1 and 
mTOR, to the SCF
FBXW7
 complex leading to substrate ubiquitylation and often targeted 
proteasome degradation (Nash et al. 2001; Bai et al. 1996) . It was therefore important to 
investigate whether FBXW7 facilitated UBE2QL1 proteasome degradation. SKRC47 
cells were transfected with UBE2QL1 and EV-FLAG, or UBE2QL1 and FBXW7 and a 
degradation assay was carried out with protein levels been measured at serial time points 
following the addition of the protein synthesis inhibitor, cyclohexamide. There was no 
increase in UBE2QL1 protein degradation with the addition of FBXW7 detected (Figure 
6.8-A). The E2 ubiquitin conjugating CDC34 has been shown to be recruited to the 
SCF
βTRCP
 E3 complex leading to the ubiquitlylation of substrates such as IκBα (Read et 
al. 2000). Following an in silico search (http://elm.eu.org/) using the full length CDC34 
protein sequence (NP_004350), the presence of a βTRCP phosphodegron motif, 
DSGTEES, was detected within CDC34 at amino acid residues 230-236 (Figure 6.9) and 
studies have shown CDC34 is degraded by the SCF
βTRCP
 complex under specific cellular 
conditions, thus E2 conjugating enzymes can be ubiquitylated by the same E3 ligase 
complexes that they interact with to ubiquitylate their substrates (Fernandez-Sanchez et 
al. 2010; Sadowski et al. 2007). It was therefore speculated that although UBE2QL1 may 
be ubiquitylated by SCF
FBXW7
, due to the presence of its FBXW7 phosphodegron,
 
which 
most likely occurs under unknown specific cellular conditions, UBE2QL1 may also 
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functioning as an E2 conjugating enzyme for SCF
FBXW7
. It is widely accepted that SCF 
E2 conjugating enzymes interact to the E3 complex via the ring-finger protein RBX-1 ( 
Jin & Harper 2002; Spratt et al. 2012). We therefore determined whether UBE2QL1 and 
RBX1 interacted within the cell by co-immunoprecipitation, which demonstrated an 
interaction in vivo (Figure 6.8-B) thus suggesting UBE2QL1 may interact with FBXW7 
via RBX-1 within the SCF complex.  
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Figure 6.8 FBXW7 does not facilitate the degradation of UBE2QL1 under normal 
cellular conditions and UBE2QL1 interacts with endogenous RBX-1 
A, SKRC47 Cells were transfected with indicated plasmids treated with 100µg/ml 
cyclohexamide (CHX) 24hrs post transfection and collected at the indicated times. IB 
analysis was undertaken with the indicated antibodies. Anti-β-actin was used as loading 
control, n=3. B, Immunoprecipitation (IP), in HEK293 cells transfected with EV-MYC or 
MYC-UBE2QL1, with anti-MYC along with immunoblot (IB) analysis with anti-RBX-1 
and anti-MYC demonstrated UBE2QL1 and RBX-1 protein interaction. 10µg of protein 
lysate was immunoblotted with anti-RBX-1 (input).  
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Figure 6.9 Schematic illustration of Cdc34 protein domains 
Cdc34 is an E2 conjugating enzyme for the SCF
βTRCP
 E3 complex. It consists of a 
170aa core UBC domain containing an active cysteine residue at (C93) and an acidic 
c-terminal tail domain shown to be important in its interaction to the E3 complex. A 
βTRCP phosphodegron binding domain was detected at residues 230-236. 
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6.2.4   FBXW7 substrate degradation assays  
 Given the association between UBE2QL1, FBXW7 and RBX-1 this suggested 
UBE2QL1 may function as an E2 conjugating enzyme for the SCF
FBXW7
 E3 ligase 
complex contributing to the ubiquitylation of its protein substrates. Although a number of 
outcomes can occur from substrate ubiquitylation depending on the ubiquitin linkages 
formed by the E2 enzyme (Figure 1.7), it was decided to initially determine if SCF
FBXW7
 
protein substrate proteasomal degradation was enhanced by UBE2QL1. A UBE2QL1 
stably expressing RCC cell line was used to determine if re-expression of UBE2QL1 
caused a decrease in SCF
FBXW7 
substrate half life, thus suggesting UBE2QL1 may be 
targeting the substrates for proteasomal degradation. Protein lysates from the UBE2QL1 
or EV stably transfected SKRC47 and SKRC39 cell lines were used to compare protein 
expression levels of mTOR and cyclin E1 as these have both been shown to be targeted 
for proteasomal degradation via the SCF
FBXW7 
complex (see section 1.5).  UBE2QL1 
stably expressing cells displayed a marked decrease of both cyclin E1 and total mTOR 
expression compared to EV controls (Figure 6.10). To determine if this decrease in 
mTOR and cyclin E1 expression was due to enhanced protein degradation and not 
another mechanism such as a change in transcriptional regulation, a degradation assay 
was carried out which involved exposing UBE2QL1 or EV transfected SKRC47 cells to 
the protein synthesis inhibitor cycloheximide and extracting cells at serial time points. 
mTOR and cyclin E1 protein levels were measured at serial time points following the 
addition of cycloheximide twenty four hours post transfection. A significant serial 
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reduction in both cyclin E1 and mTOR levels in cells transfected with myc-UBE2QL1 
compared with cells transfected with myc-EV was detected indicating that degradation of 
these FBXW7 targets is enhanced by UBE2QL1 (Figure 6.11). 
 207 
 
 
Figure 6.10 UBE2QL1 stable clones demonstrate decreased cyclin E1 and 
mTOR expression compared to controls 
Protein lysate was extracted from SKRC47 and SKRC39 stable clones expressing 
FLAG- UBE2QL1 (UBE2QL1) and FLAG-EV (EV) and 10μg of protein was 
immunoblotted with the indicated antibodies. Anti-β-actin was used as a loading 
control. 
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Figure 6.11 UBE2QL1 enhances mTOR and cyclin E1 degradation 
SKRC47 Cells were transfected with myc-UBE2QL1 and myc-EV and were treated with 
100µg/ml cyclohexamide (CHX) 24hrs post transfection and collected at the indicated 
times. Upper panels, 10μg of protein was immunoblotted with anti-mTOR (A) and anti-
cyclin E1 (B). Anti-β-actin was used as loading control. Lower panels, relative densities 
of mTOR (left) and cyclin E1 (right) to β-actin by densitometry, normalised to time point 
zero. (unpaired t-test, error bars = SEM, n = 3, * P<0.05). 
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As these experiments suggested UBE2QL1 is involved in the regulation of cyclin 
E1 expression, t(5;19)(p15.3;q12) associated renal tumours from individuals III:I and 
III:II (two oncocytomas and one chromophobe RCC) were stained for cyclin E1 
expression in immunohistochemistry experiments by Dr Anne-Bine Skytte and increased 
cyclin E1 expression (compared to normal kidney) was detected (Figure 6.12) thus 
demonstrating UBE2QL1 is likely involved in the regulation of cyclin E1 expression. 
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Figure 6.12  Immunohistochemistry with cyclin E1 (cyclin E1) in 
t(5;19)(p15.3;q13.1) associated renal tumours carried out by Anne-Bine Skytte 
(A) cyclin E1 immunohistochemistry (IHC) in a t(5;19)(p15.3;q13.1) associated 
renal oncocytoma showing up-regulation. (B) cyclin E1 IHC in a sporadic renal 
oncocytoma showing no evidence of up-regulation to compare to (A). (C) cyclin 
E1 IHC in a t(5;19)(p15.3;q13.1) associated chromophobe RCC showing up-
regulation. (D) cyclin E1 IHC in a sporadic clear cell RCC showing no evidence 
of up-regulation to compare with (A) and (C). All images are at x10 
magnification. 
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6.3    Conclusion 
 UBE2QL1 shows homology to the class I of E2 ubiquitin conjugating enzymes as 
it only consists of the catalytic core domain (UBC domain) while class II and class III E2 
conjugating enzymes contain additional N- or C- terminal extensions and class IV contain 
both (Wijk & Timmers 2010). The UBC domain contains an active cysteine in all active 
E2 ubiquitin conjugating enzymes that bind ubiquitin via a thioester bond prior to the 
interaction with their E3 ligases. It was demonstrated that UBE2QL1 bound ubiquitin via 
a predicted active cysteine residue C88. The UBE2QL1-ubiquitin interaction was 
disrupted by β-mercaptoethanol capable of reducing thioester bonds thus suggesting 
UBE2QL1 bound ubiquitin at C88 through the formation of a thioester bond, confirming 
its likely function as an E2 conjugating enzyme. The majority of E2 enzymes require the 
interaction to an E3 ligase to facilitate the ubiquitylation of the substrate protein (see 
section 1.4). An FBXW7 phosphodegron was identified in UBE2QL1 and an interaction 
was demonstrated between UBE2QL1 and FBXW7 isoforms α and γ in vivo as the 
proteins partially co-localised within the cell and were co-immunoprecipitated. It was 
also demonstrated that UBE2QL1 interacts with endogenous RBX-1, the RING-finger 
protein shown to bind E2 conjugating enzymes within the SCF complex, therefore it may 
be that the UBE2QL1  interaction with FBXW7 isoforms is via the SCF complex.  
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The FBXW7 phosphodegron motif has only been identified in FBXW7 substrates, 
targeting these substrates for ubiquitylation via the SCF
FBXW7
 complex, it was therefore 
initially thought that UBE2QL1 was likely an SCF
FBXW7
 substrate. Initial degradation 
assays did not suggest UBE2QL1 was targeted for degradation by FBXW7 under normal 
cellular conditions and further experiments demonstrated that UBE2QL1 was involved in 
the targeted degradation of FBXW7 substrates cyclin E1 and mTOR. This was further 
confirmed with both a t(5;19)(p15.3;q13.1) oncocytoma and chromophobe demonstrating 
cyclin E1 up regulation compared to normal kidney. It is also interesting to note that 
CDC34 an E2 ubiquitin conjugating enzyme for the SCF complex shown to function with 
the SCF
βTRCP
 complex leading to the degradation of substrates such as IκBα and β-
catenin, also contains an F-box phosphodegron motif that targets substrates to the βTRCP 
F-box. CDC34 has been shown to be targeted for proteasomal degradation by the 
SCF
βTRCP
 complex under specifc conditions, thus E2 conjugating enzymes are often 
regulated by the same E3 ligase complexes that they bind to ubiquitylate substrates 
(Fernandez-Sanchez et al. 2010; Sadowski et al. 2007). This suggested that although the 
UBE2QL1/FBXW7 interaction was initially identified due to the presence of the FBXW7 
motif within UBE2QL1, studies have suggested it likely also functions as a ubiquitin 
conjugating enzyme for the SCF complex. Studies here did not suggest UBE2QL1 was 
targeted for degradation by FBXW7 under normal cellular conditions and it is likely that 
a specific stimulus is needed to induce FBXW7-dependent proteasomal degradation 
similar to that of βTRCP-dependent degradation of CDC34. Further experiment’s to 
determine if the decreased degradation of FBXW7 substrates, mTOR and cyclin E1, 
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detected in UBE2QL1 expressing cell lines, along with the up regulation of cyclin E1 in 
UBE2QL1 deficient tumours, is either due to UBE2QL1 functioning as an E2 ubiquitin 
conjugating enzyme for the SCF
FBXW7
 complex or an alternative mechanism, and whether 
or not this plays a role in the tumour suppressor function of UBE2QL1 (see section 7.4). 
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Chapter Seven: Discussion 
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7.1    UBE2QL1 is a novel RCC TSG gene and E2 conjugating enzyme  
 The characterisation of a constitutional translocation, t(5;19)(p15.3;q12), 
associated with a familial predisposition to RCC, led to the identification of a novel 
candidate RCC gene, UBE2QL1. It was determined that UBE2QL1 demonstrated TSG 
activity and was inactivated in 37% of sporadic RCC by promoter region 
hypermethylation and/or allele deletions. Disruption of both UBE2QL1 alleles were 
identified in one sporadic RCC and in an oncocytoma in one of the t(5;19)(p15.3;q12) 
patients thus following Knudson’s ‘two hit’ model and reinforcing the evidence that 
UBE2QL1 functions as a TSG (see section 1.1.2). The absence of frequent intragenic 
mutations of UBE2QL1 is reminiscent of RASSF1A, a known TSG often inactivated by 
methylation and/or allele loss in sporadic RCC (see section 1.3.4). The function of 
UBE2QL1 had not previously been characterised though it shows homology to the class 
of E2 ubiquitin conjugating enzymes and was demonstrated to contain an active cysteine 
residue (C88) that binds ubiquitin similar to that of other E2 conjugating enzymes. 
Recently a number of components of the ubiquitin-mediated proteolysis pathway 
(UMPP) were found to be mutated in RCC, though at a very small frequency (1-3%) 
when not including VHL (Guo et al. 2011). It is interesting that UBE2QL1 is another 
member of the UMPP pathway with deregulation detected in 37% of sporadic RCCs thus 
substantiating the importance of the UMPP pathway in RCC. UMPP pathway 
components are often capable of regulating numerous proteins involved in different 
pathways. It can therefore be seen why the disruption of components of the UMPP 
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pathway is a common mechanism of tumourigenesis in a number of cancers including 
RCC, as a number of important regulatory pathways can be disrupted from the genetic 
and/or epigenetic dysregulation of a single UMPP component. Many of the UMPP 
components that are disrupted in RCC are often involved in the mTOR, HIF and/or 
Wnt/β-catenin pathways, for example VHL has been demonstrated to regulate 
components of both the HIF and Wnt/β-catenin pathways, suggesting dysregulation of 
these pathways play an important role in RCC tumourigenesis (see section 1.5.2).  
 
7.2    UBE2QL1 regulates oncogenes mTOR and cyclin E1 
Although the mechanism of tumour suppression of several inherited RCC genes 
(e.g. VHL, FH, and SDHB) have been linked to HIF-1/2 related pathways, evidence of 
HIF target dysregulation in t(5;19)(p15.3;q12) associated renal tumours was not 
identified and there was no relationship between UBE2QL1 status and the presence or 
absence of a VHL mutation in sporadic RCC. UBE2QL1 was demonstrated to interact 
with FBXW7α/γ isoforms and the SCF component RBX-1 suggesting it may play a role 
within the SCF
FBXW7
 complex. It was demonstrated that UBE2QL1 potentially regulates 
FBXW7 substrates, cyclin E1 and mTOR and with both of these proteins demonstrating 
oncogenic properties in numerous cancers, it could therefore be speculated that the 
mechanism of UBE2QL1 tumour suppression activity involves that regulation of these 
oncogenic products. Investigations showed UBE2QL1 stably expressing cell lines 
demonstrating a significant decrease in anchorage independent growth also exhibited a 
marked decrease in both mTOR and cyclin E1 expression, and  two t(5;19)(p15.3;q12) 
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tumours demonstrated a dramatic cyclin E1 up-regulation compared to normal kidney. 
cyclin E1 is essential for the control of the cell cycle and accumulates during G1-S phase 
(Koff et al. 1992; Möröy & Geisen 2004). Over-expression of cyclin E1 has been 
observed in many tumours and results in chromosome instability contributing to 
tumourigenesis (Donnellan & Chetty 1999). mTOR activation is common in sporadic 
RCC, though in many cases the exact mechanism of this deregulation is unknown, and 
mTOR inhibitors have shown promise in clinical trials for the treatment of metastatic 
RCC (Anandappa et al. 2010; Gerullis et al. 2010; Marín et al. 2012). VHL-inactivated 
RCC are invariably clear cell, yet those associated with germline FLCN  mutations 
(causing Birt-Hogg-Dubé syndrome) represent a variety of histopathological subtypes 
(similar to that of the t(5;19)(p15.3;q12)) and interestingly the FLCN gene product has 
been implicated in mTOR pathway regulation (Baba et al. 2006; Chen et al. 2008; 
Hasumi et al. 2009). Thus impaired degradation of mTOR may contribute to the 
development of RCC associated with UBE2QL1 inactivation.  
 
7.3    E2 ubiquitin conjugating enzymes in cancer 
 There is relatively little information regarding the potential role of E2 conjugating 
enzymes in cancers with only a few reports of increased E2 enzyme expression in some 
cancers (e.g. UbcH10 and E2-EPF) (Okamoto et al. 2003b, 2003b; Tedesco et al. 2007; 
Roos et al. 2011; Seghatoleslam et al. 2012). UBE2QL1 is the first E2 conjugating 
enzyme shown to demonstrate TSG activity. It was originally depicted that E3 enzymes 
were the only components that brought substrate specificity to the ubiquitin cascade with 
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E1 and E2 enzymes functioning as ubiquitin carriers (see section 1.4.1), thus the tumour 
suppressor or oncogenic properties of E3 ligases could be easily recognised due to their 
specific nature (Ardley & Robinson 2005) and many components of E3 ligase complexes 
have been implicated in numerous cancers (Sun 2003; Sun 2006; Bernassola et al. 2008). 
With recent research demonstrating E2 conjugating enzymes also playing an important 
role in the biological outcome of a substrate as the length and type of ubiquitin chain(s) 
assembled can affect the fate of the substrate(s) thus providing another level of 
specificity, it could be speculated that E2 enzymes may play are more important role in 
disease and cancer than originally contemplated (see section 1.4.1). 
 
 CDC34 is the most well characterized E2 for SCF, mainly because experiments 
have been undertaken in yeast which specifically uses Cdc34 only (Schwob et al. 1994; 
Mathias et al. 1998). Although it is thought that human SCF can use alternate E2s, 
limited data only exists for members of the UBCH5 family (Gonen et al. 1999; Popov et 
al. 2010). Interestingly, it has been suggested that the choice of E2 may influence 
substrate outcome by virtue of the ubiqutin chains formed. Thus CDC34 promotes 
substrate degradation through its promotion of K48 linked ubiquitin chains necessitated 
by its acidic loop  and has been shown to promote the degradation of c-myc by SCF
FBXW7
 
whereas the E2 UBCH5, promotes stabilization of c-myc by SCF
βTRCP
 through the 
formation of heterotypic linked ubiquitin chains (Popov et al. 2010; Petroski & Deshaies 
2005). It was demonstrated that UBE2QL1 carries monoubiquitin, but it is not clear 
whether UBE2QL1 acts alone to build a polyubiquitin chain by sequential transfer of 
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single ubiquitins, as described for CDC34 (Kleiger et al. 2009; Pierce et al. 2009) or 
whether UBE2QL1 acts in concert with another E2 to promote chain assembly. 
UBE2QL1 lacks the acidic tail of CDC34 which has been demonstrated to be essential 
for poly-ubiquitination of substrates of the SCF complex, but not for the initial mono-
ubiquitination (Gazdoiu et al. 2007) and it may be that UBE2QL1 provides the rate 
limiting step to enable initial transfer of monoubiquitin prior to the efficient transfer of 
subsequent ubiquitins by another E2, for example CDC34. Further investigations are 
required to elucidate the precise function of UBE2QL1 and the relationship between 
UBE2QL1 growth suppression, E2 activity and FBXW7 function (see section 7.4).
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7.4 Future experiments 
 
7.4.1   Investigations of UBE2QL1 function within the cell 
As expression of UBE2QL1 promoted the degradation of mTOR and cyclin E1, 
both substrates of FBXW7 and preliminary co-immunoprecipitations suggested 
UBE2QL1 does bind to RBX-1 (the E2 binding component of the SCF complex) in vivo, 
this suggested UBE2QL1 may function as an E2 conjugating enzyme for the SCF
FBXW7
 
complex. A standard in vitro ubiquitin assay could be performed which includes all 
purified components of the SCF
FBXW7
complex (RBX-1, CUL-1, SKP1 and FBXW7) 
along with the human E1 – activating enzyme, ubiquitin (often GST or His tagged), E2 
conjugating enzyme (UBE2QL1) and FBXW7 substrates cyclin E1 and mTOR. Other 
FBXW7 substrates may also be ubiquitylated by UBE2QL1 and could therefore also be 
investigated. The reaction involves incubating all the protein components with a specific 
ubiquitination buffer including ATP as the reaction is ATP dependent. Controls include 
reactions in the absence of the E1 enzyme, E2 enzyme and ubiquitin. Samples would be 
loaded onto SDS-PAGE gels and blotted with the respective antibodies to detect 
substrates and ubiquitin (Choo & Zhang 2009). In vivo ubiquitin assays could also be 
carried out to confirm any in vitro results. These would involve transfecting a UBE2QL1 
null cell line with UBE2QL1 and an epitope tagged ubiquitin (i.e. His tag). After 48 
hours cells would be lysed and protein extracted. Immunoprecipitations and/or pulldown 
assays would be undergone to extract ubiquitin and substrate proteins from the protein 
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lysate. SDS-PAGE would be used to confirm substrate ubiquitylation using the respective 
antibodies. Controls would include substituting UBE2QL1 with empty plasmid. These 
assays can also be undertaken using the proteasome inhibitor, MG-132, thus preventing 
substrate proteasomal degradation. 
 
Further work would also be required to determine how exactly UBE2QL1 causes 
substrate ubiquitination and whether this also requires other E2s (i.e.CDC34) and, if so, 
which one(s). The in vitro and in vivo ubiquitination assay described above would help 
determine if UBE2QL1 substrates are mono or poly ubiquitinated. Commercial 
antibodies are now available that can detect specific ubiquitin linkages, for example 
antibodies that specifically detect K48-linked ubiquitin chains only (Boston Biochem), 
thus allowing detection of the specific ubiquitin linkages UBE2QL1 attaches to its 
substrates.  
 
7.4.2   UBE2QL1 tumour suppressor activity 
UBE2QL1 stable expression in a UBE2QL1 null expressing cell line 
demonstrated tumour suppressor activity with decreased anchorage independent growth 
and decreased proliferation. UBE2QL1 knockdown experiments in a UBE2QL1 
expressing cell line such as HEK293 would help confirm this data, as these would be 
predicted to show increased proliferation and anchorage independent growth in colony 
growth assays and soft agar assays respectively, compared to the UBE2QL1 expressing 
cell lines. Attempts were made to knockdown UBE2QL1 using the only available (non-
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verified) silencer select siRNA (Invitrogen). As no antibody was available for UBE2QL1, 
knockdowns had to be verified using QRT-PCR. A knockdown of only 20% was 
demonstrated thus would not be sufficient to determine UBE2QL1 knockdown affects in 
the cell. A more successful method may be to use UBE2QL1 shRNA vectors that can be 
used to produce stable knockdowns of proteins as these vectors contain an antibiotic 
resistant gene and thus shRNA transfected cells can be selected for leading to stable 
integration of the shRNA expression cassette into the host genome. As many assays such 
as soft agar and colony assays require a long incubation period stable knockdowns are an 
advantage as siRNA often only produces a knockdown for up to 5-7 days.  
 
To determine if mTOR deregulation is one of the key mechanisms involved in 
UBE2QL1 TSG activity, the activity of the mTOR inhibitor, rapamycin, could be 
assessed using UBE2QL1 knockdown cell lines along side UBE2QL1 expressing controls 
(Yip et al. 2010). Thus if rapamycin treatment on UBE2QL1 null cell lines reversed the 
knockdown affects on the cells, this would suggest UBE2QL1 regulation of mTOR is an 
important aspect of its TSG activity.  
 
UBE2QL1 has been shown to act as a novel tumour suppressor gene in RCC, it 
would be interesting to determine if its TSG function is specific to RCC or if it acts as a 
general TSG and therefore would be disrupted in other cancers. To assess this UBE2QL1 
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promoter methylation, gene deletion and mutation analysis could be carried out on a 
panel of other sporadic tumours.  
 
7.5    Conclusion 
 Due to recent advances and affordability in genome sequencing technology, the 
majority of investigations to identify novel disease genes are now been initiated through 
exome or whole genome sequencing of patients, and though this research has greatly 
increased the rate at which disease associated genes are identified, it is important to note 
that UBE2QL1, like RASSF1A, would not have been identified through exome 
sequencing (Peters et al. 2007; Loginov et al. 2009). This demonstrates that although 
exome sequencing studies have become a fundamental tool in identifying causative genes 
it is important that other methods of gene identification continue to be utilized to allow a 
complete analysis of the causative genetic and epigenetic abnormalities within a disease.  
 
  This research has illustrated how the analysis of rare inherited forms of RCC can 
allow the identification of candidate RCC TSGs involved in the more common sporadic 
forms of the disease. The findings in this thesis have increased the knowledge of familial 
and sporadic RCC tumourigenesis and have confirmed recent reports of the importance of 
the UMPP pathway in RCC. This research also presents a novel finding in which a 
component (UBE2QL1), other than an E3 ligase, of the ubiquitin cascade has been shown 
to function as a TSG, thus warranting further investigations to determine UBE2QL1 
function and specificity within the cell. 
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Chapter Eight: Appendices 
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8.1    Primer sequences 
8.1.1   PCR and sequencing primers 
Product Direction Primer sequence 
UBE2QL1 Ex1  F AGCAACACTGCACGCAGGT 
R GTGAGCAGCTCCATGCAGAT 
UBE2QL1 Ex2a F GACCAACACCGAGTTCATCC 
R CGCTGGTGTAGTCAGAGCAG 
UBE2QL1 Ex2b F AGACATCAGAAATCCCCACG 
R ATTCAGGATGCAGTTCTGGC 
VHL Ex1  F AGTCCGGCCCGGAGGAACT 
R TGCTGGGTCGGGCCTAAGC 
VHL Ex2 F CACCGGTGTGGCTCTTTAACAA 
R ACATCAGGCAAAAATTGAGAACTGG 
VHL Ex3 F CCTTGTACTGAGACCCTAGTCTGCCACT 
R CAAGACTCATCAGTACCATCAAAAGCTG 
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8.1.2   t(5;19)(p15.3;q12) primers 
Derivative 
breakpoint 
Purpose Direction Primer sequence 
der(5) PCR F TGTTGCAGTTCTTTTCAGTTTCG 
PCR R AACAAAGTGTTGGACATTTAGCAAA 
der(5) Seq F TGTTGCAGTTCTTTTCAGTTTCG 
Seq R TTTAGAGGAGCCATGCAGGT 
der(19) PCR F AGTGGGAAATAGCTCTAGGAATGG 
PCR R GCCAAGTGGCTTCACAAGTATCT 
der(19) Seq F ACTTAACAGACTGCCCTGGTG 
Seq R TCATTCACTGAGCACTGTAGTGAC 
 
8.1.3   Vector sequencing primers 
Vector Direction Primer sequence 
pFLAG-CMV4 F AATGTCGTAATAACCCCGCCCC GTTGACGC 
R TATTAGGACAAGGCTGGTGGG CAC 
pCMV-myc F TATTAGGACAAGGCTGGTGGG CAC 
PGEM-T Easy  F TAATACGACTCACTATAGGG 
R ACACTATAGAATACTCAAGC 
pcDNA3.1 F TAATACGACTCACTATAGGG 
 R GCCTCGACTGTGCCTTCTA 
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8.1.4   Cloning primers 
Gene Direction Primer sequence 
UBE2QL1  F GG AAT TCA CTC ATG AAG GAG CTG CAG 
GAC 
R TTG GGA TCC CAG ACA TCA GCC GTC 
GGA 
 
8.1.5    Site directed mutagenesis primers 
Gene product Direction Primer sequence 
UBE2QL1 C88A F CGGCGGCGCCATCGCCATGGAGCTGCTC 
R GAGCAGCTCCATGGCGATGGCGCCGCCG 
UBE2QL1 C88S F GGCGGCGCCATCAGCATGGAGCTGC 
R GCAGCTCCATGCTGATGGCGCCGCC 
 
8.1.6   COBRA primers 
Gene Direction Primer sequence 
UBE2QL1  F YGTTYGTATATATATATTATATAGTGGTAGTAGTAGT 
OR CAACACCRAATCCTTATCCACCTAATA 
IR CTCTCRTCCACCAACTCCACRAAAATA 
Note – Y = C or T, R= A or G 
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8.1.7   Custom designed MLPA probes 
UBE2QL1 
exon 
Probe Probe sequence Chr5 
position (bp) 
Exon 1 LPO GGGTTCCCTAAGGGTTGGATCACCTTCAGATTGTCT
GTGGCAGGACATGAAGGAGACCAACA 
6449124 - 
6449179     
RPO CCGAGTTCATCCTGCTCAACCTCACCTTAAAATCAC
CAGTCTAGATTGGATCTTGCTGGCAC 
Exon 1+ LPO GGGTTCCCTAAGGGTTGGATAGAGACGCCACGCTC
ATGAGTGGCAAGGCTCTGAAATTTCATCA 
6453375 - 
6453440 
RPO GCATGAGTAAAAGCTGTTGGAAATGGCAGTCGGTA
ACTTTCTAGATTGGATCTTGCTGGCAC 
Exon 1- LPO GGGTTCCCTAAGGGTTGGATCGAGAGGACGGTCTG
TCTGTCTCTACAGCAAACTGCATGCAGTGAGTGC 
6444047 - 
6444112 
RPO TCTTGAGCAGTGGCTACAAGCTCTGTCTGGAGCAC
CCTAGTTTCTAGATTGGATCTTGCTGGCAC 
Exon 2 LPO GGGTTCCCTAAGGGTTGGAACTCCGTCCCAGTGAC
GTTCTAACCTGGTTTTTCTTCTC 
6491287 – 
6491352 
RPO ATCTCACGCAGGGACGGATCTGTAGAAAAGCTGTA
TCTAGATTGGATCTTGCTGGCAC 
Exon 2+ LPO GGGTTCCCTAAGGGTTGGACAGGGGCTTGCACCTT
CCAAACTGAAATTCTGCAGTG 
6497546 - 
6497611 
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RPO CATGTCTACTGCTGAGGGCTGTAGTGACAAGACTC
TAGATTGGATCTTGCTGGCAC 
Exon 2- LPO GGGTTCCCTAAGGGTTGGACTTGGAAGTCCACTAC
TTCGATGGTTGGTAATTATGCGCCTGCCAGTACAT 
6490089 – 
6490172 
RPO AAAGCTCAGCCAGTTCTTTCCAGGCATTTCTGCAA
ACGAGTACCCTCTAGATTGGATCTTGCTGGCAC 
 
8.1.8   LOH microsatellite marker primers 
Microsatellite 
Marker 
Chr 5 
position 
(bp) 
Chr 
band 
Direction Primer sequence 
D5S2505 5869996-
5870453 
 
P15.32 F TGTTGGAAGACTTCTCAGCC 
R CACACATGCTGTGTCTCTCA 
D5S2054 5944886-
5945198 
P15.32 F TGAGATTTTCAGCCCACC 
R AGCCACTTCCCGATGTT 
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8.1.9   RT-PCR primers 
Gene Direction Primer sequence 
UBE2QL1 F CACCAGGTGGACAAGGACTC 
R GTAGCTTCAGCTTCCTTGCG 
GAPDH F GACCCCTTCATGACCTCAACTACA 
R CTAAGCAGTTGGTGGTGCAGGA 
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8.2    Plasmid Maps 
8.2.1   PGEM-T 
[www.promega.com/products/pcr/pcr-cloning/pgem_t-easy-vector-systems/] 
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8.2.2   PCDNA 3.1- 
[//tools.invitrogen.com/content/sfs/manuals/pcdna3_1_man.pdf] 
 
 
 233 
 
 
8.2.3   pFLAG-CMV-4 
[//www.sigmaaldrich.com/catalog/product/sigma/e7158?lang=en&region=GB] 
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8.2.4   p3xFLAG-MYC-CMV-24 
[//www.sigmaaldrich.com/catalog/product/sigma/e9283?lang=en&region=GB] 
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8.2.5 pCMV-MYC 
[//www.clontech.com/GB/Products/Protein_Expression_and_Purification/Myc-
Tagged_Protein_Purification/Myc_and_HA_Vectors?sitex=10030:22372:US] 
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8.3    UBE2QL1 nucleotide and amino acid sequence 
 
1   ATGAAGGAGCTGCAGGACATCGCGCGCCTTAGCGACCGCTTCATCTCCGTGGAGCTGGTGGACGAGAGC 
1   -M--K--E--L--Q--D--I--A--R--L--S--D--R--F--I--S--V--E--L--V--D--E--S-    
70  CTGTTCGACTGGAACGTGAAGCTGCACCAGGTGGACAAGGACTCGGTGCTGTGGCAGGACATGAAGGAG 
24  -L--F--D--W--N--V--K--L--H--Q--V--D--K--D--S--V--L--W--Q--D--M--K--E- 
140 ACCAACACCGAGTTCATCCTGCTCAACCTCACCTTCCCCGACAACTTCCCCTTCTCGCCGCCCTTCATG 
47  -T--N--T--E--F--I--L--L--N--L--T--F--P--D--N--F--P--F--S--P--P--F--M- 
210 CGGGTGCTCAGCCCGCGCCTGGAGAACGGCTACGTGCTGGACGGCGGCGCCATCTGCATGGAGCTGCTC 
70  -R--V--L--S--P--R--L--E--N--G--Y--V--L--D--G--G--A--I--C--M--E--L--L- 
280 ACGCCGCGCGGCTGGTCCAGCGCCTACACCGTGGAGGCCGTCATGCGCCAGTTCGCAGCCAGCCTGGTC 
93  -T--P--R--G--W--S--S--A--Y--T--V--E--A--V--M--R--Q--F--A--A--S--L--V- 
350 AAGGGCCAGGGACGGATCTGTAGAAAAGCTGGCAAATCAAAAAAGTCCTTCAGTCGCAAGGAAGCTGAA 
116 -K--G--Q--G--R--I--C--R--K--A--G--K--S--K--K--S--F--S--R--K--E--A--E- 
420 GCTACCTTTAAGAGTTTGGTGAAGACGCATGAAAAATATGGTTGGGTCACCCCGCCCGTGTCCGACGGC 
139 -A--T--F--K--S--L--V--K--T--H--E--K--Y--G--W--V--T--P--P--V--S--D--G- 
490 TGA 
162 -*- 
 
[www.ensembl.org] 
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8.4   UBE2QL1 Orthologue sequence variation 
Species 
Ensemble identifier & gene name 
% sequence 
alignment to 
human 
UBE2QL1 
Bushbaby (Otolemur Garnettii) 
ENSOGAG00000032403UBE2QL1 
100 
Elephant (Loxodonta africana) 
ENSLAFG00000027273UBE2QL1 
100 
Gorilla (Gorilla gorilla) 
ENSGGOG00000024242UBE2QL1 
100 
Microbat (Myotis Lucifugus) 
ENSMLUG00000029107UBE2QL1 
100 
Pig (Sus scrofa) 
ENSSSCG00000017105UBE2QL1 
100 
Chicken (Gallus gallus) 
ENSGALG00000013065UBE2QL1 
99 
Chimpanzee (Pan troglodytes) 
ENSPTRG00000033811UBE2QL1 
99 
Dog (Canis lupus familiaris) 
ENSCAFG00000030271UBE2QL1 
99 
Mouse (Mus musculus) 
ENSMUSG00000052981Ube2ql1 
99 
Opossum (Monodelphis 
domestica) 
ENSMODG00000028962UBE2QL 
99 
Orangutan (Pongo abelii) 
ENSPPYG00000015331UBE2QL1 
99 
Rat (Rattus norvegicus) 
ENSRNOG00000034075Ube2ql1 
99 
Turkey (Meleagris gallopavo) 
ENSMGAG00000006402UBE2QL 
99 
Anole lizard (Anolis carolinensis) 
ENSACAG00000000772UBE2QL1 
98 
Guinea Pig (Cavia porcellus) 
ENSCPOG00000021028UBE2QL1 
96 
Xenopus (Xenopus tropicalis) 
ENSXETG00000001734ube2ql1 
95 
Chinese softshell turtle 
(Pelodiscus sinensis) 
ENSPSIG00000015214UBE2QL1 
94 
Zebrafish (Danio rerio) 
ENSDARG00000079276UBE2QL1 
92 
Fugu (Takifugu rubripes) 
ENSTRUG00000011783UBE2QL1 
91 
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Medaka (Oryzias latipes) 
ENSORLG00000014317UBE2QL1 
91 
Tilapia (Oreochromis niloticus) 
ENSONIG00000007760UBE2QL1 
91 
Platyfish ( Xiphophorus 
maculatus) 
ENSXMAG00000013614UBE2QL 
90 
Stickleback (Gasterosteus 
aculeatus) 
ENSGACG00000008986UBE2QL1 
90 
Tetraodon (Tetraodon 
nigroviridis) 
ENSTNIG00000009260UBE2QL1 
90 
Cod (Gadus morhua) 
ENSGMOG00000013361UBE2QL 
88 
Marmoset (Callithrix jacchus) 
ENSCJAG00000008686LOC100392145 
88 
Panda (Ailuropoda melanoleuca) 
ENSAMEG00000006771UBE2QL1 
86 
Pika (Ochotona princeps) 
ENSOPRG00000019027UBE2QL1 
83 
Wallaby (Macropus eugenii) 
ENSMEUG00000003995UBE2QL1 
83 
Armadillo (Dasypus 
novemcinctus) 
ENSDNOG00000024031 
82 
Platypus (Ornithorhynchus 
anatinus) 
ENSOANG00000001753UBE2QL1 
77 
Tasmanian devil (Sarcophilus 
harrisii) 
ENSSHAG00000009846UBE2QL1 
73 
Coelacanth (Latimeria 
chalumnae) 
ENSLACG00000001694UBE2QL1 
71 
Zebra Finch (Taeniopygia 
guttata) 
ENSTGUG00000007820UBE2QL1 
71 
Fruitfly (Drosophila 
melanogaster) 
FBgn0031896CG4502 
66 
Kangaroo rat (Dipodomys ordii) 
ENSDORG00000011538Ube2ql1 
57 
Rabbit (Oryctolagus cuniculus) 
ENSOCUG00000028162UBE2QL1 
51 
Armadillo (Dasypus 
novemcinctus) 
ENSDNOG00000024355UBE2QL1 
47 
Sea Squirt (Ciona savignyi) 
ENSCSAVG00000002205 
43 
Sea Squirt (Ciona intestinalis) 
ENSCING00000005637 
14 
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8.5   UBE2QL1 known single nucleotide polymorphisms (SNPs) 
 
Position in 
cDNA 
Position in 
protein 
Type of 
mutation 
Source 
identified in 
Frequency Variation ID 
c.G114C p.S38S synonymous NHLBI Exome 
Sequencing 
Project 
0.022% TMP_ESP_5_6449120 
c.C300T p.A100A synonymous dbSNP NA rs11959306 
c.G441A p.T147T synonymous dbSNP + 
1000 
Genomes 
0.002% rs114648003 
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